CN114250227A - Expression vector for high-level expression of foreign gene - Google Patents
Expression vector for high-level expression of foreign gene Download PDFInfo
- Publication number
- CN114250227A CN114250227A CN202011026481.5A CN202011026481A CN114250227A CN 114250227 A CN114250227 A CN 114250227A CN 202011026481 A CN202011026481 A CN 202011026481A CN 114250227 A CN114250227 A CN 114250227A
- Authority
- CN
- China
- Prior art keywords
- sequence
- seq
- identity
- region
- aav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 198
- 239000013604 expression vector Substances 0.000 title claims abstract description 168
- 230000014509 gene expression Effects 0.000 title claims abstract description 116
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 98
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 97
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 97
- 230000001105 regulatory effect Effects 0.000 claims abstract description 92
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 75
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 36
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims description 238
- 241000700605 Viruses Species 0.000 claims description 92
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 76
- 229920001184 polypeptide Polymers 0.000 claims description 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 71
- 241000701022 Cytomegalovirus Species 0.000 claims description 67
- 108700019146 Transgenes Proteins 0.000 claims description 66
- 108091026890 Coding region Proteins 0.000 claims description 64
- 108010081667 aflibercept Proteins 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 62
- 239000003623 enhancer Substances 0.000 claims description 61
- 229960002833 aflibercept Drugs 0.000 claims description 50
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 42
- 210000004962 mammalian cell Anatomy 0.000 claims description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 230000008488 polyadenylation Effects 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- 230000001225 therapeutic effect Effects 0.000 claims description 27
- 108010006025 bovine growth hormone Proteins 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 24
- 238000002347 injection Methods 0.000 claims description 24
- 239000007924 injection Substances 0.000 claims description 24
- 108090000565 Capsid Proteins Proteins 0.000 claims description 21
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 21
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 241000702421 Dependoparvovirus Species 0.000 claims description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 17
- 241000288906 Primates Species 0.000 claims description 17
- 208000002780 macular degeneration Diseases 0.000 claims description 17
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 15
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 15
- 208000022873 Ocular disease Diseases 0.000 claims description 14
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims description 10
- 239000000854 Human Growth Hormone Substances 0.000 claims description 10
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 10
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 10
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 10
- 238000011144 upstream manufacturing Methods 0.000 claims description 10
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 8
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 8
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 7
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 7
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 7
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 102000007469 Actins Human genes 0.000 claims description 6
- 108010085238 Actins Proteins 0.000 claims description 6
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 6
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims description 6
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims description 6
- 241000283073 Equus caballus Species 0.000 claims description 5
- 229960000723 ampicillin Drugs 0.000 claims description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 5
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 5
- 241000271566 Aves Species 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 102100026720 Interferon beta Human genes 0.000 claims description 4
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 241000282465 Canis Species 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 108010022394 Threonine synthase Proteins 0.000 claims description 2
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 abstract description 14
- 230000003248 secreting effect Effects 0.000 abstract description 2
- 239000013598 vector Substances 0.000 description 146
- 235000018102 proteins Nutrition 0.000 description 67
- 239000000203 mixture Substances 0.000 description 57
- 108020004414 DNA Proteins 0.000 description 52
- 108091033319 polynucleotide Proteins 0.000 description 41
- 102000040430 polynucleotide Human genes 0.000 description 41
- 239000002157 polynucleotide Substances 0.000 description 41
- 239000002773 nucleotide Substances 0.000 description 40
- 125000003729 nucleotide group Chemical group 0.000 description 40
- 239000000047 product Substances 0.000 description 36
- 238000001476 gene delivery Methods 0.000 description 32
- 230000001965 increasing effect Effects 0.000 description 24
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 22
- 239000002245 particle Substances 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 20
- -1 e.g. Substances 0.000 description 19
- 230000003612 virological effect Effects 0.000 description 19
- 238000001890 transfection Methods 0.000 description 18
- 241000700159 Rattus Species 0.000 description 16
- 210000001508 eye Anatomy 0.000 description 15
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000004806 packaging method and process Methods 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 108020004705 Codon Proteins 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000014616 translation Effects 0.000 description 12
- 239000013603 viral vector Substances 0.000 description 12
- 239000013607 AAV vector Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000002207 retinal effect Effects 0.000 description 11
- 238000013519 translation Methods 0.000 description 11
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 10
- 229960004359 iodixanol Drugs 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 210000005252 bulbus oculi Anatomy 0.000 description 9
- 210000000234 capsid Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 210000002845 virion Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000013643 reference control Substances 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000012228 culture supernatant Substances 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 108091092195 Intron Proteins 0.000 description 6
- 101150010110 Map3k8 gene Proteins 0.000 description 6
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001124 posttranscriptional effect Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 4
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 3
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 210000001742 aqueous humor Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical class S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical compound C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 2
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 2
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 2
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 241000714165 Feline leukemia virus Species 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101100179429 Homo sapiens IFNB1 gene Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 2
- ATNKHRAIZCMCCN-BZSNNMDCSA-N Lys-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N ATNKHRAIZCMCCN-BZSNNMDCSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 230000027311 M phase Effects 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 2
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 210000000411 amacrine cell Anatomy 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000003161 choroid Anatomy 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000002287 horizontal cell Anatomy 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 239000013608 rAAV vector Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960003876 ranibizumab Drugs 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 210000003994 retinal ganglion cell Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- LMGGOGHEVZMZCU-FGJMKEJPSA-N (2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,7,12-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-2-carboxylic acid Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(O)=O)C1 LMGGOGHEVZMZCU-FGJMKEJPSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical class CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- DZBIMLCMMYGJFY-UHFFFAOYSA-N 6-(methylideneamino)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(N=C)=N1 DZBIMLCMMYGJFY-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 108010044087 AS-I toxin Proteins 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 1
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- OZNSCVPYWZRQPY-CIUDSAMLSA-N Arg-Asp-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OZNSCVPYWZRQPY-CIUDSAMLSA-N 0.000 description 1
- FFEUXEAKYRCACT-PEDHHIEDSA-N Arg-Ile-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(O)=O FFEUXEAKYRCACT-PEDHHIEDSA-N 0.000 description 1
- NGTYEHIRESTSRX-UWVGGRQHSA-N Arg-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NGTYEHIRESTSRX-UWVGGRQHSA-N 0.000 description 1
- ADPACBMPYWJJCE-FXQIFTODSA-N Arg-Ser-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O ADPACBMPYWJJCE-FXQIFTODSA-N 0.000 description 1
- ZUVMUOOHJYNJPP-XIRDDKMYSA-N Arg-Trp-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZUVMUOOHJYNJPP-XIRDDKMYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 1
- SRUUBQBAVNQZGJ-LAEOZQHASA-N Asn-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N SRUUBQBAVNQZGJ-LAEOZQHASA-N 0.000 description 1
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 1
- GWNMUVANAWDZTI-YUMQZZPRSA-N Asn-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N GWNMUVANAWDZTI-YUMQZZPRSA-N 0.000 description 1
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 1
- QNNBHTFDFFFHGC-KKUMJFAQSA-N Asn-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QNNBHTFDFFFHGC-KKUMJFAQSA-N 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 1
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 1
- IDDMGSKZQDEDGA-SRVKXCTJSA-N Asp-Phe-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 IDDMGSKZQDEDGA-SRVKXCTJSA-N 0.000 description 1
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 1
- ZUNMTUPRQMWMHX-LSJOCFKGSA-N Asp-Val-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O ZUNMTUPRQMWMHX-LSJOCFKGSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- XGIAHEUULGOZHH-GUBZILKMSA-N Cys-Arg-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N XGIAHEUULGOZHH-GUBZILKMSA-N 0.000 description 1
- NDNZRWUDUMTITL-FXQIFTODSA-N Cys-Ser-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NDNZRWUDUMTITL-FXQIFTODSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000626621 Geobacillus Species 0.000 description 1
- XKBASPWPBXNVLQ-WDSKDSINSA-N Gln-Gly-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XKBASPWPBXNVLQ-WDSKDSINSA-N 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 1
- UXXIVIQGOODKQC-NUMRIWBASA-N Gln-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O UXXIVIQGOODKQC-NUMRIWBASA-N 0.000 description 1
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 1
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 1
- GXMXPCXXKVWOSM-KQXIARHKSA-N Glu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N GXMXPCXXKVWOSM-KQXIARHKSA-N 0.000 description 1
- VMKCPNBBPGGQBJ-GUBZILKMSA-N Glu-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VMKCPNBBPGGQBJ-GUBZILKMSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- FBEJIDRSQCGFJI-GUBZILKMSA-N Glu-Leu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O FBEJIDRSQCGFJI-GUBZILKMSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- OGCIHJPYKVSMTE-YUMQZZPRSA-N Gly-Arg-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OGCIHJPYKVSMTE-YUMQZZPRSA-N 0.000 description 1
- VXKCPBPQEKKERH-IUCAKERBSA-N Gly-Arg-Pro Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O VXKCPBPQEKKERH-IUCAKERBSA-N 0.000 description 1
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- FYVHHKMHFPMBBG-GUBZILKMSA-N His-Gln-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N FYVHHKMHFPMBBG-GUBZILKMSA-N 0.000 description 1
- LCNNHVQNFNJLGK-AVGNSLFASA-N His-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N LCNNHVQNFNJLGK-AVGNSLFASA-N 0.000 description 1
- HZWWOGWOBQBETJ-CUJWVEQBSA-N His-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O HZWWOGWOBQBETJ-CUJWVEQBSA-N 0.000 description 1
- CSTDQOOBZBAJKE-BWAGICSOSA-N His-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N)O CSTDQOOBZBAJKE-BWAGICSOSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101000704156 Homo sapiens Sarcalumenin Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000714192 Human spumaretrovirus Species 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DFJJAVZIHDFOGQ-MNXVOIDGSA-N Ile-Glu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DFJJAVZIHDFOGQ-MNXVOIDGSA-N 0.000 description 1
- NYEYYMLUABXDMC-NHCYSSNCSA-N Ile-Gly-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)N NYEYYMLUABXDMC-NHCYSSNCSA-N 0.000 description 1
- HUWYGQOISIJNMK-SIGLWIIPSA-N Ile-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HUWYGQOISIJNMK-SIGLWIIPSA-N 0.000 description 1
- PFPUFNLHBXKPHY-HTFCKZLJSA-N Ile-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)O)N PFPUFNLHBXKPHY-HTFCKZLJSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 238000012351 Integrated analysis Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- BAJIJEGGUYXZGC-CIUDSAMLSA-N Leu-Asn-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N BAJIJEGGUYXZGC-CIUDSAMLSA-N 0.000 description 1
- BTNXKBVLWJBTNR-SRVKXCTJSA-N Leu-His-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O BTNXKBVLWJBTNR-SRVKXCTJSA-N 0.000 description 1
- OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- FGZVGOAAROXFAB-IXOXFDKPSA-N Leu-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(C)C)N)O FGZVGOAAROXFAB-IXOXFDKPSA-N 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- BTEMNFBEAAOGBR-BZSNNMDCSA-N Leu-Tyr-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BTEMNFBEAAOGBR-BZSNNMDCSA-N 0.000 description 1
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 1
- MWVUEPNEPWMFBD-SRVKXCTJSA-N Lys-Cys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCCN MWVUEPNEPWMFBD-SRVKXCTJSA-N 0.000 description 1
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
- LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 description 1
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 1
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- RKIIYGUHIQJCBW-SRVKXCTJSA-N Met-His-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RKIIYGUHIQJCBW-SRVKXCTJSA-N 0.000 description 1
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 1
- FXBKQTOGURNXSL-HJGDQZAQSA-N Met-Thr-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O FXBKQTOGURNXSL-HJGDQZAQSA-N 0.000 description 1
- PNHRPOWKRRJATF-IHRRRGAJSA-N Met-Tyr-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 PNHRPOWKRRJATF-IHRRRGAJSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 210000005156 Müller Glia Anatomy 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 101100441075 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) crf2 gene Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 102000010175 Opsin Human genes 0.000 description 1
- 108050001704 Opsin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- JOXIIFVCSATTDH-IHPCNDPISA-N Phe-Asn-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JOXIIFVCSATTDH-IHPCNDPISA-N 0.000 description 1
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 1
- GLUYKHMBGKQBHE-JYJNAYRXSA-N Phe-Val-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 GLUYKHMBGKQBHE-JYJNAYRXSA-N 0.000 description 1
- YUPRIZTWANWWHK-DZKIICNBSA-N Phe-Val-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N YUPRIZTWANWWHK-DZKIICNBSA-N 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 1
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 1
- CLJLVCYFABNTHP-DCAQKATOSA-N Pro-Leu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O CLJLVCYFABNTHP-DCAQKATOSA-N 0.000 description 1
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- BNFVPSRLHHPQKS-WHFBIAKZSA-N Ser-Asp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O BNFVPSRLHHPQKS-WHFBIAKZSA-N 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 1
- GRSLLFZTTLBOQX-CIUDSAMLSA-N Ser-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N GRSLLFZTTLBOQX-CIUDSAMLSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- QGAHMVHBORDHDC-YUMQZZPRSA-N Ser-His-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CN=CN1 QGAHMVHBORDHDC-YUMQZZPRSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- RRVFEDGUXSYWOW-BZSNNMDCSA-N Ser-Phe-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RRVFEDGUXSYWOW-BZSNNMDCSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- MQCPGOZXFSYJPS-KZVJFYERSA-N Thr-Ala-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MQCPGOZXFSYJPS-KZVJFYERSA-N 0.000 description 1
- JVTHIXKSVYEWNI-JRQIVUDYSA-N Thr-Asn-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JVTHIXKSVYEWNI-JRQIVUDYSA-N 0.000 description 1
- LIXBDERDAGNVAV-XKBZYTNZSA-N Thr-Gln-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O LIXBDERDAGNVAV-XKBZYTNZSA-N 0.000 description 1
- GMXIJHCBTZDAPD-QPHKQPEJSA-N Thr-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N GMXIJHCBTZDAPD-QPHKQPEJSA-N 0.000 description 1
- MGJLBZFUXUGMML-VOAKCMCISA-N Thr-Lys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MGJLBZFUXUGMML-VOAKCMCISA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- VUXIQSUQQYNLJP-XAVMHZPKSA-N Thr-Ser-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N)O VUXIQSUQQYNLJP-XAVMHZPKSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- BKVICMPZWRNWOC-RHYQMDGZSA-N Thr-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O BKVICMPZWRNWOC-RHYQMDGZSA-N 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LTLBNCDNXQCOLB-UBHSHLNASA-N Trp-Asp-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 LTLBNCDNXQCOLB-UBHSHLNASA-N 0.000 description 1
- UDCHKDYNMRJYMI-QEJZJMRPSA-N Trp-Glu-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UDCHKDYNMRJYMI-QEJZJMRPSA-N 0.000 description 1
- HXNVJPQADLRHGR-JBACZVJFSA-N Trp-Glu-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N HXNVJPQADLRHGR-JBACZVJFSA-N 0.000 description 1
- XGFGVFMXDXALEV-XIRDDKMYSA-N Trp-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N XGFGVFMXDXALEV-XIRDDKMYSA-N 0.000 description 1
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
- JLKVWTICWVWGSK-JYJNAYRXSA-N Tyr-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JLKVWTICWVWGSK-JYJNAYRXSA-N 0.000 description 1
- QFHRUCJIRVILCK-YJRXYDGGSA-N Tyr-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O QFHRUCJIRVILCK-YJRXYDGGSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 1
- 101150107399 UTR1 gene Proteins 0.000 description 1
- 101150058257 UTR2 gene Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- UDLYXGYWTVOIKU-QXEWZRGKSA-N Val-Asn-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UDLYXGYWTVOIKU-QXEWZRGKSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- PMDOQZFYGWZSTK-LSJOCFKGSA-N Val-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C PMDOQZFYGWZSTK-LSJOCFKGSA-N 0.000 description 1
- OACSGBOREVRSME-NHCYSSNCSA-N Val-His-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(O)=O OACSGBOREVRSME-NHCYSSNCSA-N 0.000 description 1
- RHYOAUJXSRWVJT-GVXVVHGQSA-N Val-His-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RHYOAUJXSRWVJT-GVXVVHGQSA-N 0.000 description 1
- JZWZACGUZVCQPS-RNJOBUHISA-N Val-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N JZWZACGUZVCQPS-RNJOBUHISA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- KISFXYYRKKNLOP-IHRRRGAJSA-N Val-Phe-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N KISFXYYRKKNLOP-IHRRRGAJSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 1
- BZDGLJPROOOUOZ-XGEHTFHBSA-N Val-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](C(C)C)N)O BZDGLJPROOOUOZ-XGEHTFHBSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004883 computer application Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical class O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000050995 human FLT1 Human genes 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical group N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical class CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950005848 olivomycin Drugs 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 229950008558 ulinastatin Drugs 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 108010088854 urinastatin Proteins 0.000 description 1
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present disclosure relates to an expression vector for high level expression of a foreign gene, the expression vector comprising a regulatory nucleic acid molecule that enhances gene expression, the regulatory nucleic acid molecule comprising, in 5 'to 3' order, a tripartite leader sequence (TPL) of an adenovirus and an enhancer element (eMLP) of the major late promoter of the adenovirus. The expression vector can obviously improve the expression level of the exogenous gene, can improve the protein expression level coded by the intracellular exogenous gene by more than tens of times, and can improve the protein level coded by the secretory exogenous gene by several times.
Description
Technical Field
The present disclosure relates to a gene expression vector, and more particularly to a vector mediating the high expression of exogenous genes in cells and applications thereof.
Background
Exogenous genes are delivered to specific tissues or cells by using the vector, and diseases such as genetic diseases, tumors, degenerative diseases and the like are treated or prevented by using expressed exogenous proteins or non-coding RNA molecules, so that the method is a treatment mode with wide prospect.
Viral vectors are a gene delivery vector that has been rapidly developed in recent years, and among them, vectors of adeno-associated virus (AAV) are becoming the best vector choice for gene therapy due to their low immunogenicity, non-integration, and properties that mediate long-term expression of foreign genes.
Researchers have developed promoters with high transcriptional activity such as CMV and CAG, and have improved the expression efficiency of foreign genes. However, gene expression levels in mammalian cells are regulated at multiple levels, including transcriptional, post-transcriptional mRNA stability, translational, and post-translational protein stability. Thus, where delivery of a foreign gene into a mammalian cell is desired, for example in gene therapy, optimization can be made from a number of perspectives as described above, such as gene transcription and translation regulatory elements, copy number of the foreign gene, integration site of the foreign gene in the host cell genome, RNA processing and mRNA stability, translational modification of proteins by the host cell itself, and the like.
Thus, there is a need for improved methods and optimized expression vectors for expressing genes in cells, particularly mammalian cells, to ensure long-term high-level expression of exogenous genes.
Disclosure of Invention
In order to solve the problems in the prior art, the present disclosure provides a method of the present invention that includes various sequence elements that promote and maintain the expression of a foreign gene, so as to ensure long-term high-level expression of the foreign gene.
Accordingly, in one aspect, the present disclosure provides a regulatory nucleic acid molecule for enhancing gene expression, the regulatory nucleic acid molecule comprising, in 5 'to 3' order, a tripartite leader sequence (TPL) of an adenovirus and an enhancer element (eMLP) of a major late promoter of the adenovirus, wherein:
the tripartite leader sequence (TPL) of the adenovirus has a TPL sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4 or a sequence at least 85% identical thereto;
the enhancer element (eMLP) of the major late promoter of the adenovirus has an eMLP sequence selected from the group consisting of SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8 or a sequence having at least 85% identity thereto.
In one aspect, the present disclosure provides an expression vector comprising, in 5 'to 3' order:
(a) a promoter region;
(b) a 5' UTR region;
(c) a coding sequence encoding a polypeptide gene product;
(d) a polyadenylation region (polyA);
wherein the 5' UTR region comprises the aforementioned regulatory nucleic acid molecule;
the coding sequence is operably linked to the promoter region.
In one aspect, the present disclosure provides a recombinant virus comprising:
a) a capsid protein; and
b) the aforementioned expression vector.
In one aspect, the present disclosure provides a pharmaceutical composition comprising the aforementioned expression vector and/or recombinant virus and a pharmaceutically acceptable excipient.
In one aspect, the present disclosure provides an isolated host cell transfected or transduced with the aforementioned expression vector.
In one aspect, the disclosure provides an isolated host cell infected with the aforementioned recombinant virus.
In one aspect, the present disclosure provides a method for expressing a transgene in a mammalian cell, the method comprising contacting one or more mammalian cells with an amount of the foregoing expression vector and/or recombinant virus, wherein the secreted polypeptide is expressed in the one or more mammalian cells at a level.
In one aspect, the present disclosure provides a method for treating or preventing a disease in a mammal in need of such treatment or prevention, the method comprising administering to the mammal an effective amount of the aforementioned expression vector, recombinant virus, pharmaceutical composition, and/or host cell.
The invention can obviously improve the expression level of the aflibercept, and can improve the expression level of intracellular aflibercept protein by more than ten times and improve the protein level of secreted aflibercept by several times compared with a vector which uses a pure CMV promoter/enhancer to start an aflibercept expression frame.
Drawings
Figure 1 shows the structure of the AO expression vector of the present disclosure.
FIG. 2 shows the levels of Aflibercept protein in cells after transfection of the Aflibercept expression vector into 293T cells (FIG. 2A) and ARPE-19 cells (FIG. 2B).
FIG. 3 shows the levels of Aflibercept protein in the supernatant after transfection of Aflibercept expression vectors into 293T cells (FIG. 2A) and ARPE-19 cells (FIG. 2B).
FIG. 4 shows the levels of aflibercept protein in cells following AAV virus infection of ARPE-19 cells.
FIG. 5A shows the average AAV genomic copy number in a cell after AAV virus infection of ARPE-19 cells; FIG. 5B shows secreted Aflibercept protein levels in the supernatant for each AAV genomic copy in cells following AAV infection in ARPE-19 cells.
FIG. 6 shows the correlation analysis of intracellular and secreted Aflibercepts following transfection of Aflibercept expression vectors or infection of 293T cells and ARPE-19 cells with AAV virus.
FIG. 7 shows intracellular and secreted Aflibercept protein levels following injection of AO virus into BN rat retinas, where BLK is a control rat eyeball draw sample without AO virus injection; b2_20R, B2_21R and B2_22R are obtained from the eyeball of a rat injected with AO-1 virus; b2_26R, B2_26L and B2_29L are obtained from the eyeball of a rat injected with AO-2 virus; b2_30L, B2_31L and B2_32R are obtained from the eyeball of a rat injected with AO-3 virus; b2_37R, B2_36L, B2_38R and B2_39L are obtained from the eyeball of a rat injected with AO-4 virus.
Detailed Description
Definition of
In the present invention, unless otherwise specified, scientific and technical terms used herein have the meanings that are commonly understood by those skilled in the art. Also, protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology related terms, and laboratory procedures used herein are all terms and conventional procedures used extensively in the relevant art. Meanwhile, in order to better understand the present invention, the definitions and explanations of related terms are provided below.
As used herein, "carrier" refers to a macromolecule or association of macromolecules that includes or is associated with a polynucleotide and can be used to mediate delivery of the polynucleotide to a cell. Illustrative vectors include, for example, plasmids, viral vectors (i.e., viruses such as adeno-associated virus), liposomes, and other gene delivery vehicles.
The term "AAV" is an abbreviation for adeno-associated virus, and can be used to refer to the virus itself or derivatives thereof. The term encompasses all subtypes as well as naturally occurring and recombinant forms, unless otherwise required. The term "AAV" encompasses AAV type 1 (AAV-1), AAV type 2 (AAV-2), AAV type 3 (AAV-3), AAV type 4 (AAV-4), AAV type 5 (AAV-5), AAV type 6 (AAV-6), AAV type 7 (AAV-7), AAV type 8 (AAV-8), avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, and ovine AAV. "primate AAV" refers to AAV infecting a primate, "non-primate AAV" refers to AAV infecting a non-primate mammal, and "bovine AAV" refers to AAV infecting a bovine mammal, and the like.
An "AAV virus" or "AAV viral particle" or "rAAV vector particle" refers to a viral particle composed of at least one AAV capsid protein (typically composed of all capsid proteins of a wild-type AAV) and an encapsidation polynucleotide. If the particle includes a heterologous polynucleotide (i.e., a polynucleotide other than the wild-type AAV genome, such as a transgene to be delivered to a mammalian cell), it is often referred to as a recombinant AAV vector or rAAV. Typically, the heterologous polynucleotide is flanked by AAV Inverted Terminal Repeats (ITRs).
As used herein, the term "replication defective" with respect to an AAV viral vector of the present invention means that the AAV vector is unable to independently replicate and package its genome. For example, when a subject's cells are infected with rAAV virions, the heterologous gene is expressed in the infected cells, however, rAAV cannot replicate further due to the fact that the infected cells lack AAV rep and cap genes and helper function genes.
As used herein, an "AAV variant" or "AAV mutant" refers to a viral particle comprised of a variant AAV capsid protein, wherein the variant AAV capsid protein comprises at least one amino acid difference (e.g., amino acid substitution, amino acid insertion, amino acid deletion) relative to a corresponding parental AAV capsid protein, and wherein the variant capsid protein confers increased infectivity to retinal cells compared to the infectivity of retinal cells of an AAV virion comprising the corresponding parental AAV capsid protein, wherein the AAV capsid protein does not comprise the amino acid sequences present in naturally occurring AAV capsid proteins. The polynucleotide expression vectors of the present disclosure can be packaged in variant AAV particles to facilitate delivery of the expression vectors to specific cell types (e.g., retinal cells) in a target tissue.
As used herein, the term "packaging" refers to a series of intracellular events that result in the assembly and encapsidation of AAV particles.
As used herein, the terms AAV "rep" and "cap" gene refer to polynucleotide sequences encoding replication and encapsidation proteins of adeno-associated virus. AAV rep and cap are referred to herein as AAV "packaging genes".
As used herein, the term "helper virus" of an AAV refers to a virus that allows mammalian cells to replicate and package the AAV (e.g., a wild-type AAV). A variety of such helper viruses for AAV are known in the art, including adenovirus, herpesvirus, and poxvirus (e.g., vaccinia). Although adenovirus type 5 of subgroup C is most commonly used, adenoviruses encompass many different subgroups. Many adenoviruses of human, non-human mammalian and avian origin are known and available from stores such as the ATCC. Viruses of the herpes family include, for example, Herpes Simplex Virus (HSV) and Epstein-Barr virus (EBV) as well as Cytomegalovirus (CMV) and pseudorabies virus (PRV); also available from depositories such as ATCC.
As used herein, the term "helper viral function" refers to a function encoded in the helper viral genome that allows replication and packaging of AAV (along with other requirements for replication and packaging as described herein). As described herein, "helper virus functions" can be provided in a variety of ways, including by providing helper viruses or providing production cells with, for example, trans polynucleotide sequences encoding essential functions. For example, a plasmid or other expression vector comprising a nucleotide sequence encoding one or more adenoviral proteins is transfected into a producer cell along with a rAAV vector.
As used herein, the term "gene" or "coding sequence" refers to a nucleotide sequence that encodes a gene product in vitro or in vivo. The term "transgene" refers to a coding sequence or gene that is delivered into a cell by a vector. The coding sequence or gene may encode a peptide or polypeptide molecule.
As used herein, "therapeutic gene" and "therapeutic protein" refer to a gene or protein that, when expressed, confers a beneficial effect on the cell or tissue or mammal in which it is present, in which it is expressed. Examples of beneficial effects can be alleviation or amelioration of signs or symptoms of a condition or disease, prevention or inhibition of a condition or disease, or imparting a desired characteristic. Therapeutic genes and proteins include genes and proteins that correct genetic defects in a cell or mammal.
A "therapeutically effective amount" or "effective amount" of an expression vector, recombinant virus, or pharmaceutical composition of the invention is an amount sufficient to cause a reduction in one or more signs or symptoms of a disease or medical condition in a subject, wherein the subject can be a human or non-human mammal.
As used herein, the term "gene product" refers to the desired expression product of a polynucleotide sequence (e.g., a peptide or protein).
As used herein, the terms "polypeptide" and "protein" refer to polymers of amino acids of any length. The term "peptide" refers to a polymer of amino acids of about 50 amino acids or less. The term also encompasses amino acid polymers that have been modified as by, for example, disulfide bond formation, glycosylation, lipidation, or phosphorylation. In some examples, the polypeptide can have a length of greater than 50 amino acids.
As used herein, a "secreted protein" or "secreted polypeptide" of a "secreted protein" is any protein secreted by or exported from a living cell. One non-limiting example of a secreted protein for use with the presently described expression vectors is sFLT-1.
"comprising" means that the listed elements are, for example, essential in the compositions, methods, kits, etc., but that other elements may be included to form, for example, the compositions, methods, kits, etc., within the scope of the claims. For example, an expression vector that "comprises" a gene encoding a therapeutic polypeptide operably linked to a promoter is one that may contain elements other than the gene and promoter (e.g., polyadenylation sequences, enhancer elements, other genes, linker domains, etc.).
"consisting essentially of … …" is intended to mean a limitation on the scope of a particular material or step described, e.g., as a composition, method, kit, etc., that does not materially affect one or more of the basic and novel characteristics of the composition, method, kit, etc. For example, an expression vector "consisting essentially of" a gene encoding a therapeutic polypeptide operably linked to a promoter and polyadenylation sequence may comprise additional sequences, e.g., linker sequences, so long as they do not substantially affect the transcription or translation of the gene. As another example, a variant or mutant polypeptide fragment "consisting essentially of" the recited sequence has an amino acid sequence of the sequence plus or minus about 10 amino acid residues at the boundaries of the sequence based on the full-length untreated polypeptide from which it is derived, e.g., 10, 9, 8, 7,6, 5,4, 3,2, or 1 fewer than the binding amino acid residues or 1, 2,3, 4,5, 6, 7,8, 9, or 10 more residues than the binding amino acid residues.
"consisting of … …" means that any element, step, or ingredient not specified in the claims is excluded from the composition, method, or kit. For example, an expression vector "consisting of" a gene encoding a therapeutic polypeptide operably linked to a promoter and a polyadenylation sequence "consists of only the promoter, the polynucleotide sequence encoding the therapeutic polypeptide, and the polyadenylation sequence. As another example, a polypeptide "consisting of" a recited sequence contains only the recited sequence.
As used herein, "expression vector" is intended to encompass vectors, e.g., plasmids, minicircles, viral vectors, liposomes, etc., that encode a gene product of interest and are used to deliver the polynucleotide to the intended target cell.
As used herein, "promoter" encompasses a DNA sequence that directs RNA polymerase to bind and thereby promote RNA synthesis. Promoters and corresponding protein or polypeptide expression may be ubiquitous (meaning having strong activity in a wide range of cells, tissues and species) or cell type specific, tissue specific or species specific. Promoters may be "constitutive" (meaning persistently active) or "inducible" (meaning that the promoter may be activated or inactivated by the presence or absence of a biological or non-biological agent). Also included in the nucleic acid constructs or vectors of the invention are enhancer sequences, which may or may not be contiguous with the promoter sequence. Enhancer sequences affect promoter-dependent gene expression and may be located in the 5 'region or the 3' region of the native gene.
As used herein, "enhancer" encompasses cis-acting elements that stimulate or inhibit transcription of adjacent genes. Enhancers that inhibit transcription are also referred to as "silencers". Enhancers can function in either orientation at a distance of a few thousand base pairs (kb) from the coding sequence and a position downstream of the transcribed region (i.e., can be related to the coding sequence).
As used herein, "polyadenylation signal sequence" encompasses the recognition region required for endonuclease cleavage of an RNA transcript, followed by the polyadenylation consensus sequence AATAAA. The polyadenylation signal sequence provides a "polyA site", i.e., a site on the RNA transcript to which adenine residues will be added by post-transcriptional polyadenylation.
As used herein, the term "operably linked" refers to the juxtaposition of genetic elements (e.g., promoters, enhancers, termination signal sequences, polyadenylation sequences, etc.) in a relationship permitting them to operate in the intended manner. For example, a promoter is operably linked to a coding region if it helps to initiate transcription of the coding sequence. Intervening residues may be present between the promoter and the coding region so long as this functional relationship is maintained.
As used herein, the term "heterologous" refers to an entity that is of a different genotype from the rest of the entity to which it is compared. For example, polynucleotides introduced into plasmids or vectors derived from different species by genetic engineering techniques are heterologous polynucleotides. As another example, a promoter removed from its native coding sequence and operably linked to a coding sequence not found in nature is a heterologous promoter. Thus, for example, a rAAV comprising a heterologous nucleic acid encoding a heterologous gene product is a rAAV comprising nucleic acid not normally comprised in a naturally-occurring wild-type AAV, and the encoded heterologous gene product is a gene product not normally encoded by a naturally-occurring wild-type AAV.
As used herein, the term "endogenous" with respect to a nucleotide molecule or gene product refers to a nucleic acid sequence (e.g., a gene or genetic element) or gene product (e.g., RNA, protein) that naturally occurs in or is associated with a host virus or cell.
As used herein, the term "native" refers to a nucleotide sequence (e.g., a gene) or a gene product (e.g., RNA, protein) that is present in a wild-type virus or cell.
As used herein, the term "variant" refers to a mutant of a reference polynucleotide or polypeptide sequence, e.g., a native polynucleotide or polypeptide sequence, i.e., having less than 100% sequence identity to the reference polynucleotide or polypeptide sequence. In other words, a polypeptide variant includes at least one amino acid difference (e.g., amino acid substitution, amino acid insertion, amino acid deletion) relative to a reference polypeptide sequence (e.g., a native polypeptide sequence), and a polynucleotide variant includes at least one nucleotide or nucleoside difference (e.g., nucleotide or nucleoside substitution, insertion, or deletion) relative to a reference polynucleotide sequence (e.g., a native polynucleotide sequence).
As used herein, the term "sequence identity" or "percent identity" refers to the degree of identity between two or more polynucleotides when aligned using a nucleotide sequence alignment program; or the degree of identity between two or more polypeptide sequences when aligned using an amino acid sequence alignment program. Similarly, the term "identical" or percent "identity," when used in the context of two or more nucleotides or amino acid sequences, refers to two sequences that are the same or have a particular percentage of amino acid residues or nucleotides when compared and aligned for maximum correspondence, e.g., as measured using a sequence comparison algorithm (e.g., Smith-Waterman algorithm, etc.) or by visual inspection. For example, percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (1970, journal of molecular biology (J.mol. biol.), 48:444-453) algorithm, which has been incorporated into the GAP program in the GCG software package, using either the Blossum62 matrix or the PAM250 matrix with GAP weights of 16, 14, 12, 10, 8, 6, or 4 and length weights of 1, 2,3, 4,5, or 6. As another example, the percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package, using the nwsgapdna. cmp matrix and GAP weights of 40, 50, 60, 70, or 80 and length weights of 1, 2,3, 4,5, or 6. A particularly preferred set of parameters (which should be used unless otherwise specified) is the Blossum62 scoring matrix, a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5. Percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of e.meyers and w.miller (1989, computer applications in bioscience (cabaos), 4:11-17), which has been incorporated into the ALIGN program (version 2.0), using the PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The nucleic acid and protein sequences described herein can be used as "query sequences" to search public databases to, for example, identify other family members or related sequences. This search can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul et al (1990, journal of molecular biology, 215: 403-10). A BLAST nucleotide search can be performed using NBLAST program (score 100, word length 12) to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed using the XBLAST program (score 50, word length 3) to obtain amino acid sequences homologous to the protein molecules of the invention. To obtain gapped alignments for comparison purposes, gapped BLAST as described in Altschul et al (1997, Nucleic Acids Res., 25: 3389-. When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.
As used herein, the terms "biological activity" and "biological activity" refer to an activity attributed to a particular biological element in a cell. For example, "biological activity" of an "immunoglobulin", "antibody" or fragment or variant thereof refers to the ability to bind an antigenic determinant and thereby promote immune function. As another example, the biological activity of a polypeptide or functional fragment or variant thereof refers to the ability of the polypeptide or functional fragment or variant thereof to perform its native function, e.g., binding, enzymatic activity, etc. As a third example, the biological activity of a gene regulatory element (e.g., promoter, enhancer, kozak sequence, etc.) refers to the ability of the regulatory element, or a functional fragment or variant thereof, respectively, to regulate the expression of (i.e., promote, enhance, or activate translation of) a gene to which it is operably linked.
As used herein, the term "administration" or "introducing" refers to the delivery of a vector for recombinant protein expression to a cell, a cell and/or an organ of a subject, or a subject. Such administration or introduction may occur in vivo, in vitro, or ex vivo. The vector for expressing the gene product can be introduced into the cell by transfection, which generally means insertion of heterologous DNA into the cell by physical means (e.g., calcium phosphate transfection, electroporation, microinjection, or lipofection); or by infection or transduction, which generally refers to the introduction of a nucleic acid molecule into a cell by an infectious agent (i.e., a virus or viral vector).
In general, a cell is referred to as "transduced", "infected", "transfected" or "transformed" according to the method used to administer, introduce or insert the heterologous DNA (i.e., vector) to the cell. When DNA is introduced into a cell by a virus or viral vector, the cell is transduced with exogenous or heterologous DNA. When DNA is introduced into a cell by non-viral methods, the cell is transfected with exogenous or heterologous DNA. Non-viral methods include chemical methods (e.g., lipofection) and non-chemical methods. The terms "transduced" and "infected" are used interchangeably herein to refer to a cell that has received heterologous DNA or a heterologous polynucleotide from a virus or viral vector.
As used herein, the term "host cell" refers to a cell that has been transduced, infected, transfected or transformed with a vector. The vector may be a plasmid, a viral particle, a phage, or the like. Culture conditions (e.g., temperature, pH, etc.) are those previously used with the host cell selected for expression, and will be apparent to those skilled in the art. It is understood that the term "host cell" refers to the originally transduced, infected, transfected or transformed cell and its progeny.
The terms "treatment" and "treating" refer to the alleviation of one or more signs or symptoms of a disease or disorder.
The terms "disease," "disorder," and "medical condition" are synonymous and are used interchangeably herein.
"ocular disease" refers to a disease, illness, or condition that affects or involves the eye or one or more portions or regions of the eye. Thus, ocular diseases include retinal diseases or diseases that affect the light sensitive layer of the posterior tissues of the eye. The eye contains the eyeball and the tissues and fluids that make up the eyeball, the periocular muscles (e.g., the oblique and rectus muscles), and the portion of the optic nerve within or near the eyeball.
A tissue "explant" is a piece of tissue that has been transferred from an animal to a nutrient medium.
The terms "individual", "host", "subject" and "patient" are used interchangeably herein and refer to a mammal, including but not limited to: human and non-human primates, including apes and humans; mammalian sport animals (e.g., horses); mammalian farm animals (e.g., sheep, goats, etc.); mammalian pets (dogs, cats, etc.); and rodents (e.g., mice, rats, etc.).
Various compositions and methods of the invention are described below. Although specific compositions and methods are exemplified herein, it should be understood that any of a number of alternative compositions and methods are suitable and suitable for practicing the present invention. It will also be appreciated that the expression constructs and methods of the invention can be evaluated using standard procedures in the art.
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry and immunology, which are within the skill of the art. Such techniques are well described in the literature, e.g., molecular cloning: a laboratory Manual (Molecular Cloning: A laboratory Manual), second edition (Sambrook et al, 1989); oligonucleotide Synthesis (oligo Synthesis) (edited by m.j. gate, 1984); animal Cell Culture (Animal Cell Culture), edited by r.i. freshney, 1987; methods in Enzymology (Methods in Enzymology), Academic Press, Inc.; handbook of experimental immunology (edited by d.m.weir and c.c.blackwell); gene Transfer Vectors for Mammalian Cells (Gene Transfer Vectors for Mammarian Cells) (edited by J.M.Miller and M.P.Calos, 1987); current Protocols in molecular Biology (Current Protocols in molecular Biology) (edited by F.M. Ausubel et al, 1987); PCR: polymerase Chain Reaction (PCR: the polymerase Chain Reaction), ed (edited by Mullis et al, 1994); and Current protocols in Immunology (J.E. Coligan et al, 1991), each of which is expressly incorporated herein by reference.
Several aspects of the invention are described below with reference to example applications for illustration. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the invention. One skilled in the relevant art will readily recognize, however, that the invention can be practiced without one or more of the specific details, or with other methods. The present invention is not limited by the illustrated ordering of acts or events, as some acts may occur in different orders and/or concurrently with other acts or events. Moreover, not all illustrated acts or events are required to implement a methodology in accordance with the present invention.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Furthermore, to the extent that the terms "includes", "including", "includes", "having", "has", "with", or variants thereof are used in the detailed description and/or the claims, such terms are intended to be inclusive (in a manner similar to the term "comprising").
The terms "about" or "approximately" mean that the particular value determined by one of ordinary skill in the art is within an acceptable error range, which will depend in part on how the value is measured or determined, i.e., limited by the measurement system. For example, "about" can mean within 1 or a standard deviation of greater than 1, according to practice in the art. Alternatively, "about" or "approximately" may mean a range of up to 20%, preferably up to 10%, more preferably up to 5% and more preferably still up to 1% of a given value. Alternatively, particularly for biological systems or methods, the term may mean within an order of magnitude of a value, preferably within 5-fold and more preferably within 2-fold of the value. When particular values are described in the present application and claims, unless otherwise specified, it should be assumed that the term "about" means within an acceptable error range for the particular value.
All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. It should be understood that in case of conflict, the present disclosure supersedes any disclosure incorporated herein.
It is further noted that the claims may be drafted to exclude any optional element. Accordingly, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only," etc. in connection with the recitation of claim elements, or use of a "negative type" limitation.
The disclosure in the publications discussed herein is provided solely for their purpose of illustration prior to the filing date of the present application. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such publication by virtue of prior invention. In addition, the dates of publication provided may be different from the actual publication dates which may need to be independently determined.
Unless otherwise indicated, all terms used herein have the same meaning as they would to one skilled in the art and the practice of the present invention will employ conventional techniques of microbiology and recombinant DNA technology, which are within the knowledge of one skilled in the art.
Detailed description of the preferred embodiments
In one aspect, the present disclosure provides a regulatory nucleic acid molecule for enhancing gene expression, the regulatory nucleic acid molecule comprising, in 5 'to 3' order, a tripartite leader sequence (TPL) of an adenovirus and an enhancer element (eMLP) of a major late promoter of the adenovirus, wherein:
the tripartite leader sequence (TPL) of the adenovirus has a TPL sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4 or a sequence at least 85% identical thereto;
the enhancer element (eMLP) of the major late promoter of the adenovirus has an eMLP sequence selected from the group consisting of SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8 or a sequence having at least 85% identity thereto.
In some embodiments of the present disclosure, the regulatory nucleic acid molecule has a sequence selected from the group consisting of the sequences set forth in SEQ ID NOS 19-34 or a sequence having at least 85% identity thereto.
In some preferred embodiments of the present disclosure, the regulatory nucleic acid molecule has the sequence shown in SEQ ID No. 22, 25, 26 or 33 or a sequence having at least 85% identity thereto.
In some preferred embodiments of the present disclosure, the regulatory nucleic acid molecule has the sequence shown in SEQ ID NO. 26 or a sequence having at least 85% identity thereto.
In one aspect, the present disclosure provides an expression vector comprising, in 5 'to 3' order:
(a) a promoter region;
(b) a 5' UTR region;
(c) a coding sequence encoding a polypeptide gene product;
(d) a polyadenylation region (polyA);
wherein the 5' UTR region comprises the aforementioned regulatory nucleic acid molecule;
the coding sequence is operably linked to the promoter region.
In some embodiments of the disclosure, the (a) promoter region is selected from the group consisting of Cytomegalovirus (CMV) promoter, actin promoter, elongation factor 1 α (EF1 α) promoter, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter; the promoter region of (a) comprises the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity therewith.
In some embodiments of the disclosure, the polypeptide gene product is a therapeutic protein.
In some preferred embodiments of the present disclosure, the therapeutic protein is selected from an anti-angiogenic polypeptide or alpha-1 antitrypsin.
In some preferred embodiments of the present disclosure, the anti-angiogenic polypeptide comprises soluble fms-like tyrosine kinase-1 (sFLT-1) or a VEGF-binding fragment of sFLT-1.
In some preferred embodiments of the present disclosure, the anti-angiogenic polypeptide is aflibercept; preferably, the amino acid of aflibercept is shown in SEQ ID NO 10; more preferably, the nucleic acid encoding aflibercept is shown in SEQ ID NO 11.
In some embodiments of the disclosure, the polyadenylation region is selected from the human growth hormone (HGH or HGH), bovine growth hormone (BGH or BGH), or β -globin (β -globin) polyA sequences.
In some preferred embodiments of the present disclosure, the polyadenylation region comprises the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto.
In some embodiments of the present disclosure, the expression vector further comprises (i) a first enhancer region, said (i) first enhancer region being located upstream of said (a) promoter region.
In some preferred embodiments of the present disclosure, the (i) first enhancer region comprises a sequence selected from the CMV enhancer or the EF 1a enhancer.
In some preferred embodiments of the present disclosure, the (i) first enhancer region comprises the CMV enhancer sequence shown in SEQ ID NO. 13 or a sequence having at least 85% identity thereto.
In some embodiments of the present disclosure, the expression vector further comprises (ii) an intron region located downstream of the (b)5' UTR region and upstream of the (c) coding sequence encoding the polypeptide gene product.
In some preferred embodiments of the present disclosure, the (ii) intron region comprises a sequence selected from the SV40 intron, the elongation factor 1 α (EF1 α) intron, the actin intron, or the CMVc intron.
In some preferred embodiments of the present disclosure, the (ii) intron region comprises the SV40 intron sequence shown in SEQ ID NO:14 or a sequence having at least 85% identity thereto.
In some embodiments of the present disclosure, the expression vector further comprises (iii) a second enhancer region located downstream of the (c) coding sequence encoding the polypeptide gene product and upstream of the (d) polyadenylation region.
In some preferred embodiments of the present disclosure, the (iii) second enhancer region comprises an Expression Enhancer Sequence (EES).
In some preferred embodiments of the present disclosure, the (iii) second enhancer region comprises a Scaffold Attachment Region (SAR) of interferon.
In some preferred embodiments of the present disclosure, the scaffold attachment region Sequence (SAR) is the human scaffold attachment region of human interferon-beta (IFNB SAR).
In some preferred embodiments of the present disclosure, the human interferon-beta human scaffold attachment region (IFNB SAR) comprises the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto.
In some embodiments of the disclosure, the expression vector further comprises an Inverted Terminal Repeat (ITR) at the 5 'end of (iv) upstream of the (i) first enhancer and an Inverted Terminal Repeat (ITR) at the 3' end of (v) downstream of the (d) polyadenylation region.
In some preferred embodiments of the present disclosure, the (iv) Inverted Terminal Repeat (ITR) at the 5 'end or the (v) Inverted Terminal Repeat (ITR) at the 3' end comprises an Inverted Terminal Repeat (ITR) selected from Adenovirus (AV) or adeno-associated virus (AAV);
in some preferred embodiments of the present disclosure, the (iv)5' Inverted Terminal Repeat (ITR) comprises the AAV ITR shown in SEQ ID NO 16 or a sequence having at least 85% identity thereto.
In some preferred embodiments of the present disclosure, the (v) Inverted Terminal Repeat (ITR) at the 3' terminus comprises the AAV ITR shown in SEQ ID NO:17 or a sequence having at least 85% identity thereto.
In some embodiments of the present disclosure, the expression vector further comprises (vi) a selectable marker gene.
In some preferred embodiments of the present disclosure, the (vi) selectable marker gene is located downstream of the Inverted Terminal Repeat (ITR) at the 3' end of (v).
In some preferred embodiments of the present disclosure, the (vi) selectable marker gene is selected from the group consisting of an ampicillin resistance gene, a hygromycin resistance gene, a neomycin resistance gene, a bialaphos resistance gene, and a dihydrofolate reductase gene.
In some preferred embodiments of the present disclosure, the ampicillin resistance gene comprises the sequence shown as SEQ ID NO 18 or a sequence having at least 85% identity thereto.
In some embodiments of the disclosure, the expression vector comprises, 5 'to 3':
(i) a first enhancer region comprising the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto;
(a) a promoter region comprising the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity thereto;
(b) a 5'UTR region, the 5' UTR region comprising a regulatory nucleic acid molecule consisting of the TPL sequence shown in SEQ ID NO. 2 and the eMLP sequence shown in SEQ ID NO. 8 or a sequence having at least 85% identity thereto;
(c) a coding sequence encoding a polypeptide gene product;
(iii) a second enhancer region comprising the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto; and
(d) a polyadenylation region comprising the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto, and
optionally wherein the expression vector does not comprise an RNA export signal.
In some embodiments of the disclosure, the expression vector comprises, 5 'to 3':
(i) a first enhancer region comprising the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto;
(a) a promoter region comprising the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity thereto;
(ii) an intron region comprising the SV40 intron sequence shown as SEQ ID NO. 14 or a sequence having at least 85% identity thereto;
(b) a 5'UTR region, the 5' UTR region comprising a regulatory nucleic acid molecule consisting of the TPL sequence shown in SEQ ID NO. 2 and the eMLP sequence shown in SEQ ID NO. 8 or a sequence having at least 85% identity thereto;
(c) a coding sequence encoding a polypeptide gene product, wherein the coding sequence is operably linked to the promoter region;
(iii) a second enhancer region comprising the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto;
(d) a polyadenylation region comprising the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto.
In some embodiments of the disclosure, the expression vector comprises, 5 'to 3':
(iv) an Inverted Terminal Repeat (ITR) at the 5 'end, the Inverted Terminal Repeat (ITR) at the 5' end comprising the AAV ITR set forth in SEQ ID NO 16 or a sequence having at least 85% identity thereto;
(i) a first enhancer region comprising the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto;
(a) a promoter region comprising the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity thereto;
(ii) an intron region comprising the SV40 intron sequence shown as SEQ ID NO. 14 or a sequence having at least 85% identity thereto;
(b) a 5'UTR region, the 5' UTR region comprising a regulatory nucleic acid molecule consisting of the TPL sequence shown in SEQ ID NO. 2 and the eMLP sequence shown in SEQ ID NO. 8 or a sequence having at least 85% identity thereto;
(c) a coding sequence encoding a polypeptide gene product;
(iii) a second enhancer region comprising the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto;
(d) a polyadenylation region comprising the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto.
In some embodiments of the disclosure, it comprises, 5 'to 3':
(iv) an Inverted Terminal Repeat (ITR) at the 5 'end, the Inverted Terminal Repeat (ITR) at the 5' end comprising the AAV ITR set forth in SEQ ID NO 16 or a sequence having at least 85% identity thereto;
(i) a first enhancer region comprising the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto;
(a) a promoter region comprising the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity thereto;
(ii) an intron region comprising the SV40 intron sequence shown as SEQ ID NO. 14 or a sequence having at least 85% identity thereto;
(b) a 5'UTR region, the 5' UTR region comprising a regulatory nucleic acid molecule consisting of the TPL sequence shown in SEQ ID NO. 2 and the eMLP sequence shown in SEQ ID NO. 8 or a sequence having at least 85% identity thereto;
(c) a coding sequence encoding a polypeptide gene product;
(iii) a second enhancer region comprising the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto;
(d) a polyadenylation region comprising the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto;
(v) (iv) a 3 'terminal Inverted Terminal Repeat (ITR), said (v)3' terminal Inverted Terminal Repeat (ITR) comprising the AAV ITR set forth in SEQ ID NO:17 or a sequence having at least 85% identity thereto.
In some embodiments of the disclosure, it comprises, 5 'to 3':
(iv) an Inverted Terminal Repeat (ITR) at the 5 'end, the Inverted Terminal Repeat (ITR) at the 5' end comprising the AAV ITR set forth in SEQ ID NO 16 or a sequence having at least 85% identity thereto;
(i) a first enhancer region comprising the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto;
(a) a promoter region comprising the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity thereto;
(ii) an intron region comprising the SV40 intron sequence shown as SEQ ID NO. 14 or a sequence having at least 85% identity thereto;
(b) a 5'UTR region, the 5' UTR region comprising a regulatory nucleic acid molecule consisting of the TPL sequence shown in SEQ ID NO. 2 and the eMLP sequence shown in SEQ ID NO. 8 or a sequence having at least 85% identity thereto;
(c) a coding sequence encoding a polypeptide gene product, which is aflibercept; preferably, the amino acid of aflibercept is shown in SEQ ID NO 10; more preferably, the nucleic acid encoding aflibercept (aflibercept) is shown in SEQ ID NO 11;
(iii) a second enhancer region comprising the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto;
(d) a polyadenylation region comprising the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto;
(v) (iv) a 3 'terminal Inverted Terminal Repeat (ITR), said (v)3' terminal Inverted Terminal Repeat (ITR) comprising the AAV ITR set forth in SEQ ID NO:17 or a sequence having at least 85% identity thereto.
In some preferred embodiments of the present disclosure, the expression vector comprises the sequence shown as SEQ ID NO 35, 36, 37 or 38 or a sequence having at least 85% identity thereto.
In some preferred embodiments of the present disclosure, the expression vector comprises the sequence shown as SEQ ID No. 36 or a sequence having at least 85% identity thereto.
In one aspect, the present disclosure provides a recombinant virus comprising:
a) a capsid protein; and
b) the aforementioned expression vector.
In some embodiments of the present disclosure, the recombinant virus is a recombinant adeno-associated virus; preferably, the adeno-associated virus is selected from the group consisting of AAV type 1 (AAV-1), AAV type 2 (AAV-2), AAV type 3 (AAV-3), AAV type 4 (AAV-4), AAV type 5 (AAV-5), AAV type 6 (AAV-6), AAV type 7 (AAV-7), AAV type 8 (AAV-8), avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, and ovine AAV.
In some preferred embodiments of the present disclosure, the adeno-associated virus is selected from AAV type 5 (AAV-5) or AAV type 6 (AAV-6).
In some preferred embodiments of the present disclosure, the capsid protein is an AAV variant 7m8 capsid protein or is derived from the AAV variant 7m8 capsid protein.
In one aspect, the present disclosure provides a pharmaceutical composition comprising the aforementioned expression vector and/or recombinant virus and a pharmaceutically acceptable excipient.
In one aspect, the present disclosure provides an isolated host cell transfected or transduced with the aforementioned expression vector.
In one aspect, the disclosure provides an isolated host cell infected with the aforementioned recombinant virus.
In one aspect, the present disclosure provides a method for expressing a transgene in a mammalian cell, the method comprising contacting one or more mammalian cells with an amount of the foregoing expression vector and/or recombinant virus, wherein the secreted polypeptide is expressed in the one or more mammalian cells at a level.
In one aspect, the present disclosure provides a method for treating or preventing a disease in a mammal in need of such treatment or prevention, the method comprising administering to the mammal an effective amount of the aforementioned expression vector, recombinant virus, pharmaceutical composition, and/or host cell.
In some preferred embodiments of the present disclosure, the disease is an ocular disease and the pharmaceutical composition is administered to the eye of the mammal.
In some preferred embodiments of the present disclosure, the pharmaceutical composition is administered to the eye of the mammal by intraocular injection or intravitreal injection.
In some preferred embodiments of the present disclosure, the ocular disease is selected from the group consisting of age-related macular degeneration (AMD), wet AMD, dry AMD, retinal neovascularization, choroidal neovascularization, and diabetic retinopathy.
In one aspect, the present disclosure provides the use of the aforementioned expression vectors, recombinant viruses, pharmaceutical compositions, and/or host cells in the preparation of a medicament for treating or preventing a disease in a mammal in need of treatment or prevention of the disease.
In some preferred embodiments of the present disclosure, the disease is an ocular disease and the pharmaceutical composition is administered to the eye of the mammal.
In some preferred embodiments of the present disclosure, the pharmaceutical composition is administered to the eye of the mammal by intraocular injection or intravitreal injection.
In some preferred embodiments of the present disclosure, the ocular disease is selected from the group consisting of age-related macular degeneration (AMD), wet AMD, dry AMD, retinal neovascularization, choroidal neovascularization, and diabetic retinopathy.
In some aspects of the disclosure, compositions for expressing a transgene in one or more eukaryotic cells are provided. In some aspects, the eukaryotic cell is a mammalian cell. In some aspects, the mammalian cell is a retinal cell, such as a retinal ganglion cell, amacrine cell, horizontal cell, bipolar cell, photoreceptor cell, cone cell, rod cell, muller glial cell, or retinal pigment epithelial cell.
In some embodiments of the disclosure, the composition is an expression vector. "expression vector" refers to a polynucleotide sequence, e.g., regulatory elements, translation initiation sequences, coding sequences, termination sequences, and the like, typically operably linked to each other, comprising two or more functional polynucleotide sequences. Typically, the polynucleotide sequence is comprised of DNA. Likewise, "expression vector for expressing a transgene in a mammalian cell" refers to a combination of two or more functional polynucleotide sequences (e.g., promoters, enhancers, 5' UTRs, switch initiation sequences, coding sequences, termination sequences, etc.) that facilitate expression of the transgene in the cell.
In some embodiments, the expression vectors of the present disclosure provide for enhanced expression of a transgene in a mammalian cell. In certain embodiments, the arrangement of two or more functional polynucleotide sequences within an expression vector of the present disclosure provides for enhanced expression of a transgene in a mammalian cell. By "enhanced" is meant that expression of the transgene is increased, enhanced, or greater in a cell carrying an expression vector of the present disclosure relative to a cell carrying a transgene operably linked to a comparable regulatory element. In other words, transgene expression by an expression vector of the present disclosure is increased, enhanced, or stronger relative to expression by an expression vector that does not include one or more optimized elements of the present disclosure (i.e., a reference control vector, such as a CMV reference control vector as described herein). In certain embodiments, the expression enhancement is specific for or limited to one or more desired cell types. In one embodiment, the transgene encodes a protein that is secreted by the cell into the aqueous environment surrounding the cell.
For example, expression of a transgene in a cell comprising an expression vector disclosed herein comprising a promoter may be enhanced, or stronger than expression of the transgene in a cell carrying a transgene operably linked to a different promoter. As another example, expression of a transgene in a cell comprising an expression vector disclosed herein including an enhancer sequence may be enhanced, or increased, enhanced, or stronger than expression of the transgene in a cell carrying a transgene operably linked to a different enhancer sequence. As another example, expression of a transgene in a cell comprising an expression vector encoding a 5'UTR disclosed herein can be enhanced, or increased, enhanced, or stronger than expression of the transgene in a cell carrying a transgene operably linked to a different 5' UTR coding sequence. As another example, expression of a transgene in a cell comprising an expression vector disclosed herein comprising an intron can be enhanced, or increased, enhanced, or stronger than expression of the transgene in a cell carrying a transgene operably linked to a different intron sequence. In yet another example, expression of the transgene in a cell comprising an expression vector comprising an intron disclosed herein can be enhanced, or increased, potentiated, or stronger than expression of the transgene in a cell carrying a transgene operably linked to a reference control vector (such as a CMV reference control vector disclosed herein).
In preferred embodiments, the polynucleotide expression vector promotes expression of the transgene (or a higher level of expression compared to a reference vector) in one or more specific cell or tissue types in vitro and in vivo. Examples of cell types include, but are not limited to, HeLa cells, HEK-293 cells, ARPE-19 cells (human retinal pigment epithelial cell line), retinal ganglion cells, amacrine cells, horizontal cells, bipolar cells, photoreceptor cells, cone cells, rod cells, Muller glia cells, and retinal pigment epithelial cells. In another embodiment, increased expression is observed in cells of a retinal tissue explant.
In some embodiments, the expression of the secreted polypeptide by the expression vector in the mammalian cell is at least about 2-fold, 3-fold, 5-fold, 9-fold, 10-fold, 20-fold, or 50-fold greater than the expression of the secreted polypeptide by the reference vector in the mammalian cell in vitro or in vivo. More typically, the expression of the secreted polypeptide is 2 to 10 fold, 5 to 10 fold, 9 to 10 fold, at least 2 fold, at least 5 fold, or at least 10 fold greater than the expression of the polypeptide in a mammalian cell by a reference vector. In other words, the expression vector expresses the secreted protein in mammalian cell culture at a level that is at least or greater than 2-fold, 5-fold, 10-fold, 50-fold, or about 5-fold to about 10-fold greater than the level of expression obtained by the reference vector in mammalian cell culture.
Without wishing to be bound by theory, it is believed that enhanced expression of the transgene in the intracellular or extracellular environment (e.g., culture supernatant or tissue matrix) results from faster accumulation of the gene product in the cell or a more stable gene product in the cell. Thus, enhanced transgene expression by the expression vectors of the present disclosure can be observed in a variety of ways. For example, if a transgene is operably linked to comparable regulatory elements (such as those in a CMV reference control vector as described herein), enhanced expression can be observed by detecting expression of the transgene, followed by detecting exposure of the expression vector to the cell earlier than expressed (e.g., 7 days, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks or more earlier than expressed). Enhanced expression with increasing amounts of gene product per cell can also be observed. For example, the amount of gene product per mammalian cell may be increased 2-fold or more, e.g., increased 3-fold or more, increased 4-fold or more, increased 5-fold or more, or increased 10-fold or more. Enhanced expression may also be observed with increasing numbers of mammalian cells expressing detectable levels of the transgene carried by the expression vector. For example, the number of mammalian cells expressing detectable levels of the transgene may be increased 2-fold or more, e.g., increased 3-fold or more, increased 4-fold or more, increased 5-fold or more, or increased 10-fold or more. As another example, the polynucleotides of the invention can promote detectable levels of transgenes in a greater percentage of cells compared to conventional expression vectors; for example, while a conventional vector can promote detectable levels of transgene expression, e.g., in less than 5% of the cells in a region, a polynucleotide of the invention promotes detectable levels of expression in 5% or more of the cells in the region; for example, 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, in some cases 50% or more, 55% or more of the contact; 60% or more, 65% or more, 70% or more, 75% or more (e.g., 80% or more, 85% or more, 90% or more, 95% or more) of the cells will express a detectable level of the gene product. Enhanced expression with altered cell viability and/or function may also be observed.
Expression vectors of the present disclosure typically include a promoter region. In certain embodiments, the promoter region promotes expression of the coding sequence in mammalian cells. In some cases, the promoter is a ubiquitous promoter, i.e., it is a promoter that is active in a wide range of cells, tissues and species. Suitable examples include actin, Cytomegalovirus (CMV), elongation factor 1 α (EF1 α), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoters.
In some embodiments, the polynucleotide comprises one or more enhancers. Enhancers are nucleic acid elements that enhance transcription. In some embodiments, the expression vector includes a first enhancer upstream of the coding sequence and a second enhancer downstream of the coding sequence. Suitable exemplary enhancers include, but are not limited to, EF1 α, CMV, intact EES or portions thereof, such as 410-564EES or 511-810 EES. EES (expression enhancer sequence) corresponds to the human scaffold attachment region of human interferon-beta or SAR (Agarwal, M et al (1998) "enhancement of retroviral vector expression in primary T cells mediated by the scaffold attachment region" [ J. virol.) ] 72 (5: 3720-. The nuclear scaffold binding region (SAR) is an AT-rich stretch of DNA sequence, also known as the Matrix Attachment Region (MAR). Researches show that the SAR region sequence of human interferon gene is added in the expression frame of exogenous gene, which is beneficial to preventing methylation silencing of exogenous gene and maintaining long-term stable expression of exogenous gene.
The Tripartite leader sequence (TPL) of adenovirus is the UTR sequence at the 5' end of the major late transcribed mRNA of adenovirus, and research shows that the TPL sequence can promote translation of mRNA, and the translation level of the mRNA containing the TPL sequence at the 5' end is obviously higher than that of the mRNA without the TPL sequence at the 5' end.
The Major Late Promoter (MLP) of adenovirus is a common Promoter for controlling the transcription of most Late genes after the replication of adenovirus genome begins, and the activity of MLP is obviously enhanced once the replication of adenovirus genome begins. An enhancer sequence (eMLP) of adenovirus late gene promoter is added near the promoter, so that the expression level of the exogenous gene can be obviously improved.
In some embodiments, the expression vector includes a sequence encoding a 5' untranslated region, i.e., a polynucleotide sequence encoding 5' of the untranslated region of the coding sequence, also referred to as a 5' UTR. In some embodiments, the 5' UTR does not contain a polynucleotide ATG. Suitable exemplary 5' UTR sequences include, but are not limited to, sequences selected from: i) triple leader sequence (TPL) from Adenovirus (Logan, J et al (6 1984) "triple leader sequence of Adenovirus enhances translation of mRNA in the late stage of infection (Adenoviral leader sequences of mRNA laterovefter infection)", (Proc. Natl. Acad. Sci. USA) 81: 3655-); ii) enhancer element sequences from the adenovirus major late promoter (eMLP) (Durocher, Y et al (2002) "High-level and High-throughput recombinant proteins produced by transient transfection of human 293-EBNA1cells grown in suspension by High-level and High-throughput recombinant proteins (High-level and High-throughput recombinant protein production by transformed transformation of sub-growth human 293-EBNA1 cells)", "nucleic acid research (Nucl. acids. Res., (30 (2): e 9); (iii) UTR 1; and (iv) UTR 2. In a preferred embodiment, the 5' UTR comprises in 5' to 3' order TPL and eMLP sequences.
In some embodiments, the expression vector further comprises an intron comprising a splice donor/acceptor region. In some embodiments, the intron is located downstream of the promoter region and upstream of the translation initiation sequence of the gene. Introns are DNA polynucleotides that are transcribed into RNA by intron splicing and are removed during mRNA processing. Expression vectors containing introns are generally expressed more highly than those without introns. Introns can stimulate expression between 2-fold and 500-fold (Buchman and Berg,1988, Mol cell biology (Mol CellBio), 8(10): 4395). The efficiently spliced intron contains a pre-splice donor, a branch point and a Py-rich region (Senapathy et al, 1990; "methods in enzymology" (meth. enzymol.) 183,252-78; Wu and Krainer, 1999; "molecular cell biology", 19(5): 3225-36). The 5 'intron is generally more effective than the intron at the 3' end (Huang and Gorman, 1990; "molecular cell biology", 10: 1805). While introns are known to generally increase gene expression levels, the specific increase (if any) of a given cDNA is empirical and must be tested; for example, chimeric introns in the pSI vector increased CAT expression 21-fold, but luciferase expression only 3-fold. Exemplary intron sequences include, but are not limited to, sequences from actin, elongation factor 1 α (EF1 α), enhancer element from adenovirus major late promoter (eMLP), and CMVc.
The coding sequence to be expressed in a cell may be any polynucleotide sequence, for example, a gene or cDNA encoding a gene product, such as a polypeptide. The coding sequence may be heterologous to the promoter sequence and/or 5'UTR sequence to which said coding sequence is operably linked, i.e. said coding sequence is not naturally operably associated with said promoter or 5' UTR. Alternatively, the coding sequence may be endogenous to a promoter sequence and/or 5'UTR sequence to which the coding sequence is operably linked, i.e. the coding sequence is naturally associated with the promoter or 5' UTR. The gene product may act internally on the mammalian cell, or it may act externally, e.g., it may be secreted. For example, when the transgene is a therapeutic gene, the coding sequence can be any gene that encodes a desired gene product, or a functional fragment or variant thereof, which can be used as a therapeutic agent for treating a disease or disorder. Thus, the coding sequence in the expression vector may encode, for example, an opsin protein or a protein that inhibits VEGF, or the polynucleotide may encode a protein or enzyme effective to reduce one or more signs or symptoms of a disease.
In various preferred embodiments, the transgene encodes a peptide or protein that is secreted from the cell. In some embodiments, the secreted protein is a therapeutic protein or a protein effective to treat a disease in a subject. In some embodiments, the therapeutic protein is an anti-angiogenic polypeptide or a polypeptide that inhibits the growth of new blood vessels (angiogenesis). In some forms, the secreted protein is an anti-VEGF protein or a protein that inhibits Vascular Endothelial Growth Factor (VEGF). Examples of anti-VEGF proteins include ranibizumab (ranibizumab), bevacizumab (bevacizumab), and aflibercept. Another example of an anti-VEGF polypeptide is soluble fms-like tyrosine kinase-1 (sFLT-1). In other cases, the secreted protein includes or consists of a VEGF-binding protein or a functional fragment thereof (as any one disclosed in U.S. patent nos. 5,712,380, 5,861,484, and 7,071,159), or a VEGF-binding fusion protein as disclosed, for example, in U.S. patent No. 7,635,474. In some forms, the secreted protein comprises or consists of a single chain antibody (such as, for example, a single chain anti-VEGF antibody). According to one embodiment, the transgene encodes sFLT-1, and in a more specific embodiment, the transgene encodes human sFLT-1. Alternatively, the transgene may comprise a sequence encoding a functional VEGF-binding fragment of sFLT-1 (Wiesmann et al, 1997; Cell (Cell), 91: 695-. According to another example, the transgene encodes A1AT or alpha-1 antitrypsin (Chiuchiolo et al, 2013,24(4): 161-.
sFLT-1 is a soluble truncated form of the VEGF receptor FLT-1 and is also known as soluble vascular endothelial growth factor receptor-1 (sVEGFR-1). Recombinant sFLT-1 binds and inhibits VEGF (Kendall and Thomas, 1993; Proc. Natl. Acad. Sci. USA 90(22): 10705-10709). In nature, recombinant sFLT-1 is produced by alternative mRNA splicing and lacks the membrane proximal immunoglobulin-like domain, transmembrane region (transmembrane spanning region), and intracellular tyrosine kinase domain. As described herein, "soluble" FLT-1 or sFLT-1 refers to FLT-1, said FLT-1 is not limited to a cell membrane. Unbound sFLT-1 can diffuse freely in the extracellular space or in solution.
In one embodiment of the invention, the transgene coding sequence is modified or "codon optimized" to enhance expression by replacing infrequently represented codons with more frequently represented codons. The coding sequence is a portion of the mRNA sequence that encodes the amino acids for translation. During translation, each of the 61 trinucleotide codons is translated into one of 20 amino acids, resulting in degeneracy or redundancy in the genetic code. However, different cell types and different animal species will utilize trnas that encode the same amino acid at different frequencies (each carrying an anticodon). When a gene sequence contains codons that are infrequently represented by the corresponding tRNA, the ribosomal translation mechanism may slow, thereby preventing efficient translation. Expression may be improved by "codon optimisation" of a particular species in which the coding sequence is altered to encode the same protein sequence using codons highly expressed and/or used by highly expressed human proteins (Cid-Arregui et al, 2003; "journal of virology" 77: 4928). In one aspect, the coding sequence is optimized for translation in primates. In one aspect of the invention, the coding sequence of the transgene is modified to replace codons that are not frequently expressed in mammals or primates with codons that are frequently expressed in primates. For example, in some embodiments, the coding sequence encoded by the transgene encodes a polypeptide having at least 85% sequence identity, e.g., at least 90% sequence identity, e.g., at least 95% sequence identity, at least 98% identity, at least 99% identity, to a polypeptide encoded by a sequence disclosed above or herein, wherein at least one codon of the coding sequence has a higher tRNA frequency in humans than the corresponding codon in the sequence disclosed above or herein.
In some embodiments, the expression vector of the invention further comprises an RNA export signal. RNA export signals are cis-acting post-transcriptional regulatory elements that enhance the export of RNA from the nucleus. Exemplary RNA export sequences include, but are not limited to, sequences from The hepatitis b virus post-transcriptional regulatory element (HPRE) and woodchuck hepatitis virus post-transcriptional element (WPRE) (Higashimoto, T et al, "woodchuck hepatitis virus post-transcriptional regulatory element reduces read-through transcription from retroviral vectors (The wood hepatitis virus site-transcriptional regulatory elements)," gene therapy (GeneTher.) (2007, 9 months, 14(17): 1298-.
In some embodiments, the expression vector of the invention further comprises a polyadenylation region. As understood in the art, RNA polymerase II transcripts terminate by cleavage and addition of a polyadenylation region, which may also be referred to as the poly (a) signal, poly (a) region, or poly (a) tail. The polyA region contains multiple consecutive adenosine monophosphate, which typically has a repeat of the motif AAUAAA. Several effective polyadenylation sites have been identified, including those from SV40, bovine growth hormone, human growth hormone, and rabbit beta globin (Xu et al, 2001; "Gene (Gene) 272(1-2): 149-. The most effective polyA signal for expression of a transgene in a mammalian cell may depend on the cell type and species of interest and the particular vector used. In some embodiments of the invention, the expression vector comprises a polyA region selected from the group consisting of: bovine Growth Hormone (BGH), Human Growth Hormone (HGH), and beta-globin (beta globin).
As understood by one of ordinary skill, two or more of the above-mentioned polynucleotide elements may be combined to produce the expression vectors of the present disclosure. Thus, for example, an expression vector may comprise, in 5' to 3' order, in operable linkage, a CMV enhancer, CMV or EF1 α promoter, optionally a CMVc or EF1 α intron, UTR1, UTR2 or TPL and eMLP 5' UTR, the coding sequence or secreted polypeptide of sFLT1, the entire EES, 410-and 564-EES or 511-and 810-EES enhancer, optionally a HPRE or WPRE RNA export sequence, and a BGH, HGH or β globin polyadenylation signal sequence.
Another expression vector may include, in 5' to 3' order, a CMV enhancer, a CMV promoter, a 5' UTR including a TPL sequence and an eMLP sequence, a coding sequence encoding a therapeutic agent (e.g., a therapeutic polypeptide), a full length EES enhancer, and an HGH polyA signal sequence in operable linkage. In particular embodiments, the coding sequence encodes an anti-angiogenic polypeptide. In particular embodiments, the coding sequence is codon optimized. In certain of these embodiments, the expression vector includes one or more sequences selected from SEQ ID NOS 35-38.
As one of ordinary skill in the art will recognize, the expression vector may optionally contain other elements, including but not limited to restriction sites to facilitate cloning and regulatory elements for the particular gene expression vector. Examples of regulatory sequences include ITRs of AAV vectors, bacterial sequences of plasmid vectors, attP sites or attB sites of phage integrase vectors, and transposable elements of transposons.
As disclosed herein, in some aspects of the invention, expression vectors are used to deliver genes to animal cells, e.g., to determine the effect of genes on cell viability and/or function, to treat cellular disorders, and the like. Thus, in some aspects of the invention, compositions for expressing a transgene in a mammalian cell are provided as gene delivery vectors, wherein the gene delivery vectors include the expression vectors of the present disclosure.
The gene delivery vectors of the present disclosure encompass any convenient gene delivery vector for delivering a polynucleotide sequence to a mammalian cell. For example, the vector may comprise single-stranded nucleic acid or double-stranded nucleic acid, such as single-stranded DNA or double-stranded DNA. For example, the gene delivery vector can be DNA, e.g., naked DNA, such as a plasmid or minicircle, and the like. The vector may comprise single-stranded RNA or double-stranded RNA, including modified forms of RNA. In another example, the gene delivery vector may be an RNA, such as an mRNA or a modified mRNA.
As another example, the gene delivery vector may be a viral vector derived from a virus, such as adenovirus, adeno-associated virus (AAV), lentivirus, herpes virus, alphavirus or retrovirus, such as Moloney (Moloney) murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), havey (Harvey) murine sarcoma virus (hamsv), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), Feline Leukemia Virus (FLV), foamy virus, Friend (Friend) murine leukemia virus, Murine Stem Cell Virus (MSCV) and Rous (Rous) sarcoma virus (RSV) or lentivirus. Although the examples encompassing the use of adeno-associated viruses are described in more detail below, it is contemplated that one of ordinary skill will recognize that similar knowledge and skills in the art may also be applied to non-AAV gene delivery vectors. See, e.g., the discussion of retroviral vectors in, e.g., U.S. patent No. 7,585,676 and U.S. patent No. 8,900,858, and adenoviral vectors in, e.g., U.S. patent No. 7,858,367, the entire disclosures of which are incorporated herein by reference.
In some embodiments, the gene delivery vector is a recombinant adeno-associated virus (rAAV). In this example, the expression vector is flanked at the 5 'and 3' ends by functional AAV Inverted Terminal Repeat (ITR) sequences. By "functional AAV ITR sequence" is meant an ITR sequence that is used as intended to rescue, replicate and package AAV virions. Thus, the AAV ITRs for use in the gene delivery vectors of the invention need not have a wild-type nucleotide sequence and may be altered by insertion, deletion or substitution of nucleotides, or the AAV ITRs may be derived from any of several AAV serotypes, e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 10. Preferred AAV vectors have all or part of the wild-type Rep and Cap genes deleted, but retain functional flanking ITR sequences. In particular embodiments, the AAV viral vector is AAV2 variant 7m8.
In some embodiments, the expression vector is encapsidated within an AAV capsid, which may be derived from any adeno-associated virus serotype, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, etc., any of which may serve as a gene delivery vector. For example, the AAV capsid may be a wild-type capsid or a native capsid. Wild type AAV capsids of particular interest comprise AAV2, AAV5, and AAV 9. However, as with the ITRs, the capsid need not have a wild-type nucleotide sequence, but rather can be altered relative to the wild-type sequence by insertion, deletion or substitution of nucleotides in the VP1, VP2 or VP3 sequences so long as the capsid is capable of transducing mammalian cells. In other words, the AAV capsid may be a variant AAV capsid comprising one or more amino acid substitutions, deletions, or insertions relative to the parental capsid protein or AAV capsid protein from which it is derived. Variant AAVs of particular interest include those disclosed in U.S. patent 9,193,956, the entire disclosure of which is incorporated herein by reference. In some embodiments, the variant AAV comprises a 7m8 variant capsid protein (which may be referred to herein as aav2.7m8 or 7m8.aav2) disclosed in U.S. patent 9,193,956. .
Preferably, the rAAV is replication-defective, in that the AAV vector is unable to independently replicate and package its genome further. For example, when cones are transduced with rAAV virions, the gene is expressed in the transduced cones, however, rAAV cannot replicate due to the fact that the transduced cones lack AAV rep and cap genes as well as helper functions.
Standard methods can be used to generate gene delivery vectors (e.g., rAAV virions) that encapsidate the expression vectors of the disclosure. For example, in the case of rAAV virions, an AAV expression vector according to the present invention can be introduced into a producer cell, followed by introduction of an AAV helper construct, wherein the helper construct comprises an AAV coding region capable of expression in the producer cell and which AAV coding region can complement AAV helper functions not present in the AAV vector. A helper virus and/or additional vector is then introduced into the producer cell, wherein the helper virus and/or additional vector provides helper functions capable of supporting efficient rAAV virus production. The producer cells are then cultured to produce rAAV. These steps are performed using standard methods. AAV packaging cells and packaging techniques are used to prepare replication-defective AAV virions that encapsidate the recombinant AAV vectors of the invention by standard techniques known in the art. Examples of these methods can be found, for example, in: U.S. patent No. 5,436,146; U.S. patent No. 5,753,500, U.S. patent No. 6,040,183, U.S. patent No. 6,093,570, and U.S. patent No. 6,548,286, which are expressly incorporated herein by reference in their entirety. Wang et al (US 2002/0168342) describe additional compositions and methods for packaging, which are also incorporated herein by reference in their entirety.
Any concentration of viral particles suitable for efficient transduction of mammalian cells can be prepared for contacting mammalian cells in vitro or in vivo. For example, it may be at 10 per ml8Viral particles are formulated at a concentration of one or more vector genomes (vg/mL), e.g., 5X 10 per mL8A vector genome; 10 per ml9A vector genome; 5X 10 per ml 910 per ml of vector genome105X 10 vector genomes per ml10A vector genome; 10 per ml11A vector genome; 5X 10 per ml11A vector genome; 10 per ml12A vector genome; 5X 10 per ml12A vector genome; 10 per ml13A vector genome; 1.5X 10 per ml13A vector genome; 3X 10 per ml13A vector genome; 5X 10 per ml13A vector genome; 7.5X 10 per ml13A vector genome; 9X 10 per ml13A vector genome; 1X 10 per ml145X 10 vector genomes per ml14One or more vector genomes, but usually not more than 1X 10 per ml15And (3) a vector genome. Similarly, any total number of viral particles suitable to provide appropriate cell transduction to confer a desired effect or treat a disease may be administered to a mammal. In various preferred embodiments, at least 108A plurality of; 5X 108A plurality of; 109A plurality of; 5X 1091, 10105 x 10 pieces of10A plurality of; 1011A plurality of; 5X 1011A plurality of; 1012A plurality of; 5 is prepared from1012A plurality of; 1013A plurality of; 1.5X 1013A plurality of; 3X 1013A plurality of; 5X 1013A plurality of; 7.5X 1013A plurality of; 9X 10131,1 × 1014Or 5X 1014One or more virus particles, but generally not more than 1X 10 virus particles per eye15And (4) respectively. Any suitable number of vectors can be administered to the mammalian or primate eye. In one embodiment, the method comprises a single administration; in other embodiments, multiple administrations may be performed over time as deemed appropriate by the attending clinician.
The subject viral vectors can be formulated into pharmaceutical compositions comprising any suitable unit dose of the vector, which can be administered to a subject to produce a change in the subject or to treat a disease in the subject. In some embodiments, a unit dose includes, but is not limited to, 1 × 10 of a viral vector8One or more vector genomes, e.g., at least about 1X 1091,1 × 10101,1 × 10111,1 × 10121,1 × 10131,1 × 1014Or at least about 3 x 1014One or more vector genomes, in some cases, at least about 1X 1014A vector genome, but usually not more than 4X 1015And (3) a vector genome. In some cases, the unit dose comprises up to about 5 x 1015A vector genome, e.g. 1X 1014Or 5X 1014With less or no vector genome, e.g. 1X 10131,1 × 10121,1 × 10111,1 × 1010Or 1 x 109One or less, and in some cases, 1X 10, vector genomes8A vector genome of 1X 10 or less, and usually not less than8And (3) a vector genome. In some cases, the unit dose comprises 1 × 10101 to 1011And (3) a vector genome. In some cases, the unit dose comprises 1 × 1010To 3 x 1012And (3) a vector genome. In some cases, the unit dose comprises 1 × 109To 3 x 1013And (3) a vector genome. In some cases, a unit doseComprises 1 × 108To 3 x 1014And (3) a vector genome. In some cases, the unit dose comprises about 1 × 1010From one to about 5X 1014And (3) a vector genome.
In some cases, the multiplicity of infection (MOI) can be used to measure the unit dose of a pharmaceutical composition. MOI refers to the ratio or fold of vector or viral genome to cells into which nucleic acid can be delivered. In some cases, the MOI may be 1 × 106And (4) respectively. In some cases, the MOI may be 1 × 105-1×107And (4) respectively. In some cases, the MOI may be 1 × 104-1×108And (4) respectively. In some cases, a recombinant virus of the disclosure is at least about 1 × 1011,1 × 1021,1 × 103、1×1041,1 × 1051,1 × 1061,1 × 1071,1 × 1081,1 × 1091,1 × 10101,1 × 10111,1 × 10121,1 × 10131,1 × 10141,1 × 10151,1 × 10161,1 × 1017And 1X 1018And (4) the MOI. In some cases, the recombinant virus of the disclosure is 1 × 108To 3 x 1014And (4) the MOI. In some cases, recombinant viruses of the present disclosure are up to about 1 × 1011,1 × 1021,1 × 103、1×1041,1 × 1051,1 × 1061,1 × 1071,1 × 1081,1 × 1091,1 × 10101,1 × 10111,1 × 10121,1 × 10131,1 × 10141,1 × 10151,1 × 10161,1 × 1017And 1X 1018And (4) the MOI.
In some aspects, the amount of the pharmaceutical composition comprises about 1 x 108From one to about 1X 1015 About 1X 10 of recombinant virus9From one to about 1X 1014 About 1X 10 of recombinant virus10From one to about 1X 1013Recombinant virus or about 1X 1011From one to about 3X 1012And (3) recombinant viruses.
In preparing the rAAV compositions, any host cell for producing rAAV virions can be employed, including, but not limited to, e.g., mammalian cells (e.g., 293 cells), insect cells (e.g., SF9 cells), microorganisms, and yeast. The host cell may also be a packaging cell in which the AAV rep and cap genes are stably maintained in the host cell or a producer cell in which the AAV vector genome is stably maintained and packaged. Exemplary packaging and production cells are derived from SF-9, 293, A549, or HeLa cells. AAV vectors are purified and formulated using standard techniques known in the art.
The invention encompasses pharmaceutical compositions comprising an expression vector or gene delivery vector described herein and a pharmaceutically acceptable carrier, diluent, or excipient. For example, one embodiment is a pharmaceutical composition comprising a recombinant virus comprising a polynucleotide of the present disclosure and a pharmaceutically acceptable excipient. In particular embodiments, the recombinant virus is a recombinant adeno-associated virus (AAV). The expression vector or gene delivery vector can be combined with pharmaceutically acceptable carriers, diluents, and agents that can be used to prepare formulations that are generally safe, non-toxic, and desirable and include acceptable excipients for primate use. Such excipients may be solid, liquid, semi-solid or gaseous (in the case of aerosol compositions). Examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Supplementary active compounds may also be incorporated into these formulations. The solution or suspension for the formulation may comprise: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl paraben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetate, citrate or phosphate; detergents, such as Tween (Tween)20 to prevent aggregation; and compounds for regulating tonicity, such as sodium chloride or dextrose. The pH can be adjusted with an acid or base (e.g., hydrochloric acid or sodium hydroxide). In particular embodiments, the pharmaceutical composition is sterile.
In the case of contacting cone cells in vivo, the expression vector or a gene delivery vector comprising the expression vector may be considered suitable for delivery to the eye.
Pharmaceutical compositions suitable for use in the present invention further comprise sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Thus, the pharmaceutical compositions may be in the form of sterile injectable solutions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, or Phosphate Buffered Saline (PBS). In some cases, the composition is sterile and should have fluidity to the extent that it is easy to inject. In certain embodiments, the compositions are stable under the conditions of manufacture and storage, and are preserved against the contaminating action of microorganisms (e.g., bacteria and fungi). The carrier can be, for example, a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like). In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the internal composition can be brought about by including in the composition an agent that delays absorption (e.g., aluminum monostearate and gelatin).
If desired, sterile solutions may be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a base dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
In one embodiment, the composition is prepared with a carrier that protects the expression vector from rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid may be used. Methods for preparing such formulations will be apparent to those skilled in the art. The materials are also commercially available. Liposomal suspensions (comprising liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These formulations can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
It is particularly advantageous to formulate oral, ophthalmic or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suitable as unitary dosages for the subjects to be treated; each unit containing a predetermined amount of gene delivery or expression vector calculated to produce the desired therapeutic effect in association with the desired pharmaceutical carrier. The specification for the dosage unit form of the invention is dictated by the gene delivery vector, the unique characteristics of the expression vector and the particular therapeutic effect to be achieved.
The pharmaceutical composition can be contained in a container, package, or dispenser (e.g., a syringe, such as a prefilled syringe) with instructions for administration.
By "pharmaceutically acceptable excipient" is meant a material, substance, diluent or carrier that is substantially non-toxic to the cells or subject to which it is to be administered. That is, a pharmaceutically acceptable excipient may be incorporated into a pharmaceutical composition and administered to a cell or patient without substantially causing an undesirable biological effect or interacting in a deleterious manner with any of the other components of the composition in which the pharmaceutically acceptable excipient is contained.
Expression vectors or gene delivery vectors (e.g., recombinant viruses (virions)) can be incorporated into pharmaceutical compositions for administration to mammalian patients, particularly primates and more particularly humans. The expression vector or gene delivery vector (e.g., viral particle) may be formulated in a non-toxic, inert, pharmaceutically acceptable aqueous carrier having a pH preferably in the range of 3 to 8, more preferably in the range of 6 to 8, or even more preferably in the range of 7 to 8. Such sterile compositions will include vectors or viral particles containing a nucleic acid encoding a therapeutic molecule dissolved in an aqueous buffer having an acceptable pH upon reconstitution.
In some embodiments, the pharmaceutical compositions provided herein comprise a therapeutically effective amount of the carrier or viral particle in admixture with a pharmaceutically acceptable carrier and/or excipient, e.g., saline, phosphate buffered saline, phosphate, and optionally one or more other agents, such as amino acids, polymers, polyols, sugars, buffers, preservatives, proteins, and inorganic salts (e.g., sodium chloride). Exemplary amino acids, polymers, and sugars and the like are octylphenoxy polyethoxyethanol compounds, polyethylene glycol monostearate compounds, polyoxyethylene sorbitan fatty acid esters, sucrose, fructose, dextrose, maltose, glucose, mannitol, dextran, sorbitol, inositol, galactitol, xylitol, lactose, trehalose, bovine or human serum albumin, citrate, acetate, ringer's and Hank's (Hank's) solution, cysteine, arginine, carnitine, alanine, glycine, lysine, valine, leucine, polyvinylpyrrolidone, polyethylene, and ethylene glycol. Preferably, such formulations are stable at 4 ℃ for at least six months.
In some embodiments, the pharmaceutical compositions provided herein include buffers such as Phosphate Buffered Saline (PBS) or sodium phosphate/sulfate, tris buffers, glycine buffers, sterile water, and other buffers known to those of ordinary skill, such as those described by Good et al, (1966) Biochemistry 5(2) 467-477. The pH of the buffer may be in the range of 6.5 to 7.75, preferably 7 to 7.5, and most preferably 7.2 to 7.4. The pharmaceutical compositions can include an adenovirus or adeno-associated adenovirus vector delivery system comprising an expression vector of the disclosure.
The ability to deliver the expression vectors of the invention to selected target cells in vivo and obtain a therapeutically effective amount of the gene product in the cells and in the extracellular environment following a transduction event may be beneficial for the treatment of a number of different diseases, including those that are dependent on the growth of new blood vessels, where the goal of treatment may be to provide the target cells with the ability to secrete a therapeutically effective amount of an anti-angiogenic protein. While not wishing to be bound by any theory, even when the gene delivery vector is able to successfully transduce only a fraction of the target cells, an expression vector that is capable of enhancing expression and ultimately therapeutic protein secretion may help provide a clinically significant benefit to the patient. High levels of secretion of therapeutic proteins by transduced cells may help balance the infectivity or transduction efficiency achieved with any given dose or gene therapy round.
Thus, expression vectors and gene delivery vectors, collectively referred to herein as "compositions," can be used to express transgenes in animal cells. For example, the compositions can be used to study, e.g., determine the effect of a gene on cell viability and/or function. As another example, the compositions may be used in medicine, for example, to treat a disorder. The methods and compositions of the present disclosure may be used to treat any condition that can be at least partially addressed by gene therapy of cells. Cells include, but are not limited to, blood, eye, liver, kidney, heart, muscle, stomach, intestine, pancreas, and skin.
Accordingly, the present invention provides a method for treating or preventing a disease or disorder (e.g., an ocular disease or disorder) in a subject in need thereof, the method comprising administering to the subject in need thereof a viral vector or viral particle comprising an expression vector of the invention encoding a therapeutic gene product. In a preferred embodiment, the therapeutic gene product is a secreted polypeptide or a protein that is secreted or exported from the cell after synthesis in the cell, and the expression vector comprises, in 5 'to 3' order: (i) a first enhancer region comprising a CMV sequence (SEQ ID NO: 13); (a) a promoter region comprising a CMV sequence (SEQ ID NO: 9); (b) a 5' UTR region comprising, in 5' to 3' order, a TPL sequence and an eMLP sequence (SEQ ID NO:2 and SEQ ID NO:7, respectively); (c) a coding sequence encoding a peptide or polypeptide; (iii) a second enhancer region comprising a human IFNB SAR (SEQ ID NO: 15); and (d) an HGH polyadenylation site (SEQ ID NO: 12).
In related embodiments, some methods provide for expression of a gene in a cell in vitro or in vivo, the method comprising contacting the cell with a composition of the disclosure. In some embodiments, the contacting occurs in vitro. In some embodiments, the contacting occurs in vivo, i.e., the composition is administered to a subject. The composition may be administered parenterally by intravenous injection or oral infusion. In certain embodiments, the composition is administered to the eye by injection, for example to the retina, lower retina, or vitreous. In certain embodiments, the composition is administered by retinal injection, subretinal injection, or intravitreal injection. In certain embodiments, the composition is administered topically or directly to a tissue or organ of interest, for example by injection into the liver.
The subject can be a mammal, including, for example, a human subject in need of treatment for a particular disease or condition.
For the case where mammalian cells are contacted in vitro with an expression vector or gene delivery vector comprising an expression vector, the cells can be from any mammalian species, e.g., rodent (e.g., mouse, rat, gerbil, squirrel), rabbit, cat, dog, goat, sheep, pig, horse, cow, primate, human. The cells may be from an established cell line or may be primary cells, which
The terms "primary cell," "primary cell line," and "primary culture" are used interchangeably herein to refer to cells and cell cultures derived from a subject and allow for a limited number of passages, i.e., divisions, of a growing culture in vitro. For example, a primary culture is a culture that may have been passaged 0,1, 2, 4,5, 10, or 15 times, but not enough to undergo a crisis stage. Typically, the primary cell lines of the invention are maintained in vitro for less than 10 passages.
If the cells are primary cells, the cells may be harvested from the mammal by any convenient method, e.g., whole explants, biopsies, etc. The collected cells may be dispersed or suspended with a suitable solution. Such a solution will typically be a balanced salt solution, such as physiological saline, PBS, hank's balanced salt solution, or the like, conveniently supplemented with fetal bovine serum or other naturally occurring factors at low concentrations (typically 5-25mM) in combination with an acceptable buffer. Convenient buffers include HEPES, phosphate buffer, lactate buffer, and the like. The cells may be used immediately or may be stored, frozen for extended periods of time, thawed and capable of being reused. In this case, cells are typically frozen in 10% DMSO, 50% serum, 40% buffered medium, or some other such solution as is commonly used in the art, to preserve the cells at such freezing temperatures and to be thawed in a manner as is commonly known in the art for thawing frozen cultured cells.
To facilitate expression of the transgene, the expression vector or the gene delivery vector including the expression vector is contacted with the cell for about 30 minutes to 24 hours or more, e.g., 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 16 hours, 18 hours, 20 hours, 24 hours, etc. The expression vector or gene delivery vector comprising the expression vector can be provided to the subject cells one or more times (e.g., once, twice, three times, or more than three times) and the cells are allowed to incubate with the agent(s) for a time after each contact event (e.g., 16-24 hours), after which the medium is replaced with fresh medium and the cells are further cultured. Contacting the cells can occur in any medium and under any culture conditions that promote cell survival. For example, the cells may be suspended in any suitable convenient nutrient medium, such as Iscove's modified DMEM or RPMI 1640, supplemented with foetal calf serum or heat-inactivated goat serum (about 5-10%), L-glutamine, thiols, especially 2-mercaptoethanol, and antibiotics, such as penicillin and streptomycin. The culture may contain growth factors to which the cells respond. As defined herein, a growth factor is a molecule capable of promoting the survival, growth and/or differentiation of cells in culture or in intact tissues through specific action on transmembrane receptors. Growth factors include polypeptide factors and non-polypeptide factors.
Typically, an effective amount of an expression vector or gene delivery vector comprising an expression vector is provided to produce transgene expression in a cell. As discussed elsewhere herein, an effective amount can be readily determined empirically, e.g., by detecting the presence or level of a transgene product, by detecting an effect on cell viability or function, etc. Typically, expression will be enhanced 2-fold or more, e.g., 3-fold, 4-fold or 5-fold or more, in some cases 10-fold, 20-fold or 50-fold or more, e.g., 100-fold, relative to expression from a reference or control expression vector. One example of a reference expression vector for comparison purposes is the CMV reference expression vector described herein. In particular embodiments, the transgene encodes a secreted protein, and the expression vector expresses the secreted protein in the mammalian cell at a level that is at least 2-fold, 5-fold, 10-fold, 5-fold to 15-fold, or 10-fold to 15-fold greater than the level of expression of the secreted protein in the mammalian cell by the CMV reference control expression vector. According to some embodiments, when the transgene is a transgene encoding a non-secreted protein, the expression vector of the invention expresses the non-secreted protein in the mammalian cell at a level that is about the same as, within 10-20%, about 1.5-fold or about 2-fold less than the level of expression of the non-secreted protein in the mammalian cell by the CMV reference control expression vector. The expression level of secreted protein for each expression vector can be measured by an immunoassay or an antigen capture assay, and can be expressed as the amount or concentration of protein per volume of supernatant (e.g., cell culture medium or supernatant) in the extracellular environment.
Immunoassays for measuring The presence and amount (and thus The expression level) of proteins in biological or cellular samples are known in The art (e.g., Hage, d.s. (1999) "Immunoassays" (Analytical Chemistry), "71 (12) in Analytical Chemistry 294-. Typically, immunoassays are based on the reaction between a target protein and an antibody or antibody fragment that specifically binds to the protein. Immunoassays can be carried out in liquid phase or solid phase systems, but for ease of detection, a solid phase may be preferred. Suitable immunoassays include, but are not limited to, sandwich and competition assays, western blots, ELISA (enzyme linked immunosorbent assays), Radioimmunoassays (RIA), Fluorescent Immunoassays (FIA), and the like. The biological sample may be cell culture medium or supernatant (a sample taken from a culture without lysing the cells), cell lysate, whole cells, blood, serum, plasma, or other bodily fluids or tissues. In some embodiments, such as when the transgene is a selectable marker, the cell population can be enriched for those comprising the expression vector by separating the modified cells from the remaining population. The separation may be carried out by any convenient separation technique appropriate for the selectable marker used. For example, if the transgene is a fluorescent label, the cells may be isolated by fluorescence activated cell sorting, whereas if the transgene is a cell surface label, the cells may be separated from the heterogeneous population by affinity separation techniques, such as magnetic separation, affinity chromatography, "panning" with affinity reagents attached to a solid matrix, or other convenient techniques. Techniques for providing accurate separation include fluorescence activated cell sorters, which may have varying degrees of complexity, such as multi-color channels, low and obtuse angle light scatter detection channels, impedance channels, and the like. Cells can be selected for dead cells by using a dye (e.g., propidium iodide) associated with the dead cells. Any technique that is not unduly detrimental to cell viability may be employed. In this way a highly enriched cell composition of cells comprising the polynucleotide is achieved. By "highly enriched" is meant that the genetically modified cells will be 70% or more, 75% or more, 80% or more, 85% or more, 90% or more of the cellular composition, for example about 95% or more or 98% or more of the cellular composition.
For the case where the cell is contacted with the expression vector or gene delivery vector comprising the expression vector in vivo, the subject can be any mammal, e.g., a rodent (e.g., mouse, rat, gerbil), rabbit, cat, dog, goat, sheep, pig, horse, cow, human, or non-human primate.
The methods and compositions of the invention may be used to treat any condition that can be at least partially addressed by gene therapy of cells. Cells include, but are not limited to, blood, eye, liver, kidney, heart, muscle, stomach, intestine, pancreas, and skin. One embodiment is a method for treating a medical condition in a subject in need of treatment, the method comprising administering to the subject a gene delivery vector containing an expression vector as disclosed herein, wherein the expression vector encodes a polypeptide effective to reduce one or more signs or symptoms of the medical condition. In some embodiments, the medical condition is an ocular disease, the gene delivery vector is an adeno-associated virus, and the polypeptide is a polypeptide secreted by a cell transduced by the vector. In one embodiment, the secreted protein inhibits VEGF signaling. For example, the secreted protein may be a VEGF-binding protein. In some embodiments, the ocular disease is choroidal neovascularization or macular degeneration. Particular forms of macular degeneration may include acute macular degeneration, non-exudative age-related macular degeneration, and exudative age-related macular degeneration. Administration may be by any suitable means, including, for example, ocular delivery, intravitreal injection, intraocular injection, retinal injection, subretinal injection, parenteral administration, intravenous injection or infusion, and injection into the liver.
Age related macular degeneration (AMD) is a common eye disease and is a significant cause of vision loss in the elderly. Advanced AMD can be classified into dry AMD and wet AMD, depending on the ocular fundus manifestations. VEGF-induced pathologic choroidal neovascularization is a central mechanism for the onset and progression of wet AMD, which can lead to exudation, hemorrhage, and fibrous scarring. anti-VEGF therapy is the most effective way to treat wet AMD, but the efficacy of anti-VEGF antibody injections is only sustained for a short period of time, thus requiring repeated ocular injections. The protein coding sequence capable of expressing and blocking the biological activity of VEGF is delivered to the fundus by using a gene therapy vector such as adeno-associated virus (AAV), so that the continuous expression of the protein capable of blocking the biological activity of VEGF can be realized, and the continuous inhibition of pathological choroid neovascularization by single administration can be realized.
In some embodiments, the gene delivery vector is administered to the eye of a subject in need of treatment. In some embodiments, the gene delivery vector is administered to the subject by intraocular injection, by intravitreal injection, or by any other convenient mode or route of administration. In some embodiments, the subject is a human subject having or at risk of developing macular degeneration or ocular neovascularization.
In some embodiments, the methods result in a therapeutic benefit, such as preventing the development of a disorder, halting the progression of a disorder, reversing the progression of a disorder, and the like. In some embodiments, the method includes the step of detecting whether a therapeutic benefit is achieved. The ordinarily skilled artisan will understand that such measurement of treatment efficacy will be appropriate for the particular disease being modified, and will recognize appropriate detection methods for measuring treatment efficacy.
It is desirable that transgene expression obtained using a transgene is robust. Thus, in some cases, transgene expression (e.g., as detected by measuring the level of a gene product) can be observed two months or less after administration (e.g., 4 weeks, 3 weeks, or 2 weeks or less after administration (e.g., 1 week after administration of the composition)) by measuring therapeutic efficacy, or the like. It is expected that transgene expression will also persist over time. Thus, in some cases, transgene expression (e.g., as detected by measuring levels of gene products) can be observed at 2 months or more (e.g., 4 months, 6 months, 8 months, or 10 months or more, in some cases, 1 year or more, e.g., 2 years, 3 years, 4 years, or 5 years, in some cases more than 5 years) after administration of the composition, by measuring therapeutic efficacy, or the like.
In certain embodiments, the methods comprise the step of detecting transgene expression in a cell, wherein expression is enhanced relative to expression from an expression vector that does not include one or more improved elements of the present disclosure (i.e., a reference control). Typically, expression will be enhanced by 2-fold or more, e.g., 3-fold, 4-fold or 5-fold or more, in some cases 10-fold, 20-fold or 50-fold or more (e.g., 100-fold) relative to expression by the reference (i.e., control expression vector), as evidenced by, e.g., early detection, higher levels of gene product, greater functional impact on the cell, etc. In one aspect, the transgene encodes a secreted polypeptide (e.g., sFLT 1).
Generally, if the subject composition is a virus (e.g., a rAAV comprising a polynucleotide expression vector of the disclosure), an effective amount for achieving a change or producing a therapeutic effect in a subject will be about 1 x 108The vector genome is one or more, in some cases, 1X 1091,1 × 10101,1 × 10111,1 × 1012Or 1X 1013One or more, in some cases, 1X 10, genomes14The number of vector genomes is one or more, and usually not more than 1X 1016And (3) a vector genome. In some cases, the amount of vector genome delivered is up to about 1 × 1016A vector genome, e.g. 1X 1015Less than one vector genome, e.g. 1X 10131,1 × 10121,1 × 10111,1 × 1010Or 1X 109A vector genome or less, in some cases, 1X 108A vector genome, and usually not less than 1X 108Individual vector geneAnd (4) grouping. In some cases, the amount of vector genome delivered is 1 × 10101 to 1011And (3) a vector genome. In some cases, the amount of vector genome delivered is 1 × 1010To 3 x 1012And (3) a vector genome. In some cases, the amount of vector genome delivered is 1 × 109To 3 x 1013And (3) a vector genome. In some cases, the amount of vector genome delivered is 1 × 108To 3 x 1014And (3) a vector genome.
In some cases, the multiplicity of infection (MOI) can be used to measure the amount of the pharmaceutical composition to be administered. In some cases, MOI may refer to the ratio or fold of vector particle or viral genome to cells to which the polynucleotide expression vector may be delivered. In some cases, the MOI may be 1 × 106And (4) respectively. In some cases, the MOI may be 1 × 1051 to 107And (4) respectively. In some cases, the MOI may be 1 × 1041 to 108And (4) respectively. In some cases, the recombinant viruses of the present disclosure are about 1 × 1011,1 × 1021,1 × 1031,1 × 1041,1 × 1051,1 × 106Or 1 x 107And (4) the MOI.
In some aspects, the individual dose is generally no less than the amount required to produce a measurable effect on the subject, and may be determined based on the pharmacokinetics and pharmacology of absorption, distribution, metabolism, and excretion ("ADME") of the composition or its byproducts, and thus based on the disposition of the composition within the subject. This includes consideration of the route of administration and dosage. Effective dosages and/or dosage regimens can be readily determined empirically, by preclinical determination, by safety and escalation and dose ranging trials, by individual clinician-patient relationships, and by in vitro and in vivo assays.
In many embodiments, the recombinant virus can be administered in conjunction with one or more additional compounds or therapies, including a second recombinant virus, a chemotherapeutic agent, surgery, a catheter device, and radiation. Combination therapy includes administration of a single pharmaceutical dosage formulation comprising a recombinant virus and one or more additional agents; also included is the administration of the recombinant virus and one or more additional agents in its own separate pharmaceutical dosage formulation. For example, the recombinant virus and the cytotoxic, chemotherapeutic or growth inhibitory agent may be administered to the patient together in a single dosage composition, e.g., as a combined preparation, or each agent may be administered as a separate dosage formulation. When separate dosage formulations are used, the VEGF-specific fusion polypeptide of the invention and one or more additional agents may be administered simultaneously or at separate staggered times, i.e., sequentially.
The term "cytotoxic agent" as used herein refers to a substance that inhibits or hinders the function of cells and/or causes cell destruction. The term is meant to include radioactive isotopes (e.g., I131, I125, Y90, and Re186), chemotherapeutic agents, and toxins such as enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof.
A "chemotherapeutic agent" is a chemical compound used to treat cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa, cyclophosphamide formulations; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa and uredopa; the class of ethyleneimine and methylenemelamine includes hexamethylmelamine, tritylamine, triethylenephosphoramide (triethylenephosphoramide), triethylenethiophosphoramide, trimethylolomelamine; nitrogen mustards such as chlorambucil, naphazel, cholorophosphamide (cholophosphamide), estramustine, ifosfamide, mechlorethamine hydrochloride, melphalan, neomustard, mechlorethamine cholesterol, prednimustine, trofosfamide, uramustine, nitrosoureas (nitrosoureas) such as carmustine, chlorouramicin, fotemustine, lomustine, nimustine, ramustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycin, actinomycin C, calicheamicin (calicheamicin), carabicin, carminomycin, carcinomycin, chromomycin, actinomycin D, daunorubicin, ditobicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marisulosin, mitomycin, mycophenolic acid, norubicin, olivomycin, pelomycin, potfiromycin, puromycin, trirubicin, roxobicin, streptonigromycin, streptonigrin, tubercidin, ubenicillin, ulinastatin (neocarzinostatin), zorubicin, antimetabolites such as methotrexate, 5-fluorouracil, folic acid analogs such as denopterin, methotrexate, pterin, triptorelbine, purine analogs such as fludarabine, 6-mercaptopurine analogs such as fludarabine, and mercaptopurine analogs such as, Thiamiprine, thioguanine, pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine;
androgens such as carposterone, drotanolone propionate, epithioandrostanol, meiandrane, testolactone, adrenal suppressing drugs such as aminoglutethimide, mitotane, trostane, folic acid supplementing drugs such as frolinic acid; acetic acid glucurolactone; (ii) an aldophosphamide glycoside; 5-aminolevulinic acid; amsacrine; bestrabuucil; a bisantrene group; edatraxate; defofamine; colchicine, diazaquinone, elfornitine; ammonium etiolate; etoglut, gallium nitrate, hydroxyurea; lentinan; lonidamine; mitoguazone, mitoxantrone; mopidanol; nisridine; pentostatin; phenamett; pirarubicin, podophyllic acid; 2-ethyl hydrazide; procarbazine; lezoxan; a texaphyrin; a germanium spiroamine; geobacillus azavor; a tri-imine quinone; 2, 2' -trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; dibromomannitol; dibromodulcitol; (ii) a paraben; gacytosine; adenine arabinoside (arabinoside); cyclophosphamide; thiotepa; paclitaxel drugs (Taxanes), such as paclitaxel (Bristol-Myers squibbonology, Princeton, n.j.); docetaxel (Aventis antonyx, france); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum drugs such as cisplatin and Carboplatin; vinblastine; platinum; etoposide (VP16) (etoposide (VP-16)); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; novoxil; noxiaoling; (ii) teniposide; daunomycin; aminopterin; (ii) an aptamer; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethyl ornithine (DMFO); tretinoin; an esperamicin class; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the foregoing. Also included in this definition are anti-hormonal agents used to modulate or inhibit the action of hormones on tumors, including, for example, anti-estrogens; such as tamoxifen, raloxifene, aromatase inhibiting 4(5) -imidazole, 4-hydroxytrytoxifen, travoxifen, keoxifene, LY 117018, onapristone, and toremifene (Faleton); and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprorelin and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the foregoing.
"growth inhibitory agent" when used herein refers to a compound or composition that inhibits cell growth, particularly cancer cell growth, in vitro or in vivo. Examples of growth inhibitory agents include agents that block the cell cycle (at other stages besides S phase), such as agents that induce G1 phase block and M phase block. Classical M-phase blockers include Vincas (vincristine and vinblastine), and topoisomerase II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that block G1 also prolong blocking to S phase, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and cytarabine.
All of the above U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to in this specification are incorporated herein by reference in their entirety.
From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
Examples
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed.
EXAMPLE 1 construction of expression vectors
To investigate the effect of the tripartite leader sequence (TPL) sequence from adenovirus and the enhancer element sequence (eMLP) from the major late promoter of adenovirus on gene expression, regulatory nucleic acid molecules consisting of the TPL sequence and the eMLP sequence were designed to regulate gene expression. The following 4 TPL sequences were selected: TPL1, TPL2, TPL3 and TPL4, the nucleotide sequences of which are respectively shown as SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 and SEQ ID NO 4. The following 4 eMLP sequences were selected: eMLP1, eMLP2, eMLP3 and eMLP4, the nucleotide sequences of which are respectively shown in SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7 and SEQ ID NO. 8. Based on the combination of the above 4 TPL sequences and 4 eMLP sequences, the following 16 regulatory nucleic acid molecules were designed:
the regulatory nucleic acid molecule 11 consists of TPL1 and eMLP1, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 19;
the regulatory nucleic acid molecule 12 consists of TPL1 and eMLP2, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 20;
the regulatory nucleic acid molecule 13 consists of TPL1 and eMLP3, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 21;
a regulatory nucleic acid molecule 14 which consists of TPL1 and eMLP4, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 22;
the regulatory nucleic acid molecule 21 consists of TPL2 and eMLP1, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 23;
the regulatory nucleic acid molecule 22 consists of TPL2 and eMLP2, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 24;
the regulatory nucleic acid molecule 23 consists of TPL2 and eMLP3, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 25;
the regulatory nucleic acid molecule 24 consists of TPL2 and eMLP4, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 26;
the regulatory nucleic acid molecule 31 consists of TPL3 and eMLP1, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 27;
a regulatory nucleic acid molecule 32, which consists of TPL3 and eMLP2, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 28;
the regulatory nucleic acid molecule 33 consists of TPL3 and eMLP3, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 29;
a regulatory nucleic acid molecule 34 consisting of TPL3 and eMLP4, the nucleotide sequence of which is shown as SEQ ID NO. 30;
the regulatory nucleic acid molecule 41 consists of TPL4 and eMLP1, and the nucleotide sequence of the regulatory nucleic acid molecule is shown as SEQ ID NO. 31;
a regulatory nucleic acid molecule 42 consisting of TPL4 and eMLP2, the nucleotide sequence of which is shown in SEQ ID NO: 32;
a regulatory nucleic acid molecule 43 consisting of TPL4 and eMLP3, the nucleotide sequence of which is shown as SEQ ID NO. 33;
the regulatory nucleic acid molecule 44 consists of TPL4 and eMLP4, and the nucleotide sequence is shown in SEQ ID NO. 34.
An expression vector of aflibercept is constructed, and the structure of the expression vector is shown in figure 1. The expression vector comprises, in 5 'to 3' order: the CMV enhancer (the nucleotide sequence of which is shown in SEQ ID NO:13), the CMV promoter (the nucleotide sequence of which is shown in SEQ ID NO:9), the TPL sequence, the eMLP sequence, the intron sequence (the nucleotide sequence of which is shown in SEQ ID NO: 14), the Kozak sequence, the aflibercept coding sequence (the coding protein of which is shown in SEQ ID NO: 10; the nucleotide sequence of which is shown in SEQ ID NO: 11), the human IFNB SAR sequence (the nucleotide sequence of which is shown in SEQ ID NO:15) and the bGH polyA sequence (the nucleotide sequence of which is shown in SEQ ID NO: 12).
The following 16 AAV-aflibercept expression vectors were constructed containing different combinations of TPL and eMLP (see table 1), numbered 11, 12, 13, 14, 21, 22, 23, 24, 31, 32, 33, 34, 41, 42, 43, 44, respectively. The 16 AAV-aflibercept expression vectors described above are identical in sequence except for the regulatory nucleic acid molecule consisting of TPL and eMLP.
A baseline control vector AAV-Afibercept-basic, numbered basic (hereinafter referred to as basic vector), comprising only the CMV enhancer and CMV promoter, the aflibercept coding sequence and the bGH polyA sequence was also constructed. The basic vector was identical to the 16 AAV-aflibercept expression vectors described above, except that it did not have TPL, eMLP and Intron sequences.
TABLE 1 combination of sequence elements of AAV vectors
Example 2 cell transfection experiment
1.293T cell transfection model
The 16 AAV-aflibercept expression vectors and the basic vector, which contained regulatory nucleic acid molecules consisting of different TPLs and emlps, constructed in example 1, were transfected into 293T cells using PEI, respectively. 48 hours after transfection, cell culture supernatant and total cell protein were harvested, respectively. Expression levels of aflibercept protein in 293T cells were analyzed using western blot, captured and detected using HRP anti-human IgG (recognizing Fc region of aflibercept) (fig. 2A), and GAPDH protein was detected using HRP anti-human GAPDH as an internal control. Secreted aflibercept proteins in 293T supernatants were analyzed by ELISA, captured and detected using anti-human IgG (Fc fragment recognizing aflibercept) antibody (fig. 3A). As a result, a number of AAV-Aflibercept vectors containing TPL and eMLP elements were found to have significantly increased intracellular and supernatant Aflibercept levels compared to the basic vector, including vectors numbered 11, 13, 14, 21, 22, 23, 24, 31, 41, 42, 43 and 44.
ARPE-19 cell transfection model
The 16 AAV-aflibercept expression vectors and basic vectors comprising regulatory nucleic acid molecules consisting of different TPL and eMLP constructed in example 1 were transfected into ARPE-19 cells using PEI, respectively. 48 hours after transfection, cell culture supernatant and total cell protein were harvested, respectively. Expression levels of aflibercept protein in ARPE-19 cells were analyzed using western blot, captured and detected using HRP anti-human IgG (recognizing Fc region of aflibercept) (fig. 2B), and GAPDH protein was detected using HRP anti-human GAPDH as an internal control. Secreted aflibercept proteins in 293T supernatants were analyzed by ELISA, captured and detected using anti-human IgG (Fc fragment recognizing aflibercept) antibody (fig. 3B). As a result, a number of AAV-Aflibercept vectors containing TPL and eMLP elements were found to have significantly increased intracellular levels of Aflibercept compared to basic vectors, including vectors numbered 11, 13, 14, 21, 22, 23, 24, 31, 41, 42, 43, and 44.
Example 3 cell infection experiments
Considering that the DNA state containing exogenous Aflibercept coding sequence has obvious difference after plasmid transfected cells and AAV virus particles infected cells, 293T cells (A) are used for further simulating the application scene of AAV gene therapyCRL-3216TM), AAV-DJ, AAV Helper packaging system (Cell Biolabs, VPK-400-DJ), and any one of the Afibercep expression vectors, for packaging to produce AAV viral particles.
The AAV virus packaging and purifying steps are as follows:
1) day 0 (Day 0): cell seeding
The 293T was inoculated into 15cm dishes (the amount of inoculation was determined by the amount of virus expected)
2) Day 1 (Day 1): plasmid transfection
15cm dish transfection system: 15 ug AAV expression plasmid +15 ug AAV Helper +15 ug g g envelope
3) Day 3 (Day 3): 48h after transfection
A. Preparation of liquid Nitrogen
B. AAV293 was digested and collected into 50ml centrifuge tubes (Corning tubes are relatively freeze tolerant), washed twice with PBS, centrifuged at 1200rpm for 5min, and PBS was blotted dry;
C. resuspending the cells in 2ml cell lysis buffer per 15cm dish (total lysate volume of each virus is no more than 6ml), freezing the cells with liquid nitrogen, thawing immediately with 37 ℃ water bath, repeating for 3 times to fully lyse the cells; freezing the cells with liquid nitrogen again, and storing at-80 deg.C, or continuing the purification process;
4) after thawing the cell lysate in a 37 ℃ water bath, adding Benzonase to a final concentration of 50U/ml (25U/ul Benzonase stock solution added with 8. mu.l to 4ml), and adding sodium deoxycholate to a final concentration of 0.5% in a 37 ℃ water bath for 30 min;
5) iodixanol (Iodixanol) density gradient solution configuration (OptPrep is 60% Iodixanol, 361625 centrifuge tube capacity is 32.4)
TABLE 2 Iodixanol (Iodixanol) Density gradient solution configuration
6) Density gradient was perfused with a 10ml syringe: sequentially filling 9ml of 15% iodixanol layer, 6ml of 25% iodixanol layer, 5ml of 40% iodixanol layer and 2ml of 60% iodixanol layer, filling from low density to high density, inserting a syringe needle to the bottom of a centrifuge tube during each filling, and avoiding generating bubbles during filling;
7) centrifuging at 4500rpm at 4 deg.C for 30 min;
8) cell lysis supernatant (about 6ml) containing virus, plated on the uppermost layer of density gradient, capped with cell lysate and trimmed;
9) centrifugation was carried out using a Beckman Ti70 rotor at 67,000rpm for 1h at 18 ℃ with maximum acceleration and braking;
10) using a 10ml syringe and 18g needle, 3-5 mm puncture (needle bevel up) at 60-40% interface, collect 3-4 ml of a layer of virus-containing 40% iodixanol liquid (avoid protein contamination at 40-25% interface); can collect about 500ul per tube;
11) collecting 1-2ul of each tube, diluting by 20 times, and measuring absorbance at 340nm, wherein the collection tubes before the highest absorbance can be retained and mixed;
12) centrifuging at the highest rotation speed by using a 100K protein concentration tube, concentrating virus supernatant, adding 20ml of PBS for rinsing once, and centrifuging again for concentration to the desired volume;
13) the virus can be further purified using a HiTrap heparin affinity column or further concentrated using a 100K low volume protein concentration tube.
After purification and quantification of AAV viruses, ARPE-19 cells were infected in vitro with viruses carrying different AAV-Aflibercept vectors. Cell culture supernatants and total cellular proteins were harvested 72 hours after infection, respectively. Expression levels of intracellular aflibercept proteins were analyzed using western blots, captured and detected using anti-human IgG (recognizing the Fc-domain of aflibercept) (fig. 4). Analysis of secreted aflibercept proteins in culture supernatants by ELISA anti-human IgG (recognizing the Fc fragment of aflibercept) was used for capture and detection (fig. 5B). As a result, it was found that a number of AAV-Aflibercept vectors containing TPL and eMLP elements had significantly increased intracellular and supernatant Aflibercept levels compared to the basic vector.
Meanwhile, DNA is extracted from a part of ARPE-19 cells infected for 72 hours, then AAV genome ITR specific primers are used for real-time PCR, the average AAV genome copy number in each experimental group of cells is determined, the virus copy number in the cells after virus infection is quantitatively analyzed (figure 5A), after the ARPE-19 cells are infected by corresponding Aflibercept expression plasmids and packaged into the obtained AAV viruses, the Aflibercept expression level corresponding to each virus copy in the cells is calculated, and the Aflibercept protein amount in the supernatant corresponding to each virus genome in each cell is averaged, so that the expression levels of various AAV-Aflibercept vectors are further accurately evaluated (figure 5B).
Example 4 Integrated analysis of different cell model data
To integrate the expression levels of the vectors in the three cell models described above in example 2 and example 3, the most potential vectors were selected for in vivo evaluation and correlation analysis was performed on the expression levels of the aflibercept proteins in the intracellular and supernatant of the cells after transfection and infection with the different AO vectors (fig. 6). Air bubble maps were generated using Aflibercept protein levels in three different cell models. The X axis represents the level of secreted Aflibercept protein in the supernatant of ARPE-19 cell transfection model, and the Y axis represents the level of secreted Aflibercept protein in the supernatant of 293T cell transfection model; the size of the air bubbles represents the level of secreted Aflibercept protein in the supernatant of the ARPE-19 cell infection model, and the depth of air bubble coloration represents the expression level of the Aflibercept protein in the ARPE-19 cell infection model cells; the font size of the numerical number above the bubble represents the expression level of the Aflibercept protein in the cell in the 293T cell transfection model; the font size of the numerical numbers on the right side of the bubbles represents the intracellular expression level of Aflibercept protein in the 293T cell transfection model.
As a result, the AAV-Aflibercept-23 and AAV-Aflibercept-24 vectors have higher protein expression levels in 293T cells and ARPE-19 cells, AAV-Aflibercept-14 has the highest protein expression in 293T cells, and AAV-Aflibercept-43 has the highest protein expression in ARPE-19 cells.
EXAMPLE 5 evaluation of the expression level of AAV-Aflibercept vector in rat retina
AAV-Aflibercept-23, AAV-Aflibercept-24, AAV-Aflibercept-43 and AAV-Aflibercept-14 are selected for subsequent development, and are respectively named as AO-1 (the nucleotide sequence of which is shown in SEQ ID NO: 35), AO-2 (the nucleotide sequence of which is shown in SEQ ID NO: 36), AO-3 (the nucleotide sequence of which is shown in SEQ ID NO: 37) and AO-4 (the nucleotide sequence of which is shown in SEQ ID NO: 38). AAV viral particles were produced by packaging using AAV8 packaging system, 293T transfected AAV8, AAV Helper and any one of Afibercep expression vectors.
TABLE 3 AAV vector name comparison Table
BN rat is taken, four viruses of AO-1, AO-2, AO-3 and AO-4 are respectively injected under retina, and 4E10 GC (genome Copies) virus is injected into eyeball of each rat. Four weeks after injection, aqueous humor was isolated for ELISA analysis of levels of secreted aflibercept protein (fig. 7A); total retinal and choroidal tissue proteins were separately extracted and used for western blot analysis of intracellular levels of aflibercept protein expression (fig. 7B, 7C).
Simultaneously, extracting retinal tissue DNA, detecting AAV genome copy number in the retinal tissue by using real-time PCR, quantitatively analyzing virus copy number in cells after virus infection (figure 7D), and calculating Aflibercept expression level corresponding to each virus copy in the cells so as to further accurately evaluate the level of secretory Aflibercept protein corresponding to each virus genome in rat retinal aqueous humor (figure 7E) after injecting four viruses of AO-1, AO-2, AO-3 and AO-4; and the level of intracellular aflibercept protein per viral genome on average in rat retina and choroid. As a result, the average AAV genome copy number in the cells is the highest in the rats injected with AO-1 virus; in rats injected with AO-2 virus, secreted aflibercept levels in aqueous humor, and intracellular mean aflibercept levels in retina and choroid were all highest (FIG. 7F, G).
Sequence listing
<110> Beijing Anlong Gene medicine technology Co., Ltd
<120> expression vector for high-level expression of foreign gene
<130> MTI20136
<160> 38
<170> SIPOSequenceListing 1.0
<210> 1
<211> 202
<212> DNA
<213> TPL1(Artificial Sequence)
<400> 1
actctcttcc gcatcgctgt ctgcgagggc cagctgttgg gctcgcggtt gaggacaaac 60
tcttcgcggt ctttccagta ctcttggatc ggaaacccgt cggcctccga acaggtactc 120
cgccgccgag ggacctgagc gagtccgcat cgaccggatc ggaaaacctc tcgagaaagg 180
cgtctaacca gtcacagtcg ca 202
<210> 2
<211> 373
<212> DNA
<213> TPL2(Artificial Sequence)
<400> 2
cttccgcatc gctgtctgcg agggccagct gttggggtga gtactccctc tcaaaagcgg 60
gcatgacttc tgcgctaaga ttgtcagttt ccaaaaacga ggaggatttg atattcactg 120
gcccgcggtg atgcctttga gggtggccgc gtccatctgg tcagaaaaga caatcttttt 180
gttgtcaagc ttccttgatg atgtcatact tatcctgtcc cttttttttc cacagctcgc 240
ggttgaggac aaactcttcg cggtctttcc agtactcttg gatcggaaac ccgtcggcct 300
ccgaacggta ctccgccacc gagggacctg agcgagtccg catcgaccgg atcggaaaac 360
ctctcgaggt acc 373
<210> 3
<211> 200
<212> DNA
<213> TPL3(Artificial Sequence)
<400> 3
actctcttcc gcatcgctgt ctgcgagggc cagctgttgg gctcgcggtt gaggacaaac 60
tcttcgcggt ctttccagta ctcttggatc ggaaacccgt cggcctccga acgtactccg 120
ccaccgaggg acctgagcga gtccgcatcg accggatcgg aaaacctctc gagaaaggcg 180
tctaaccagt cacagtcgca 200
<210> 4
<211> 200
<212> DNA
<213> TPL4(Artificial Sequence)
<400> 4
actgtcttcc ggatcgctgt ccaggagcgc cagctgttgg gctcgcggtt gagaaggtat 60
tcttcgcgat ccttccagta ctcttcgagg ggaaacccgt ctttttctgc acggtactcc 120
gcgcaaggac ctgatcgtct caagatccac gggatctgaa aacctttcga cgaaagcgtc 180
taaccagtcg caatcgcaag 200
<210> 5
<211> 400
<212> DNA
<213> eMLP1(Artificial Sequence)
<400> 5
cccccatgct ttttgatgcg tttcttacct ctggtttcca tgagccggtg tccacgctcg 60
gtgacgaaaa ggctgtccgt gtccccgtat acagacttga gaggcctgtc ctcgagcggt 120
gttccgcggt cctcctcgta tagaaactcg gaccactctg agacgaaggc tcgcgtccag 180
gccagcacga aggaggctaa gtgggagggg tagcggtcgt tgtccactag ggggtccact 240
cgctccaggg tgtgaagaca catgtccccc tcttcggcat caaggaaggt gattggttta 300
taggtgtatg ccacgtgacc gggtgttcct gaaggggggg tataaaaggg ggtgggggcg 360
cgttcgtcct cactctcttc cgcatcgctg tctgcgaggg 400
<210> 6
<211> 400
<212> DNA
<213> eMLP2(Artificial Sequence)
<400> 6
ccgcggcatg gcccttggcg cgcagcttgc ccttggagga ggcgccgcac gaggggcagt 60
gcagactttt gagggcgtag agcttgggcg cgagaaatac cgattccggg gagtaggcat 120
ccgcgccgca ggccccgcag acggtctcgc attccacgag ccaggtgagc tctggccgtt 180
cggggtcaaa aaccaggttt cccccatgct ttttgatgcg tttcttacct ctggtttcca 240
tgagccggtg tccacgctcg gtgacgaaaa ggctgtccgt gtccccgtat acagacttga 300
gaggcctgtc ctcgagcggt gttccgcggt cctcctcgta tagaaactcg gaccactctg 360
agacgaaggc tcgcgtccag gccagcacga aggaggctaa 400
<210> 7
<211> 400
<212> DNA
<213> eMLP3(Artificial Sequence)
<400> 7
cagacgggcc agggtcatgt ctttccacgg gcgcagggtc ctcgtcagcg tagtctgggt 60
cacggtgaag gggtgcgctc cgggctgcgc gctggccagg gtgcgcttga ggctggtcct 120
gctggtgctg aagcgctgcc ggtcttcgcc ctgcgcgtcg gccaggtagc atttgaccat 180
ggtgtcatag tccagcccct ccgcggcatg gcccttggcg cgcagcttgc ccttggagga 240
ggcgccgcac gaggggcagt gcagactttt gagggcgtag agcttgggcg cgagaaatac 300
cgattccggg gagtaggcat ccgcgccgca ggccccgcag acggtctcgc attccacgag 360
ccaggtgagc tctggccgtt cggggtcaaa aaccaggttt 400
<210> 8
<211> 400
<212> DNA
<213> eMLP4(Artificial Sequence)
<400> 8
cgatagcagt tcttgcaagg aagcaaagtt tttcaacggt ttgaggccgt ccgccgtagg 60
catgcttttg agcgtttgac caagcagttc caggcggtcc cacagctcgg tcacgtgctc 120
tacggcatct cgatccagca tatctcctcg tttcgcgggt tggggcggct ttcgctgtac 180
ggcagtagtc ggtgctcgtc cagacgggcc agggtcatgt ctttccacgg gcgcagggtc 240
ctcgtcagcg tagtctgggt cacggtgaag gggtgcgctc cgggctgcgc gctggccagg 300
gtgcgcttga ggctggtcct gctggtgctg aagcgctgcc ggtcttcgcc ctgcgcgtcg 360
gccaggtagc atttgaccat ggtgtcatag tccagcccct 400
<210> 9
<211> 204
<212> DNA
<213> CMV promoter (Artificial Sequence)
<400> 9
gtgatgcggt tttggcagta catcaatggg cgtggatagc ggtttgactc acggggattt 60
ccaagtctcc accccattga cgtcaatggg agtttgtttt ggcaccaaaa tcaacgggac 120
tttccaaaat gtcgtaacaa ctccgcccca ttgacgcaaa tgggcggtag gcgtgtacgg 180
tgggaggtct atataagcag agct 204
<210> 10
<211> 431
<212> PRT
<213> Abbericept (Artificial Sequence)
<400> 10
Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu
1 5 10 15
Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val
20 25 30
Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr
35 40 45
Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe
50 55 60
Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu
65 70 75 80
Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg
85 90 95
Gln Thr Asn Thr Ile Ile Asp Val Val Leu Ser Pro Ser His Gly Ile
100 105 110
Glu Leu Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr
115 120 125
Glu Leu Asn Val Gly Ile Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys
130 135 140
His Gln His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gln Ser Gly
145 150 155 160
Ser Glu Met Lys Lys Phe Leu Ser Thr Leu Thr Ile Asp Gly Val Thr
165 170 175
Arg Ser Asp Gln Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met
180 185 190
Thr Lys Lys Asn Ser Thr Phe Val Arg Val His Glu Lys Asp Lys Thr
195 200 205
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
210 215 220
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
225 230 235 240
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
245 250 255
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
260 265 270
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
275 280 285
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
290 295 300
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
305 310 315 320
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
325 330 335
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
340 345 350
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
355 360 365
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
370 375 380
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
385 390 395 400
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
405 410 415
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
420 425 430
<210> 11
<211> 1377
<212> DNA
<213> Abbericept-encoding nucleic acid (Artificial Sequence)
<400> 11
atggtctctt attgggacac gggagttctc ctgtgtgcac tgctgagctg ccttctcctc 60
accggaagtt caagtggttc cgatacaggg cggccgttcg ttgagatgta ctccgaaatt 120
ccggaaatta ttcatatgac agaaggtcgc gaactcgtta ttccgtgtcg cgtaacgtct 180
ccaaacatca cggtaacact caaaaaattc ccacttgaca cgttgatccc ggacggcaaa 240
cggattatct gggatagcag gaaaggtttt atcatttcta acgcgacgta taaagaaatc 300
gggctcctga catgcgaagc tactgtaaat ggccacttgt ataaaaccaa ttacctgacg 360
catcggcaga cgaacaccat tatagacgta gtcctgagtc cgagccacgg cattgaactt 420
agtgttggcg agaaacttgt attgaactgt acggctcgga ctgagctgaa cgtcggcata 480
gattttaatt gggagtatcc tagttcaaaa catcagcata agaaactcgt caatagggac 540
ctcaaaaccc agagtggttc tgagatgaag aagtttttgt caaccctgac gatcgatggt 600
gttacgcgct cagatcaagg gctctatacg tgtgccgcgt cttcagggct catgaccaaa 660
aagaactcca cgtttgtacg cgtgcacgaa aaagacaaga ctcatacatg cccaccttgc 720
cccgcccctg aactgcttgg cggtccctct gtatttcttt tccctcctaa accgaaagat 780
actttgatga tatcccggac ccccgaagtg acatgtgtag ttgtcgacgt atcacatgaa 840
gatccggagg ttaaatttaa ctggtacgtt gatggcgttg aagttcacaa tgctaagact 900
aaaccgaggg aagagcaata taacagtaca tatcgagtcg tatccgtatt gactgtgctc 960
caccaggact ggctgaacgg aaaggagtac aagtgcaagg tatccaataa ggccctcccg 1020
gctcccatcg aaaagaccat atcaaaggcg aaaggccagc cgagggagcc gcaggtttat 1080
actctccccc cgtccaggga cgaattgaca aagaatcagg tgagcctcac atgccttgtg 1140
aaggggttct accccagtga tattgcagtg gagtgggagt ctaacggtca acccgaaaat 1200
aattacaaga cgacacctcc ggtcttggat agcgatgggt ctttcttcct ctattcaaag 1260
ctcacggtag ataagtccag atggcaacag ggaaacgttt tttcctgctc tgtgatgcat 1320
gaagcacttc ataatcacta cacgcagaag tcactttcac tgtcaccggg aaagtaa 1377
<210> 12
<211> 208
<212> DNA
<213> bGH polyA(Artificial Sequence)
<400> 12
ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc 60
tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc 120
tgagtaggtg tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt 180
gggaagagaa tagcaggcat gctgggga 208
<210> 13
<211> 380
<212> DNA
<213> CMV enhancer (Artificial Sequence)
<400> 13
gacattgatt attgactagt tattaatagt aatcaattac ggggtcatta gttcatagcc 60
catatatgga gttccgcgtt acataactta cggtaaatgg cccgcctggc tgaccgccca 120
acgacccccg cccattgacg tcaataatga cgtatgttcc catagtaacg ccaataggga 180
ctttccattg acgtcaatgg gtggagtatt tacggtaaac tgcccacttg gcagtacatc 240
aagtgtatca tatgccaagt acgcccccta ttgacgtcaa tgacggtaaa tggcccgcct 300
ggcattatgc ccagtacatg accttatggg actttcctac ttggcagtac atctacgtat 360
tagtcatcgc tattaccatg 380
<210> 14
<211> 189
<212> DNA
<213> SV40 intron (Artificial Sequence)
<400> 14
gatccggtac tcgaggaact gaaaaaccag aaagttaact ggtaagttta gtctttttgt 60
cttttatttc aggtcccgga tccggtggtg gtgcaaatca aagaactgct cctcagtgga 120
tgttgccttt acttctaggc ctgtacggaa gtgttacttc tgctctaaaa gctgcggaat 180
tgtacccgc 189
<210> 15
<211> 790
<212> DNA
<213> human interferon-beta human scaffold attachment region (Artificial Sequence)
<400> 15
actgaagtca tgatggcatg cttctatatt attttctaaa agatttaaag ttttgccttc 60
tccatttaga cttataattc actggaattt ttttgtgtgt atggtatgac atatgggttc 120
ccttttattt tttacatata aatatatttc cctgtttttc taaaaaagaa aaagatcatc 180
attttcccat tgtaaaatgc catatttttt tcataggtca cttacatata tcaatgggtc 240
tgtttctgag ctctactcta ttttatcagc ctcactgtct atccccacac atctcatgct 300
ttgctctaaa tcttgatatt tagtggaaca ttctttccca ttttgttcta caagaatatt 360
tttgttattg tcttttgggc ttctatatac attttagaat gaggttggca agttaacaaa 420
cagctttttt ggggtgaaca tattgactac aaatttatgt ggaaagaaag tataccttca 480
caatattaag tcttttagtt catgaatata gtatgtctct ccgtttctgc attaacttag 540
acattcatta atttctctca caatttataa gtttatttag atcttcattc atttaaatct 600
tcactaacct ctcatttaca atttgtaagt tttctgggta acagtcttgc acttctttgc 660
ctagatttat ttccaagtag attattttca tacatcgtct atggtgtcat ttttaaaatg 720
taatttttca cctttttatt gctaaagaga gatgactgat tgttaatatt gatcttgtgc 780
gtggcgacct 790
<210> 16
<211> 130
<212> DNA
<213> 5'-ITR(Artificial Sequence)
<400> 16
cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg ggcgaccttt 60
ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa ctccatcact 120
aggggttcct 130
<210> 17
<211> 141
<212> DNA
<213> 3'-ITR(Artificial Sequence)
<400> 17
aggaacccct agtgatggag ttggccactc cctctctgcg cgctcgctcg ctcactgagg 60
ccgggcgacc aaaggtcgcc cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc 120
gagcgcgcag ctgcctgcag g 141
<210> 18
<211> 861
<212> DNA
<213> ampicillin resistance gene (Artificial Sequence)
<400> 18
atgagtattc aacatttccg tgtcgccctt attccctttt ttgcggcatt ttgccttcct 60
gtttttgctc acccagaaac gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca 120
cgagtgggtt acatcgaact ggatctcaac agcggtaaga tccttgagag ttttcgcccc 180
gaagaacgtt ttccaatgat gagcactttt aaagttctgc tatgtggcgc ggtattatcc 240
cgtattgacg ccgggcaaga gcaactcggt cgccgcatac actattctca gaatgacttg 300
gttgagtact caccagtcac agaaaagcat cttacggatg gcatgacagt aagagaatta 360
tgcagtgctg ccataaccat gagtgataac actgcggcca acttacttct gacaacgatc 420
ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt aactcgcctt 480
gatcgttggg aaccggagct gaatgaagcc ataccaaacg acgagcgtga caccacgatg 540
cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg gcgaactact tactctagct 600
tcccggcaac aattaataga ctggatggag gcggataaag ttgcaggacc acttctgcgc 660
tcggcccttc cggctggctg gtttattgct gataaatctg gagccggtga gcgtggaagc 720
cgcggtatca ttgcagcact ggggccagat ggtaagccct cccgtatcgt agttatctac 780
acgacgggga gtcaggcaac tatggatgaa cgaaatagac agatcgctga gataggtgcc 840
tcactgatta agcattggta a 861
<210> 19
<211> 602
<212> DNA
<213> regulatory nucleic acid molecule 11(Artificial Sequence)
<400> 19
actctcttcc gcatcgctgt ctgcgagggc cagctgttgg gctcgcggtt gaggacaaac 60
tcttcgcggt ctttccagta ctcttggatc ggaaacccgt cggcctccga acaggtactc 120
cgccgccgag ggacctgagc gagtccgcat cgaccggatc ggaaaacctc tcgagaaagg 180
cgtctaacca gtcacagtcg cacccccatg ctttttgatg cgtttcttac ctctggtttc 240
catgagccgg tgtccacgct cggtgacgaa aaggctgtcc gtgtccccgt atacagactt 300
gagaggcctg tcctcgagcg gtgttccgcg gtcctcctcg tatagaaact cggaccactc 360
tgagacgaag gctcgcgtcc aggccagcac gaaggaggct aagtgggagg ggtagcggtc 420
gttgtccact agggggtcca ctcgctccag ggtgtgaaga cacatgtccc cctcttcggc 480
atcaaggaag gtgattggtt tataggtgta tgccacgtga ccgggtgttc ctgaaggggg 540
ggtataaaag ggggtggggg cgcgttcgtc ctcactctct tccgcatcgc tgtctgcgag 600
gg 602
<210> 20
<211> 602
<212> DNA
<213> regulatory nucleic acid molecule 12(Artificial Sequence)
<400> 20
actctcttcc gcatcgctgt ctgcgagggc cagctgttgg gctcgcggtt gaggacaaac 60
tcttcgcggt ctttccagta ctcttggatc ggaaacccgt cggcctccga acaggtactc 120
cgccgccgag ggacctgagc gagtccgcat cgaccggatc ggaaaacctc tcgagaaagg 180
cgtctaacca gtcacagtcg caccgcggca tggcccttgg cgcgcagctt gcccttggag 240
gaggcgccgc acgaggggca gtgcagactt ttgagggcgt agagcttggg cgcgagaaat 300
accgattccg gggagtaggc atccgcgccg caggccccgc agacggtctc gcattccacg 360
agccaggtga gctctggccg ttcggggtca aaaaccaggt ttcccccatg ctttttgatg 420
cgtttcttac ctctggtttc catgagccgg tgtccacgct cggtgacgaa aaggctgtcc 480
gtgtccccgt atacagactt gagaggcctg tcctcgagcg gtgttccgcg gtcctcctcg 540
tatagaaact cggaccactc tgagacgaag gctcgcgtcc aggccagcac gaaggaggct 600
aa 602
<210> 21
<211> 602
<212> DNA
<213> regulatory nucleic acid molecule 13(Artificial Sequence)
<400> 21
actctcttcc gcatcgctgt ctgcgagggc cagctgttgg gctcgcggtt gaggacaaac 60
tcttcgcggt ctttccagta ctcttggatc ggaaacccgt cggcctccga acaggtactc 120
cgccgccgag ggacctgagc gagtccgcat cgaccggatc ggaaaacctc tcgagaaagg 180
cgtctaacca gtcacagtcg cacagacggg ccagggtcat gtctttccac gggcgcaggg 240
tcctcgtcag cgtagtctgg gtcacggtga aggggtgcgc tccgggctgc gcgctggcca 300
gggtgcgctt gaggctggtc ctgctggtgc tgaagcgctg ccggtcttcg ccctgcgcgt 360
cggccaggta gcatttgacc atggtgtcat agtccagccc ctccgcggca tggcccttgg 420
cgcgcagctt gcccttggag gaggcgccgc acgaggggca gtgcagactt ttgagggcgt 480
agagcttggg cgcgagaaat accgattccg gggagtaggc atccgcgccg caggccccgc 540
agacggtctc gcattccacg agccaggtga gctctggccg ttcggggtca aaaaccaggt 600
tt 602
<210> 22
<211> 602
<212> DNA
<213> regulatory nucleic acid molecule 14(Artificial Sequence)
<400> 22
actctcttcc gcatcgctgt ctgcgagggc cagctgttgg gctcgcggtt gaggacaaac 60
tcttcgcggt ctttccagta ctcttggatc ggaaacccgt cggcctccga acaggtactc 120
cgccgccgag ggacctgagc gagtccgcat cgaccggatc ggaaaacctc tcgagaaagg 180
cgtctaacca gtcacagtcg cacgatagca gttcttgcaa ggaagcaaag tttttcaacg 240
gtttgaggcc gtccgccgta ggcatgcttt tgagcgtttg accaagcagt tccaggcggt 300
cccacagctc ggtcacgtgc tctacggcat ctcgatccag catatctcct cgtttcgcgg 360
gttggggcgg ctttcgctgt acggcagtag tcggtgctcg tccagacggg ccagggtcat 420
gtctttccac gggcgcaggg tcctcgtcag cgtagtctgg gtcacggtga aggggtgcgc 480
tccgggctgc gcgctggcca gggtgcgctt gaggctggtc ctgctggtgc tgaagcgctg 540
ccggtcttcg ccctgcgcgt cggccaggta gcatttgacc atggtgtcat agtccagccc 600
ct 602
<210> 23
<211> 773
<212> DNA
<213> regulatory nucleic acid molecule 21(Artificial Sequence)
<400> 23
cttccgcatc gctgtctgcg agggccagct gttggggtga gtactccctc tcaaaagcgg 60
gcatgacttc tgcgctaaga ttgtcagttt ccaaaaacga ggaggatttg atattcactg 120
gcccgcggtg atgcctttga gggtggccgc gtccatctgg tcagaaaaga caatcttttt 180
gttgtcaagc ttccttgatg atgtcatact tatcctgtcc cttttttttc cacagctcgc 240
ggttgaggac aaactcttcg cggtctttcc agtactcttg gatcggaaac ccgtcggcct 300
ccgaacggta ctccgccacc gagggacctg agcgagtccg catcgaccgg atcggaaaac 360
ctctcgaggt acccccccat gctttttgat gcgtttctta cctctggttt ccatgagccg 420
gtgtccacgc tcggtgacga aaaggctgtc cgtgtccccg tatacagact tgagaggcct 480
gtcctcgagc ggtgttccgc ggtcctcctc gtatagaaac tcggaccact ctgagacgaa 540
ggctcgcgtc caggccagca cgaaggaggc taagtgggag gggtagcggt cgttgtccac 600
tagggggtcc actcgctcca gggtgtgaag acacatgtcc ccctcttcgg catcaaggaa 660
ggtgattggt ttataggtgt atgccacgtg accgggtgtt cctgaagggg gggtataaaa 720
gggggtgggg gcgcgttcgt cctcactctc ttccgcatcg ctgtctgcga ggg 773
<210> 24
<211> 773
<212> DNA
<213> regulatory nucleic acid molecule 22(Artificial Sequence)
<400> 24
cttccgcatc gctgtctgcg agggccagct gttggggtga gtactccctc tcaaaagcgg 60
gcatgacttc tgcgctaaga ttgtcagttt ccaaaaacga ggaggatttg atattcactg 120
gcccgcggtg atgcctttga gggtggccgc gtccatctgg tcagaaaaga caatcttttt 180
gttgtcaagc ttccttgatg atgtcatact tatcctgtcc cttttttttc cacagctcgc 240
ggttgaggac aaactcttcg cggtctttcc agtactcttg gatcggaaac ccgtcggcct 300
ccgaacggta ctccgccacc gagggacctg agcgagtccg catcgaccgg atcggaaaac 360
ctctcgaggt accccgcggc atggcccttg gcgcgcagct tgcccttgga ggaggcgccg 420
cacgaggggc agtgcagact tttgagggcg tagagcttgg gcgcgagaaa taccgattcc 480
ggggagtagg catccgcgcc gcaggccccg cagacggtct cgcattccac gagccaggtg 540
agctctggcc gttcggggtc aaaaaccagg tttcccccat gctttttgat gcgtttctta 600
cctctggttt ccatgagccg gtgtccacgc tcggtgacga aaaggctgtc cgtgtccccg 660
tatacagact tgagaggcct gtcctcgagc ggtgttccgc ggtcctcctc gtatagaaac 720
tcggaccact ctgagacgaa ggctcgcgtc caggccagca cgaaggaggc taa 773
<210> 25
<211> 773
<212> DNA
<213> regulatory nucleic acid molecule 23(Artificial Sequence)
<400> 25
cttccgcatc gctgtctgcg agggccagct gttggggtga gtactccctc tcaaaagcgg 60
gcatgacttc tgcgctaaga ttgtcagttt ccaaaaacga ggaggatttg atattcactg 120
gcccgcggtg atgcctttga gggtggccgc gtccatctgg tcagaaaaga caatcttttt 180
gttgtcaagc ttccttgatg atgtcatact tatcctgtcc cttttttttc cacagctcgc 240
ggttgaggac aaactcttcg cggtctttcc agtactcttg gatcggaaac ccgtcggcct 300
ccgaacggta ctccgccacc gagggacctg agcgagtccg catcgaccgg atcggaaaac 360
ctctcgaggt acccagacgg gccagggtca tgtctttcca cgggcgcagg gtcctcgtca 420
gcgtagtctg ggtcacggtg aaggggtgcg ctccgggctg cgcgctggcc agggtgcgct 480
tgaggctggt cctgctggtg ctgaagcgct gccggtcttc gccctgcgcg tcggccaggt 540
agcatttgac catggtgtca tagtccagcc cctccgcggc atggcccttg gcgcgcagct 600
tgcccttgga ggaggcgccg cacgaggggc agtgcagact tttgagggcg tagagcttgg 660
gcgcgagaaa taccgattcc ggggagtagg catccgcgcc gcaggccccg cagacggtct 720
cgcattccac gagccaggtg agctctggcc gttcggggtc aaaaaccagg ttt 773
<210> 26
<211> 773
<212> DNA
<213> regulatory nucleic acid molecule 24(Artificial Sequence)
<400> 26
cttccgcatc gctgtctgcg agggccagct gttggggtga gtactccctc tcaaaagcgg 60
gcatgacttc tgcgctaaga ttgtcagttt ccaaaaacga ggaggatttg atattcactg 120
gcccgcggtg atgcctttga gggtggccgc gtccatctgg tcagaaaaga caatcttttt 180
gttgtcaagc ttccttgatg atgtcatact tatcctgtcc cttttttttc cacagctcgc 240
ggttgaggac aaactcttcg cggtctttcc agtactcttg gatcggaaac ccgtcggcct 300
ccgaacggta ctccgccacc gagggacctg agcgagtccg catcgaccgg atcggaaaac 360
ctctcgaggt acccgatagc agttcttgca aggaagcaaa gtttttcaac ggtttgaggc 420
cgtccgccgt aggcatgctt ttgagcgttt gaccaagcag ttccaggcgg tcccacagct 480
cggtcacgtg ctctacggca tctcgatcca gcatatctcc tcgtttcgcg ggttggggcg 540
gctttcgctg tacggcagta gtcggtgctc gtccagacgg gccagggtca tgtctttcca 600
cgggcgcagg gtcctcgtca gcgtagtctg ggtcacggtg aaggggtgcg ctccgggctg 660
cgcgctggcc agggtgcgct tgaggctggt cctgctggtg ctgaagcgct gccggtcttc 720
gccctgcgcg tcggccaggt agcatttgac catggtgtca tagtccagcc cct 773
<210> 27
<211> 600
<212> DNA
<213> regulatory nucleic acid molecule 31(Artificial Sequence)
<400> 27
actctcttcc gcatcgctgt ctgcgagggc cagctgttgg gctcgcggtt gaggacaaac 60
tcttcgcggt ctttccagta ctcttggatc ggaaacccgt cggcctccga acgtactccg 120
ccaccgaggg acctgagcga gtccgcatcg accggatcgg aaaacctctc gagaaaggcg 180
tctaaccagt cacagtcgca cccccatgct ttttgatgcg tttcttacct ctggtttcca 240
tgagccggtg tccacgctcg gtgacgaaaa ggctgtccgt gtccccgtat acagacttga 300
gaggcctgtc ctcgagcggt gttccgcggt cctcctcgta tagaaactcg gaccactctg 360
agacgaaggc tcgcgtccag gccagcacga aggaggctaa gtgggagggg tagcggtcgt 420
tgtccactag ggggtccact cgctccaggg tgtgaagaca catgtccccc tcttcggcat 480
caaggaaggt gattggttta taggtgtatg ccacgtgacc gggtgttcct gaaggggggg 540
tataaaaggg ggtgggggcg cgttcgtcct cactctcttc cgcatcgctg tctgcgaggg 600
<210> 28
<211> 600
<212> DNA
<213> regulatory nucleic acid molecule 32(Artificial Sequence)
<400> 28
actctcttcc gcatcgctgt ctgcgagggc cagctgttgg gctcgcggtt gaggacaaac 60
tcttcgcggt ctttccagta ctcttggatc ggaaacccgt cggcctccga acgtactccg 120
ccaccgaggg acctgagcga gtccgcatcg accggatcgg aaaacctctc gagaaaggcg 180
tctaaccagt cacagtcgca ccgcggcatg gcccttggcg cgcagcttgc ccttggagga 240
ggcgccgcac gaggggcagt gcagactttt gagggcgtag agcttgggcg cgagaaatac 300
cgattccggg gagtaggcat ccgcgccgca ggccccgcag acggtctcgc attccacgag 360
ccaggtgagc tctggccgtt cggggtcaaa aaccaggttt cccccatgct ttttgatgcg 420
tttcttacct ctggtttcca tgagccggtg tccacgctcg gtgacgaaaa ggctgtccgt 480
gtccccgtat acagacttga gaggcctgtc ctcgagcggt gttccgcggt cctcctcgta 540
tagaaactcg gaccactctg agacgaaggc tcgcgtccag gccagcacga aggaggctaa 600
<210> 29
<211> 600
<212> DNA
<213> regulatory nucleic acid molecule 33(Artificial Sequence)
<400> 29
actctcttcc gcatcgctgt ctgcgagggc cagctgttgg gctcgcggtt gaggacaaac 60
tcttcgcggt ctttccagta ctcttggatc ggaaacccgt cggcctccga acgtactccg 120
ccaccgaggg acctgagcga gtccgcatcg accggatcgg aaaacctctc gagaaaggcg 180
tctaaccagt cacagtcgca cagacgggcc agggtcatgt ctttccacgg gcgcagggtc 240
ctcgtcagcg tagtctgggt cacggtgaag gggtgcgctc cgggctgcgc gctggccagg 300
gtgcgcttga ggctggtcct gctggtgctg aagcgctgcc ggtcttcgcc ctgcgcgtcg 360
gccaggtagc atttgaccat ggtgtcatag tccagcccct ccgcggcatg gcccttggcg 420
cgcagcttgc ccttggagga ggcgccgcac gaggggcagt gcagactttt gagggcgtag 480
agcttgggcg cgagaaatac cgattccggg gagtaggcat ccgcgccgca ggccccgcag 540
acggtctcgc attccacgag ccaggtgagc tctggccgtt cggggtcaaa aaccaggttt 600
<210> 30
<211> 600
<212> DNA
<213> regulatory nucleic acid molecule 34(Artificial Sequence)
<400> 30
actctcttcc gcatcgctgt ctgcgagggc cagctgttgg gctcgcggtt gaggacaaac 60
tcttcgcggt ctttccagta ctcttggatc ggaaacccgt cggcctccga acgtactccg 120
ccaccgaggg acctgagcga gtccgcatcg accggatcgg aaaacctctc gagaaaggcg 180
tctaaccagt cacagtcgca cgatagcagt tcttgcaagg aagcaaagtt tttcaacggt 240
ttgaggccgt ccgccgtagg catgcttttg agcgtttgac caagcagttc caggcggtcc 300
cacagctcgg tcacgtgctc tacggcatct cgatccagca tatctcctcg tttcgcgggt 360
tggggcggct ttcgctgtac ggcagtagtc ggtgctcgtc cagacgggcc agggtcatgt 420
ctttccacgg gcgcagggtc ctcgtcagcg tagtctgggt cacggtgaag gggtgcgctc 480
cgggctgcgc gctggccagg gtgcgcttga ggctggtcct gctggtgctg aagcgctgcc 540
ggtcttcgcc ctgcgcgtcg gccaggtagc atttgaccat ggtgtcatag tccagcccct 600
<210> 31
<211> 600
<212> DNA
<213> regulatory nucleic acid molecule 41(Artificial Sequence)
<400> 31
actgtcttcc ggatcgctgt ccaggagcgc cagctgttgg gctcgcggtt gagaaggtat 60
tcttcgcgat ccttccagta ctcttcgagg ggaaacccgt ctttttctgc acggtactcc 120
gcgcaaggac ctgatcgtct caagatccac gggatctgaa aacctttcga cgaaagcgtc 180
taaccagtcg caatcgcaag cccccatgct ttttgatgcg tttcttacct ctggtttcca 240
tgagccggtg tccacgctcg gtgacgaaaa ggctgtccgt gtccccgtat acagacttga 300
gaggcctgtc ctcgagcggt gttccgcggt cctcctcgta tagaaactcg gaccactctg 360
agacgaaggc tcgcgtccag gccagcacga aggaggctaa gtgggagggg tagcggtcgt 420
tgtccactag ggggtccact cgctccaggg tgtgaagaca catgtccccc tcttcggcat 480
caaggaaggt gattggttta taggtgtatg ccacgtgacc gggtgttcct gaaggggggg 540
tataaaaggg ggtgggggcg cgttcgtcct cactctcttc cgcatcgctg tctgcgaggg 600
<210> 32
<211> 600
<212> DNA
<213> regulatory nucleic acid molecule 42(Artificial Sequence)
<400> 32
actgtcttcc ggatcgctgt ccaggagcgc cagctgttgg gctcgcggtt gagaaggtat 60
tcttcgcgat ccttccagta ctcttcgagg ggaaacccgt ctttttctgc acggtactcc 120
gcgcaaggac ctgatcgtct caagatccac gggatctgaa aacctttcga cgaaagcgtc 180
taaccagtcg caatcgcaag ccgcggcatg gcccttggcg cgcagcttgc ccttggagga 240
ggcgccgcac gaggggcagt gcagactttt gagggcgtag agcttgggcg cgagaaatac 300
cgattccggg gagtaggcat ccgcgccgca ggccccgcag acggtctcgc attccacgag 360
ccaggtgagc tctggccgtt cggggtcaaa aaccaggttt cccccatgct ttttgatgcg 420
tttcttacct ctggtttcca tgagccggtg tccacgctcg gtgacgaaaa ggctgtccgt 480
gtccccgtat acagacttga gaggcctgtc ctcgagcggt gttccgcggt cctcctcgta 540
tagaaactcg gaccactctg agacgaaggc tcgcgtccag gccagcacga aggaggctaa 600
<210> 33
<211> 600
<212> DNA
<213> regulatory nucleic acid molecule 43(Artificial Sequence)
<400> 33
actgtcttcc ggatcgctgt ccaggagcgc cagctgttgg gctcgcggtt gagaaggtat 60
tcttcgcgat ccttccagta ctcttcgagg ggaaacccgt ctttttctgc acggtactcc 120
gcgcaaggac ctgatcgtct caagatccac gggatctgaa aacctttcga cgaaagcgtc 180
taaccagtcg caatcgcaag cagacgggcc agggtcatgt ctttccacgg gcgcagggtc 240
ctcgtcagcg tagtctgggt cacggtgaag gggtgcgctc cgggctgcgc gctggccagg 300
gtgcgcttga ggctggtcct gctggtgctg aagcgctgcc ggtcttcgcc ctgcgcgtcg 360
gccaggtagc atttgaccat ggtgtcatag tccagcccct ccgcggcatg gcccttggcg 420
cgcagcttgc ccttggagga ggcgccgcac gaggggcagt gcagactttt gagggcgtag 480
agcttgggcg cgagaaatac cgattccggg gagtaggcat ccgcgccgca ggccccgcag 540
acggtctcgc attccacgag ccaggtgagc tctggccgtt cggggtcaaa aaccaggttt 600
<210> 34
<211> 600
<212> DNA
<213> regulatory nucleic acid molecule 44(Artificial Sequence)
<400> 34
actgtcttcc ggatcgctgt ccaggagcgc cagctgttgg gctcgcggtt gagaaggtat 60
tcttcgcgat ccttccagta ctcttcgagg ggaaacccgt ctttttctgc acggtactcc 120
gcgcaaggac ctgatcgtct caagatccac gggatctgaa aacctttcga cgaaagcgtc 180
taaccagtcg caatcgcaag cgatagcagt tcttgcaagg aagcaaagtt tttcaacggt 240
ttgaggccgt ccgccgtagg catgcttttg agcgtttgac caagcagttc caggcggtcc 300
cacagctcgg tcacgtgctc tacggcatct cgatccagca tatctcctcg tttcgcgggt 360
tggggcggct ttcgctgtac ggcagtagtc ggtgctcgtc cagacgggcc agggtcatgt 420
ctttccacgg gcgcagggtc ctcgtcagcg tagtctgggt cacggtgaag gggtgcgctc 480
cgggctgcgc gctggccagg gtgcgcttga ggctggtcct gctggtgctg aagcgctgcc 540
ggtcttcgcc ctgcgcgtcg gccaggtagc atttgaccat ggtgtcatag tccagcccct 600
<210> 35
<211> 6844
<212> DNA
<213> AO-1(Artificial Sequence)
<400> 35
cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg ggcgaccttt 60
ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa ctccatcact 120
aggggttcct gcggcctcta gactcgaggc gttgacattg attattgact agttattaat 180
agtaatcaat tacggggtca ttagttcata gcccatatat ggagttccgc gttacataac 240
ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg acgtcaataa 300
tgacgtatgt tcccatagta acgccaatag ggactttcca ttgacgtcaa tgggtggagt 360
atttacggta aactgcccac ttggcagtac atcaagtgta tcatatgcca agtacgcccc 420
ctattgacgt caatgacggt aaatggcccg cctggcatta tgcccagtac atgaccttat 480
gggactttcc tacttggcag tacatctacg tattagtcat cgctattacc atggtgatgc 540
ggttttggca gtacatcaat gggcgtggat agcggtttga ctcacgggga tttccaagtc 600
tccaccccat tgacgtcaat gggagtttgt tttggcacca aaatcaacgg gactttccaa 660
aatgtcgtaa caactccgcc ccattgacgc aaatgggcgg taggcgtgta cggtgggagg 720
tctatataag cagagctctc tggctaacta ccggtcttcc gcatcgctgt ctgcgagggc 780
cagctgttgg ggtgagtact ccctctcaaa agcgggcatg acttctgcgc taagattgtc 840
agtttccaaa aacgaggagg atttgatatt cactggcccg cggtgatgcc tttgagggtg 900
gccgcgtcca tctggtcaga aaagacaatc tttttgttgt caagcttcct tgatgatgtc 960
atacttatcc tgtccctttt ttttccacag ctcgcggttg aggacaaact cttcgcggtc 1020
tttccagtac tcttggatcg gaaacccgtc ggcctccgaa cggtactccg ccaccgaggg 1080
acctgagcga gtccgcatcg accggatcgg aaaacctctc gaggtaccca gacgggccag 1140
ggtcatgtct ttccacgggc gcagggtcct cgtcagcgta gtctgggtca cggtgaaggg 1200
gtgcgctccg ggctgcgcgc tggccagggt gcgcttgagg ctggtcctgc tggtgctgaa 1260
gcgctgccgg tcttcgccct gcgcgtcggc caggtagcat ttgaccatgg tgtcatagtc 1320
cagcccctcc gcggcatggc ccttggcgcg cagcttgccc ttggaggagg cgccgcacga 1380
ggggcagtgc agacttttga gggcgtagag cttgggcgcg agaaataccg attccgggga 1440
gtaggcatcc gcgccgcagg ccccgcagac ggtctcgcat tccacgagcc aggtgagctc 1500
tggccgttcg gggtcaaaaa ccaggtttga tccggtactc gaggaactga aaaaccagaa 1560
agttaactgg taagtttagt ctttttgtct tttatttcag gtcccggatc cggtggtggt 1620
gcaaatcaaa gaactgctcc tcagtggatg ttgcctttac ttctaggcct gtacggaagt 1680
gttacttctg ctctaaaagc tgcggaattg tacccgcgcc accatggtct cttattggga 1740
cacgggagtt ctcctgtgtg cactgctgag ctgccttctc ctcaccggaa gttcaagtgg 1800
ttccgataca gggcggccgt tcgttgagat gtactccgaa attccggaaa ttattcatat 1860
gacagaaggt cgcgaactcg ttattccgtg tcgcgtaacg tctccaaaca tcacggtaac 1920
actcaaaaaa ttcccacttg acacgttgat cccggacggc aaacggatta tctgggatag 1980
caggaaaggt tttatcattt ctaacgcgac gtataaagaa atcgggctcc tgacatgcga 2040
agctactgta aatggccact tgtataaaac caattacctg acgcatcggc agacgaacac 2100
cattatagac gtagtcctga gtccgagcca cggcattgaa cttagtgttg gcgagaaact 2160
tgtattgaac tgtacggctc ggactgagct gaacgtcggc atagatttta attgggagta 2220
tcctagttca aaacatcagc ataagaaact cgtcaatagg gacctcaaaa cccagagtgg 2280
ttctgagatg aagaagtttt tgtcaaccct gacgatcgat ggtgttacgc gctcagatca 2340
agggctctat acgtgtgccg cgtcttcagg gctcatgacc aaaaagaact ccacgtttgt 2400
acgcgtgcac gaaaaagaca agactcatac atgcccacct tgccccgccc ctgaactgct 2460
tggcggtccc tctgtatttc ttttccctcc taaaccgaaa gatactttga tgatatcccg 2520
gacccccgaa gtgacatgtg tagttgtcga cgtatcacat gaagatccgg aggttaaatt 2580
taactggtac gttgatggcg ttgaagttca caatgctaag actaaaccga gggaagagca 2640
atataacagt acatatcgag tcgtatccgt attgactgtg ctccaccagg actggctgaa 2700
cggaaaggag tacaagtgca aggtatccaa taaggccctc ccggctccca tcgaaaagac 2760
catatcaaag gcgaaaggcc agccgaggga gccgcaggtt tatactctcc ccccgtccag 2820
ggacgaattg acaaagaatc aggtgagcct cacatgcctt gtgaaggggt tctaccccag 2880
tgatattgca gtggagtggg agtctaacgg tcaacccgaa aataattaca agacgacacc 2940
tccggtcttg gatagcgatg ggtctttctt cctctattca aagctcacgg tagataagtc 3000
cagatggcaa cagggaaacg ttttttcctg ctctgtgatg catgaagcac ttcataatca 3060
ctacacgcag aagtcacttt cactgtcacc gggaaagtaa actgaagtca tgatggcatg 3120
cttctatatt attttctaaa agatttaaag ttttgccttc tccatttaga cttataattc 3180
actggaattt ttttgtgtgt atggtatgac atatgggttc ccttttattt tttacatata 3240
aatatatttc cctgtttttc taaaaaagaa aaagatcatc attttcccat tgtaaaatgc 3300
catatttttt tcataggtca cttacatata tcaatgggtc tgtttctgag ctctactcta 3360
ttttatcagc ctcactgtct atccccacac atctcatgct ttgctctaaa tcttgatatt 3420
tagtggaaca ttctttccca ttttgttcta caagaatatt tttgttattg tcttttgggc 3480
ttctatatac attttagaat gaggttggca agttaacaaa cagctttttt ggggtgaaca 3540
tattgactac aaatttatgt ggaaagaaag tataccttca caatattaag tcttttagtt 3600
catgaatata gtatgtctct ccgtttctgc attaacttag acattcatta atttctctca 3660
caatttataa gtttatttag atcttcattc atttaaatct tcactaacct ctcatttaca 3720
atttgtaagt tttctgggta acagtcttgc acttctttgc ctagatttat ttccaagtag 3780
attattttca tacatcgtct atggtgtcat ttttaaaatg taatttttca cctttttatt 3840
gctaaagaga gatgactgat tgttaatatt gatcttgtgc gtggcgacct ctgtgccttc 3900
tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc tggaaggtgc 3960
cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc tgagtaggtg 4020
tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt gggaagagaa 4080
tagcaggcat gctggggagc ggccgcagga acccctagtg atggagttgg ccactccctc 4140
tctgcgcgct cgctcgctca ctgaggccgg gcgaccaaag gtcgcccgac gcccgggctt 4200
tgcccgggcg gcctcagtga gcgagcgagc gcgcagctgc ctgcaggggc gcctgatgcg 4260
gtattttctc cttacgcatc tgtgcggtat ttcacaccgc atacgtcaaa gcaaccatag 4320
tacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg cagcgtgacc 4380
gctacacttg ccagcgcctt agcgcccgct cctttcgctt tcttcccttc ctttctcgcc 4440
acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg gttccgattt 4500
agtgctttac ggcacctcga ccccaaaaaa cttgatttgg gtgatggttc acgtagtggg 4560
ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt ctttaatagt 4620
ggactcttgt tccaaactgg aacaacactc aactctatct cgggctattc ttttgattta 4680
taagggattt tgccgatttc ggtctattgg ttaaaaaatg agctgattta acaaaaattt 4740
aacgcgaatt ttaacaaaat attaacgttt acaattttat ggtgcactct cagtacaatc 4800
tgctctgatg ccgcatagtt aagccagccc cgacacccgc caacacccgc tgacgcgccc 4860
tgacgggctt gtctgctccc ggcatccgct tacagacaag ctgtgaccgt ctccgggagc 4920
tgcatgtgtc agaggttttc accgtcatca ccgaaacgcg cgagacgaaa gggcctcgtg 4980
atacgcctat ttttataggt taatgtcatg ataataatgg tttcttagac gtcaggtggc 5040
acttttcggg gaaatgtgcg cggaacccct atttgtttat ttttctaaat acattcaaat 5100
atgtatccgc tcatgagaca ataaccctga taaatgcttc aataatattg aaaaaggaag 5160
agtatgagta ttcaacattt ccgtgtcgcc cttattccct tttttgcggc attttgcctt 5220
cctgtttttg ctcacccaga aacgctggtg aaagtaaaag atgctgaaga tcagttgggt 5280
gcacgagtgg gttacatcga actggatctc aacagcggta agatccttga gagttttcgc 5340
cccgaagaac gttttccaat gatgagcact tttaaagttc tgctatgtgg cgcggtatta 5400
tcccgtattg acgccgggca agagcaactc ggtcgccgca tacactattc tcagaatgac 5460
ttggttgagt actcaccagt cacagaaaag catcttacgg atggcatgac agtaagagaa 5520
ttatgcagtg ctgccataac catgagtgat aacactgcgg ccaacttact tctgacaacg 5580
atcggaggac cgaaggagct aaccgctttt ttgcacaaca tgggggatca tgtaactcgc 5640
cttgatcgtt gggaaccgga gctgaatgaa gccataccaa acgacgagcg tgacaccacg 5700
atgcctgtag caatggcaac aacgttgcgc aaactattaa ctggcgaact acttactcta 5760
gcttcccggc aacaattaat agactggatg gaggcggata aagttgcagg accacttctg 5820
cgctcggccc ttccggctgg ctggtttatt gctgataaat ctggagccgg tgagcgtgga 5880
agccgcggta tcattgcagc actggggcca gatggtaagc cctcccgtat cgtagttatc 5940
tacacgacgg ggagtcaggc aactatggat gaacgaaata gacagatcgc tgagataggt 6000
gcctcactga ttaagcattg gtaactgtca gaccaagttt actcatatat actttagatt 6060
gatttaaaac ttcattttta atttaaaagg atctaggtga agatcctttt tgataatctc 6120
atgaccaaaa tcccttaacg tgagttttcg ttccactgag cgtcagaccc cgtagaaaag 6180
atcaaaggat cttcttgaga tccttttttt ctgcgcgtaa tctgctgctt gcaaacaaaa 6240
aaaccaccgc taccagcggt ggtttgtttg ccggatcaag agctaccaac tctttttccg 6300
aaggtaactg gcttcagcag agcgcagata ccaaatactg ttcttctagt gtagccgtag 6360
ttaggccacc acttcaagaa ctctgtagca ccgcctacat acctcgctct gctaatcctg 6420
ttaccagtgg ctgctgccag tggcgataag tcgtgtctta ccgggttgga ctcaagacga 6480
tagttaccgg ataaggcgca gcggtcgggc tgaacggggg gttcgtgcac acagcccagc 6540
ttggagcgaa cgacctacac cgaactgaga tacctacagc gtgagctatg agaaagcgcc 6600
acgcttcccg aagggagaaa ggcggacagg tatccggtaa gcggcagggt cggaacagga 6660
gagcgcacga gggagcttcc agggggaaac gcctggtatc tttatagtcc tgtcgggttt 6720
cgccacctct gacttgagcg tcgatttttg tgatgctcgt caggggggcg gagcctatgg 6780
aaaaacgcca gcaacgcggc ctttttacgg ttcctggcct tttgctggcc ttttgctcac 6840
atgt 6844
<210> 36
<211> 6844
<212> DNA
<213> AO-2(Artificial Sequence)
<400> 36
cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg ggcgaccttt 60
ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa ctccatcact 120
aggggttcct gcggcctcta gactcgaggc gttgacattg attattgact agttattaat 180
agtaatcaat tacggggtca ttagttcata gcccatatat ggagttccgc gttacataac 240
ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg acgtcaataa 300
tgacgtatgt tcccatagta acgccaatag ggactttcca ttgacgtcaa tgggtggagt 360
atttacggta aactgcccac ttggcagtac atcaagtgta tcatatgcca agtacgcccc 420
ctattgacgt caatgacggt aaatggcccg cctggcatta tgcccagtac atgaccttat 480
gggactttcc tacttggcag tacatctacg tattagtcat cgctattacc atggtgatgc 540
ggttttggca gtacatcaat gggcgtggat agcggtttga ctcacgggga tttccaagtc 600
tccaccccat tgacgtcaat gggagtttgt tttggcacca aaatcaacgg gactttccaa 660
aatgtcgtaa caactccgcc ccattgacgc aaatgggcgg taggcgtgta cggtgggagg 720
tctatataag cagagctctc tggctaacta ccggtcttcc gcatcgctgt ctgcgagggc 780
cagctgttgg ggtgagtact ccctctcaaa agcgggcatg acttctgcgc taagattgtc 840
agtttccaaa aacgaggagg atttgatatt cactggcccg cggtgatgcc tttgagggtg 900
gccgcgtcca tctggtcaga aaagacaatc tttttgttgt caagcttcct tgatgatgtc 960
atacttatcc tgtccctttt ttttccacag ctcgcggttg aggacaaact cttcgcggtc 1020
tttccagtac tcttggatcg gaaacccgtc ggcctccgaa cggtactccg ccaccgaggg 1080
acctgagcga gtccgcatcg accggatcgg aaaacctctc gaggtacccg atagcagttc 1140
ttgcaaggaa gcaaagtttt tcaacggttt gaggccgtcc gccgtaggca tgcttttgag 1200
cgtttgacca agcagttcca ggcggtccca cagctcggtc acgtgctcta cggcatctcg 1260
atccagcata tctcctcgtt tcgcgggttg gggcggcttt cgctgtacgg cagtagtcgg 1320
tgctcgtcca gacgggccag ggtcatgtct ttccacgggc gcagggtcct cgtcagcgta 1380
gtctgggtca cggtgaaggg gtgcgctccg ggctgcgcgc tggccagggt gcgcttgagg 1440
ctggtcctgc tggtgctgaa gcgctgccgg tcttcgccct gcgcgtcggc caggtagcat 1500
ttgaccatgg tgtcatagtc cagcccctga tccggtactc gaggaactga aaaaccagaa 1560
agttaactgg taagtttagt ctttttgtct tttatttcag gtcccggatc cggtggtggt 1620
gcaaatcaaa gaactgctcc tcagtggatg ttgcctttac ttctaggcct gtacggaagt 1680
gttacttctg ctctaaaagc tgcggaattg tacccgcgcc accatggtct cttattggga 1740
cacgggagtt ctcctgtgtg cactgctgag ctgccttctc ctcaccggaa gttcaagtgg 1800
ttccgataca gggcggccgt tcgttgagat gtactccgaa attccggaaa ttattcatat 1860
gacagaaggt cgcgaactcg ttattccgtg tcgcgtaacg tctccaaaca tcacggtaac 1920
actcaaaaaa ttcccacttg acacgttgat cccggacggc aaacggatta tctgggatag 1980
caggaaaggt tttatcattt ctaacgcgac gtataaagaa atcgggctcc tgacatgcga 2040
agctactgta aatggccact tgtataaaac caattacctg acgcatcggc agacgaacac 2100
cattatagac gtagtcctga gtccgagcca cggcattgaa cttagtgttg gcgagaaact 2160
tgtattgaac tgtacggctc ggactgagct gaacgtcggc atagatttta attgggagta 2220
tcctagttca aaacatcagc ataagaaact cgtcaatagg gacctcaaaa cccagagtgg 2280
ttctgagatg aagaagtttt tgtcaaccct gacgatcgat ggtgttacgc gctcagatca 2340
agggctctat acgtgtgccg cgtcttcagg gctcatgacc aaaaagaact ccacgtttgt 2400
acgcgtgcac gaaaaagaca agactcatac atgcccacct tgccccgccc ctgaactgct 2460
tggcggtccc tctgtatttc ttttccctcc taaaccgaaa gatactttga tgatatcccg 2520
gacccccgaa gtgacatgtg tagttgtcga cgtatcacat gaagatccgg aggttaaatt 2580
taactggtac gttgatggcg ttgaagttca caatgctaag actaaaccga gggaagagca 2640
atataacagt acatatcgag tcgtatccgt attgactgtg ctccaccagg actggctgaa 2700
cggaaaggag tacaagtgca aggtatccaa taaggccctc ccggctccca tcgaaaagac 2760
catatcaaag gcgaaaggcc agccgaggga gccgcaggtt tatactctcc ccccgtccag 2820
ggacgaattg acaaagaatc aggtgagcct cacatgcctt gtgaaggggt tctaccccag 2880
tgatattgca gtggagtggg agtctaacgg tcaacccgaa aataattaca agacgacacc 2940
tccggtcttg gatagcgatg ggtctttctt cctctattca aagctcacgg tagataagtc 3000
cagatggcaa cagggaaacg ttttttcctg ctctgtgatg catgaagcac ttcataatca 3060
ctacacgcag aagtcacttt cactgtcacc gggaaagtaa actgaagtca tgatggcatg 3120
cttctatatt attttctaaa agatttaaag ttttgccttc tccatttaga cttataattc 3180
actggaattt ttttgtgtgt atggtatgac atatgggttc ccttttattt tttacatata 3240
aatatatttc cctgtttttc taaaaaagaa aaagatcatc attttcccat tgtaaaatgc 3300
catatttttt tcataggtca cttacatata tcaatgggtc tgtttctgag ctctactcta 3360
ttttatcagc ctcactgtct atccccacac atctcatgct ttgctctaaa tcttgatatt 3420
tagtggaaca ttctttccca ttttgttcta caagaatatt tttgttattg tcttttgggc 3480
ttctatatac attttagaat gaggttggca agttaacaaa cagctttttt ggggtgaaca 3540
tattgactac aaatttatgt ggaaagaaag tataccttca caatattaag tcttttagtt 3600
catgaatata gtatgtctct ccgtttctgc attaacttag acattcatta atttctctca 3660
caatttataa gtttatttag atcttcattc atttaaatct tcactaacct ctcatttaca 3720
atttgtaagt tttctgggta acagtcttgc acttctttgc ctagatttat ttccaagtag 3780
attattttca tacatcgtct atggtgtcat ttttaaaatg taatttttca cctttttatt 3840
gctaaagaga gatgactgat tgttaatatt gatcttgtgc gtggcgacct ctgtgccttc 3900
tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc tggaaggtgc 3960
cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc tgagtaggtg 4020
tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt gggaagagaa 4080
tagcaggcat gctggggagc ggccgcagga acccctagtg atggagttgg ccactccctc 4140
tctgcgcgct cgctcgctca ctgaggccgg gcgaccaaag gtcgcccgac gcccgggctt 4200
tgcccgggcg gcctcagtga gcgagcgagc gcgcagctgc ctgcaggggc gcctgatgcg 4260
gtattttctc cttacgcatc tgtgcggtat ttcacaccgc atacgtcaaa gcaaccatag 4320
tacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg cagcgtgacc 4380
gctacacttg ccagcgcctt agcgcccgct cctttcgctt tcttcccttc ctttctcgcc 4440
acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg gttccgattt 4500
agtgctttac ggcacctcga ccccaaaaaa cttgatttgg gtgatggttc acgtagtggg 4560
ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt ctttaatagt 4620
ggactcttgt tccaaactgg aacaacactc aactctatct cgggctattc ttttgattta 4680
taagggattt tgccgatttc ggtctattgg ttaaaaaatg agctgattta acaaaaattt 4740
aacgcgaatt ttaacaaaat attaacgttt acaattttat ggtgcactct cagtacaatc 4800
tgctctgatg ccgcatagtt aagccagccc cgacacccgc caacacccgc tgacgcgccc 4860
tgacgggctt gtctgctccc ggcatccgct tacagacaag ctgtgaccgt ctccgggagc 4920
tgcatgtgtc agaggttttc accgtcatca ccgaaacgcg cgagacgaaa gggcctcgtg 4980
atacgcctat ttttataggt taatgtcatg ataataatgg tttcttagac gtcaggtggc 5040
acttttcggg gaaatgtgcg cggaacccct atttgtttat ttttctaaat acattcaaat 5100
atgtatccgc tcatgagaca ataaccctga taaatgcttc aataatattg aaaaaggaag 5160
agtatgagta ttcaacattt ccgtgtcgcc cttattccct tttttgcggc attttgcctt 5220
cctgtttttg ctcacccaga aacgctggtg aaagtaaaag atgctgaaga tcagttgggt 5280
gcacgagtgg gttacatcga actggatctc aacagcggta agatccttga gagttttcgc 5340
cccgaagaac gttttccaat gatgagcact tttaaagttc tgctatgtgg cgcggtatta 5400
tcccgtattg acgccgggca agagcaactc ggtcgccgca tacactattc tcagaatgac 5460
ttggttgagt actcaccagt cacagaaaag catcttacgg atggcatgac agtaagagaa 5520
ttatgcagtg ctgccataac catgagtgat aacactgcgg ccaacttact tctgacaacg 5580
atcggaggac cgaaggagct aaccgctttt ttgcacaaca tgggggatca tgtaactcgc 5640
cttgatcgtt gggaaccgga gctgaatgaa gccataccaa acgacgagcg tgacaccacg 5700
atgcctgtag caatggcaac aacgttgcgc aaactattaa ctggcgaact acttactcta 5760
gcttcccggc aacaattaat agactggatg gaggcggata aagttgcagg accacttctg 5820
cgctcggccc ttccggctgg ctggtttatt gctgataaat ctggagccgg tgagcgtgga 5880
agccgcggta tcattgcagc actggggcca gatggtaagc cctcccgtat cgtagttatc 5940
tacacgacgg ggagtcaggc aactatggat gaacgaaata gacagatcgc tgagataggt 6000
gcctcactga ttaagcattg gtaactgtca gaccaagttt actcatatat actttagatt 6060
gatttaaaac ttcattttta atttaaaagg atctaggtga agatcctttt tgataatctc 6120
atgaccaaaa tcccttaacg tgagttttcg ttccactgag cgtcagaccc cgtagaaaag 6180
atcaaaggat cttcttgaga tccttttttt ctgcgcgtaa tctgctgctt gcaaacaaaa 6240
aaaccaccgc taccagcggt ggtttgtttg ccggatcaag agctaccaac tctttttccg 6300
aaggtaactg gcttcagcag agcgcagata ccaaatactg ttcttctagt gtagccgtag 6360
ttaggccacc acttcaagaa ctctgtagca ccgcctacat acctcgctct gctaatcctg 6420
ttaccagtgg ctgctgccag tggcgataag tcgtgtctta ccgggttgga ctcaagacga 6480
tagttaccgg ataaggcgca gcggtcgggc tgaacggggg gttcgtgcac acagcccagc 6540
ttggagcgaa cgacctacac cgaactgaga tacctacagc gtgagctatg agaaagcgcc 6600
acgcttcccg aagggagaaa ggcggacagg tatccggtaa gcggcagggt cggaacagga 6660
gagcgcacga gggagcttcc agggggaaac gcctggtatc tttatagtcc tgtcgggttt 6720
cgccacctct gacttgagcg tcgatttttg tgatgctcgt caggggggcg gagcctatgg 6780
aaaaacgcca gcaacgcggc ctttttacgg ttcctggcct tttgctggcc ttttgctcac 6840
atgt 6844
<210> 37
<211> 6671
<212> DNA
<213> AO-3(Artificial Sequence)
<400> 37
cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg ggcgaccttt 60
ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa ctccatcact 120
aggggttcct gcggcctcta gactcgaggc gttgacattg attattgact agttattaat 180
agtaatcaat tacggggtca ttagttcata gcccatatat ggagttccgc gttacataac 240
ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg acgtcaataa 300
tgacgtatgt tcccatagta acgccaatag ggactttcca ttgacgtcaa tgggtggagt 360
atttacggta aactgcccac ttggcagtac atcaagtgta tcatatgcca agtacgcccc 420
ctattgacgt caatgacggt aaatggcccg cctggcatta tgcccagtac atgaccttat 480
gggactttcc tacttggcag tacatctacg tattagtcat cgctattacc atggtgatgc 540
ggttttggca gtacatcaat gggcgtggat agcggtttga ctcacgggga tttccaagtc 600
tccaccccat tgacgtcaat gggagtttgt tttggcacca aaatcaacgg gactttccaa 660
aatgtcgtaa caactccgcc ccattgacgc aaatgggcgg taggcgtgta cggtgggagg 720
tctatataag cagagctctc tggctaacta ccggtactgt cttccggatc gctgtccagg 780
agcgccagct gttgggctcg cggttgagaa ggtattcttc gcgatccttc cagtactctt 840
cgaggggaaa cccgtctttt tctgcacggt actccgcgca aggacctgat cgtctcaaga 900
tccacgggat ctgaaaacct ttcgacgaaa gcgtctaacc agtcgcaatc gcaagcagac 960
gggccagggt catgtctttc cacgggcgca gggtcctcgt cagcgtagtc tgggtcacgg 1020
tgaaggggtg cgctccgggc tgcgcgctgg ccagggtgcg cttgaggctg gtcctgctgg 1080
tgctgaagcg ctgccggtct tcgccctgcg cgtcggccag gtagcatttg accatggtgt 1140
catagtccag cccctccgcg gcatggccct tggcgcgcag cttgcccttg gaggaggcgc 1200
cgcacgaggg gcagtgcaga cttttgaggg cgtagagctt gggcgcgaga aataccgatt 1260
ccggggagta ggcatccgcg ccgcaggccc cgcagacggt ctcgcattcc acgagccagg 1320
tgagctctgg ccgttcgggg tcaaaaacca ggtttgatcc ggtactcgag gaactgaaaa 1380
accagaaagt taactggtaa gtttagtctt tttgtctttt atttcaggtc ccggatccgg 1440
tggtggtgca aatcaaagaa ctgctcctca gtggatgttg cctttacttc taggcctgta 1500
cggaagtgtt acttctgctc taaaagctgc ggaattgtac ccgcgccacc atggtctctt 1560
attgggacac gggagttctc ctgtgtgcac tgctgagctg ccttctcctc accggaagtt 1620
caagtggttc cgatacaggg cggccgttcg ttgagatgta ctccgaaatt ccggaaatta 1680
ttcatatgac agaaggtcgc gaactcgtta ttccgtgtcg cgtaacgtct ccaaacatca 1740
cggtaacact caaaaaattc ccacttgaca cgttgatccc ggacggcaaa cggattatct 1800
gggatagcag gaaaggtttt atcatttcta acgcgacgta taaagaaatc gggctcctga 1860
catgcgaagc tactgtaaat ggccacttgt ataaaaccaa ttacctgacg catcggcaga 1920
cgaacaccat tatagacgta gtcctgagtc cgagccacgg cattgaactt agtgttggcg 1980
agaaacttgt attgaactgt acggctcgga ctgagctgaa cgtcggcata gattttaatt 2040
gggagtatcc tagttcaaaa catcagcata agaaactcgt caatagggac ctcaaaaccc 2100
agagtggttc tgagatgaag aagtttttgt caaccctgac gatcgatggt gttacgcgct 2160
cagatcaagg gctctatacg tgtgccgcgt cttcagggct catgaccaaa aagaactcca 2220
cgtttgtacg cgtgcacgaa aaagacaaga ctcatacatg cccaccttgc cccgcccctg 2280
aactgcttgg cggtccctct gtatttcttt tccctcctaa accgaaagat actttgatga 2340
tatcccggac ccccgaagtg acatgtgtag ttgtcgacgt atcacatgaa gatccggagg 2400
ttaaatttaa ctggtacgtt gatggcgttg aagttcacaa tgctaagact aaaccgaggg 2460
aagagcaata taacagtaca tatcgagtcg tatccgtatt gactgtgctc caccaggact 2520
ggctgaacgg aaaggagtac aagtgcaagg tatccaataa ggccctcccg gctcccatcg 2580
aaaagaccat atcaaaggcg aaaggccagc cgagggagcc gcaggtttat actctccccc 2640
cgtccaggga cgaattgaca aagaatcagg tgagcctcac atgccttgtg aaggggttct 2700
accccagtga tattgcagtg gagtgggagt ctaacggtca acccgaaaat aattacaaga 2760
cgacacctcc ggtcttggat agcgatgggt ctttcttcct ctattcaaag ctcacggtag 2820
ataagtccag atggcaacag ggaaacgttt tttcctgctc tgtgatgcat gaagcacttc 2880
ataatcacta cacgcagaag tcactttcac tgtcaccggg aaagtaaact gaagtcatga 2940
tggcatgctt ctatattatt ttctaaaaga tttaaagttt tgccttctcc atttagactt 3000
ataattcact ggaatttttt tgtgtgtatg gtatgacata tgggttccct tttatttttt 3060
acatataaat atatttccct gtttttctaa aaaagaaaaa gatcatcatt ttcccattgt 3120
aaaatgccat atttttttca taggtcactt acatatatca atgggtctgt ttctgagctc 3180
tactctattt tatcagcctc actgtctatc cccacacatc tcatgctttg ctctaaatct 3240
tgatatttag tggaacattc tttcccattt tgttctacaa gaatattttt gttattgtct 3300
tttgggcttc tatatacatt ttagaatgag gttggcaagt taacaaacag cttttttggg 3360
gtgaacatat tgactacaaa tttatgtgga aagaaagtat accttcacaa tattaagtct 3420
tttagttcat gaatatagta tgtctctccg tttctgcatt aacttagaca ttcattaatt 3480
tctctcacaa tttataagtt tatttagatc ttcattcatt taaatcttca ctaacctctc 3540
atttacaatt tgtaagtttt ctgggtaaca gtcttgcact tctttgccta gatttatttc 3600
caagtagatt attttcatac atcgtctatg gtgtcatttt taaaatgtaa tttttcacct 3660
ttttattgct aaagagagat gactgattgt taatattgat cttgtgcgtg gcgacctctg 3720
tgccttctag ttgccagcca tctgttgttt gcccctcccc cgtgccttcc ttgaccctgg 3780
aaggtgccac tcccactgtc ctttcctaat aaaatgagga aattgcatcg cattgtctga 3840
gtaggtgtca ttctattctg gggggtgggg tggggcagga cagcaagggg gaggattggg 3900
aagagaatag caggcatgct ggggagcggc cgcaggaacc cctagtgatg gagttggcca 3960
ctccctctct gcgcgctcgc tcgctcactg aggccgggcg accaaaggtc gcccgacgcc 4020
cgggctttgc ccgggcggcc tcagtgagcg agcgagcgcg cagctgcctg caggggcgcc 4080
tgatgcggta ttttctcctt acgcatctgt gcggtatttc acaccgcata cgtcaaagca 4140
accatagtac gcgccctgta gcggcgcatt aagcgcggcg ggtgtggtgg ttacgcgcag 4200
cgtgaccgct acacttgcca gcgccttagc gcccgctcct ttcgctttct tcccttcctt 4260
tctcgccacg ttcgccggct ttccccgtca agctctaaat cgggggctcc ctttagggtt 4320
ccgatttagt gctttacggc acctcgaccc caaaaaactt gatttgggtg atggttcacg 4380
tagtgggcca tcgccctgat agacggtttt tcgccctttg acgttggagt ccacgttctt 4440
taatagtgga ctcttgttcc aaactggaac aacactcaac tctatctcgg gctattcttt 4500
tgatttataa gggattttgc cgatttcggt ctattggtta aaaaatgagc tgatttaaca 4560
aaaatttaac gcgaatttta acaaaatatt aacgtttaca attttatggt gcactctcag 4620
tacaatctgc tctgatgccg catagttaag ccagccccga cacccgccaa cacccgctga 4680
cgcgccctga cgggcttgtc tgctcccggc atccgcttac agacaagctg tgaccgtctc 4740
cgggagctgc atgtgtcaga ggttttcacc gtcatcaccg aaacgcgcga gacgaaaggg 4800
cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt cttagacgtc 4860
aggtggcact tttcggggaa atgtgcgcgg aacccctatt tgtttatttt tctaaataca 4920
ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat aatattgaaa 4980
aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt ttgcggcatt 5040
ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg ctgaagatca 5100
gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga tccttgagag 5160
ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc tatgtggcgc 5220
ggtattatcc cgtattgacg ccgggcaaga gcaactcggt cgccgcatac actattctca 5280
gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg gcatgacagt 5340
aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca acttacttct 5400
gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt 5460
aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg acgagcgtga 5520
caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg gcgaactact 5580
tactctagct tcccggcaac aattaataga ctggatggag gcggataaag ttgcaggacc 5640
acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg gagccggtga 5700
gcgtggaagc cgcggtatca ttgcagcact ggggccagat ggtaagccct cccgtatcgt 5760
agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac agatcgctga 5820
gataggtgcc tcactgatta agcattggta actgtcagac caagtttact catatatact 5880
ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga tcctttttga 5940
taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt cagaccccgt 6000
agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct gctgcttgca 6060
aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg gatcaagagc taccaactct 6120
ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgttc ttctagtgta 6180
gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc tcgctctgct 6240
aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg ggttggactc 6300
aagacgatag ttaccggata aggcgcagcg gtcgggctga acggggggtt cgtgcacaca 6360
gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg agctatgaga 6420
aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg gcagggtcgg 6480
aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt atagtcctgt 6540
cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag gggggcggag 6600
cctatggaaa aacgccagca acgcggcctt tttacggttc ctggcctttt gctggccttt 6660
tgctcacatg t 6671
<210> 38
<211> 6673
<212> DNA
<213> AO-4(Artificial Sequence)
<400> 38
cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg ggcgaccttt 60
ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa ctccatcact 120
aggggttcct gcggcctcta gactcgaggc gttgacattg attattgact agttattaat 180
agtaatcaat tacggggtca ttagttcata gcccatatat ggagttccgc gttacataac 240
ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg acgtcaataa 300
tgacgtatgt tcccatagta acgccaatag ggactttcca ttgacgtcaa tgggtggagt 360
atttacggta aactgcccac ttggcagtac atcaagtgta tcatatgcca agtacgcccc 420
ctattgacgt caatgacggt aaatggcccg cctggcatta tgcccagtac atgaccttat 480
gggactttcc tacttggcag tacatctacg tattagtcat cgctattacc atggtgatgc 540
ggttttggca gtacatcaat gggcgtggat agcggtttga ctcacgggga tttccaagtc 600
tccaccccat tgacgtcaat gggagtttgt tttggcacca aaatcaacgg gactttccaa 660
aatgtcgtaa caactccgcc ccattgacgc aaatgggcgg taggcgtgta cggtgggagg 720
tctatataag cagagctctc tggctaacta ccggtactct cttccgcatc gctgtctgcg 780
agggccagct gttgggctcg cggttgagga caaactcttc gcggtctttc cagtactctt 840
ggatcggaaa cccgtcggcc tccgaacagg tactccgccg ccgagggacc tgagcgagtc 900
cgcatcgacc ggatcggaaa acctctcgag aaaggcgtct aaccagtcac agtcgcacga 960
tagcagttct tgcaaggaag caaagttttt caacggtttg aggccgtccg ccgtaggcat 1020
gcttttgagc gtttgaccaa gcagttccag gcggtcccac agctcggtca cgtgctctac 1080
ggcatctcga tccagcatat ctcctcgttt cgcgggttgg ggcggctttc gctgtacggc 1140
agtagtcggt gctcgtccag acgggccagg gtcatgtctt tccacgggcg cagggtcctc 1200
gtcagcgtag tctgggtcac ggtgaagggg tgcgctccgg gctgcgcgct ggccagggtg 1260
cgcttgaggc tggtcctgct ggtgctgaag cgctgccggt cttcgccctg cgcgtcggcc 1320
aggtagcatt tgaccatggt gtcatagtcc agcccctgat ccggtactcg aggaactgaa 1380
aaaccagaaa gttaactggt aagtttagtc tttttgtctt ttatttcagg tcccggatcc 1440
ggtggtggtg caaatcaaag aactgctcct cagtggatgt tgcctttact tctaggcctg 1500
tacggaagtg ttacttctgc tctaaaagct gcggaattgt acccgcgcca ccatggtctc 1560
ttattgggac acgggagttc tcctgtgtgc actgctgagc tgccttctcc tcaccggaag 1620
ttcaagtggt tccgatacag ggcggccgtt cgttgagatg tactccgaaa ttccggaaat 1680
tattcatatg acagaaggtc gcgaactcgt tattccgtgt cgcgtaacgt ctccaaacat 1740
cacggtaaca ctcaaaaaat tcccacttga cacgttgatc ccggacggca aacggattat 1800
ctgggatagc aggaaaggtt ttatcatttc taacgcgacg tataaagaaa tcgggctcct 1860
gacatgcgaa gctactgtaa atggccactt gtataaaacc aattacctga cgcatcggca 1920
gacgaacacc attatagacg tagtcctgag tccgagccac ggcattgaac ttagtgttgg 1980
cgagaaactt gtattgaact gtacggctcg gactgagctg aacgtcggca tagattttaa 2040
ttgggagtat cctagttcaa aacatcagca taagaaactc gtcaataggg acctcaaaac 2100
ccagagtggt tctgagatga agaagttttt gtcaaccctg acgatcgatg gtgttacgcg 2160
ctcagatcaa gggctctata cgtgtgccgc gtcttcaggg ctcatgacca aaaagaactc 2220
cacgtttgta cgcgtgcacg aaaaagacaa gactcataca tgcccacctt gccccgcccc 2280
tgaactgctt ggcggtccct ctgtatttct tttccctcct aaaccgaaag atactttgat 2340
gatatcccgg acccccgaag tgacatgtgt agttgtcgac gtatcacatg aagatccgga 2400
ggttaaattt aactggtacg ttgatggcgt tgaagttcac aatgctaaga ctaaaccgag 2460
ggaagagcaa tataacagta catatcgagt cgtatccgta ttgactgtgc tccaccagga 2520
ctggctgaac ggaaaggagt acaagtgcaa ggtatccaat aaggccctcc cggctcccat 2580
cgaaaagacc atatcaaagg cgaaaggcca gccgagggag ccgcaggttt atactctccc 2640
cccgtccagg gacgaattga caaagaatca ggtgagcctc acatgccttg tgaaggggtt 2700
ctaccccagt gatattgcag tggagtggga gtctaacggt caacccgaaa ataattacaa 2760
gacgacacct ccggtcttgg atagcgatgg gtctttcttc ctctattcaa agctcacggt 2820
agataagtcc agatggcaac agggaaacgt tttttcctgc tctgtgatgc atgaagcact 2880
tcataatcac tacacgcaga agtcactttc actgtcaccg ggaaagtaaa ctgaagtcat 2940
gatggcatgc ttctatatta ttttctaaaa gatttaaagt tttgccttct ccatttagac 3000
ttataattca ctggaatttt tttgtgtgta tggtatgaca tatgggttcc cttttatttt 3060
ttacatataa atatatttcc ctgtttttct aaaaaagaaa aagatcatca ttttcccatt 3120
gtaaaatgcc atattttttt cataggtcac ttacatatat caatgggtct gtttctgagc 3180
tctactctat tttatcagcc tcactgtcta tccccacaca tctcatgctt tgctctaaat 3240
cttgatattt agtggaacat tctttcccat tttgttctac aagaatattt ttgttattgt 3300
cttttgggct tctatataca ttttagaatg aggttggcaa gttaacaaac agcttttttg 3360
gggtgaacat attgactaca aatttatgtg gaaagaaagt ataccttcac aatattaagt 3420
cttttagttc atgaatatag tatgtctctc cgtttctgca ttaacttaga cattcattaa 3480
tttctctcac aatttataag tttatttaga tcttcattca tttaaatctt cactaacctc 3540
tcatttacaa tttgtaagtt ttctgggtaa cagtcttgca cttctttgcc tagatttatt 3600
tccaagtaga ttattttcat acatcgtcta tggtgtcatt tttaaaatgt aatttttcac 3660
ctttttattg ctaaagagag atgactgatt gttaatattg atcttgtgcg tggcgacctc 3720
tgtgccttct agttgccagc catctgttgt ttgcccctcc cccgtgcctt ccttgaccct 3780
ggaaggtgcc actcccactg tcctttccta ataaaatgag gaaattgcat cgcattgtct 3840
gagtaggtgt cattctattc tggggggtgg ggtggggcag gacagcaagg gggaggattg 3900
ggaagagaat agcaggcatg ctggggagcg gccgcaggaa cccctagtga tggagttggc 3960
cactccctct ctgcgcgctc gctcgctcac tgaggccggg cgaccaaagg tcgcccgacg 4020
cccgggcttt gcccgggcgg cctcagtgag cgagcgagcg cgcagctgcc tgcaggggcg 4080
cctgatgcgg tattttctcc ttacgcatct gtgcggtatt tcacaccgca tacgtcaaag 4140
caaccatagt acgcgccctg tagcggcgca ttaagcgcgg cgggtgtggt ggttacgcgc 4200
agcgtgaccg ctacacttgc cagcgcctta gcgcccgctc ctttcgcttt cttcccttcc 4260
tttctcgcca cgttcgccgg ctttccccgt caagctctaa atcgggggct ccctttaggg 4320
ttccgattta gtgctttacg gcacctcgac cccaaaaaac ttgatttggg tgatggttca 4380
cgtagtgggc catcgccctg atagacggtt tttcgccctt tgacgttgga gtccacgttc 4440
tttaatagtg gactcttgtt ccaaactgga acaacactca actctatctc gggctattct 4500
tttgatttat aagggatttt gccgatttcg gtctattggt taaaaaatga gctgatttaa 4560
caaaaattta acgcgaattt taacaaaata ttaacgttta caattttatg gtgcactctc 4620
agtacaatct gctctgatgc cgcatagtta agccagcccc gacacccgcc aacacccgct 4680
gacgcgccct gacgggcttg tctgctcccg gcatccgctt acagacaagc tgtgaccgtc 4740
tccgggagct gcatgtgtca gaggttttca ccgtcatcac cgaaacgcgc gagacgaaag 4800
ggcctcgtga tacgcctatt tttataggtt aatgtcatga taataatggt ttcttagacg 4860
tcaggtggca cttttcgggg aaatgtgcgc ggaaccccta tttgtttatt tttctaaata 4920
cattcaaata tgtatccgct catgagacaa taaccctgat aaatgcttca ataatattga 4980
aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc ttattccctt ttttgcggca 5040
ttttgccttc ctgtttttgc tcacccagaa acgctggtga aagtaaaaga tgctgaagat 5100
cagttgggtg cacgagtggg ttacatcgaa ctggatctca acagcggtaa gatccttgag 5160
agttttcgcc ccgaagaacg ttttccaatg atgagcactt ttaaagttct gctatgtggc 5220
gcggtattat cccgtattga cgccgggcaa gagcaactcg gtcgccgcat acactattct 5280
cagaatgact tggttgagta ctcaccagtc acagaaaagc atcttacgga tggcatgaca 5340
gtaagagaat tatgcagtgc tgccataacc atgagtgata acactgcggc caacttactt 5400
ctgacaacga tcggaggacc gaaggagcta accgcttttt tgcacaacat gggggatcat 5460
gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt 5520
gacaccacga tgcctgtagc aatggcaaca acgttgcgca aactattaac tggcgaacta 5580
cttactctag cttcccggca acaattaata gactggatgg aggcggataa agttgcagga 5640
ccacttctgc gctcggccct tccggctggc tggtttattg ctgataaatc tggagccggt 5700
gagcgtggaa gccgcggtat cattgcagca ctggggccag atggtaagcc ctcccgtatc 5760
gtagttatct acacgacggg gagtcaggca actatggatg aacgaaatag acagatcgct 5820
gagataggtg cctcactgat taagcattgg taactgtcag accaagttta ctcatatata 5880
ctttagattg atttaaaact tcatttttaa tttaaaagga tctaggtgaa gatccttttt 5940
gataatctca tgaccaaaat cccttaacgt gagttttcgt tccactgagc gtcagacccc 6000
gtagaaaaga tcaaaggatc ttcttgagat cctttttttc tgcgcgtaat ctgctgcttg 6060
caaacaaaaa aaccaccgct accagcggtg gtttgtttgc cggatcaaga gctaccaact 6120
ctttttccga aggtaactgg cttcagcaga gcgcagatac caaatactgt tcttctagtg 6180
tagccgtagt taggccacca cttcaagaac tctgtagcac cgcctacata cctcgctctg 6240
ctaatcctgt taccagtggc tgctgccagt ggcgataagt cgtgtcttac cgggttggac 6300
tcaagacgat agttaccgga taaggcgcag cggtcgggct gaacgggggg ttcgtgcaca 6360
cagcccagct tggagcgaac gacctacacc gaactgagat acctacagcg tgagctatga 6420
gaaagcgcca cgcttcccga agggagaaag gcggacaggt atccggtaag cggcagggtc 6480
ggaacaggag agcgcacgag ggagcttcca gggggaaacg cctggtatct ttatagtcct 6540
gtcgggtttc gccacctctg acttgagcgt cgatttttgt gatgctcgtc aggggggcgg 6600
agcctatgga aaaacgccag caacgcggcc tttttacggt tcctggcctt ttgctggcct 6660
tttgctcaca tgt 6673
Claims (26)
1. A regulatory nucleic acid molecule for enhancing gene expression, said regulatory nucleic acid molecule comprising in 5 'to 3' order a tripartite leader sequence (TPL) of an adenovirus and an enhancer element (eMLP) of the major late promoter of an adenovirus, wherein:
the tripartite leader sequence (TPL) of the adenovirus has a TPL sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4 or a sequence at least 85% identical thereto;
the enhancer element (eMLP) of the major late promoter of the adenovirus has an eMLP sequence selected from the group consisting of SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8 or a sequence having at least 85% identity thereto.
2. The regulatory nucleic acid molecule of claim 1, wherein said regulatory nucleic acid molecule has a sequence selected from the group consisting of the sequences set forth in SEQ ID Nos. 19-34 or a sequence having at least 85% identity thereto;
preferably, the regulatory nucleic acid molecule has the sequence shown in SEQ ID NO. 22, 25, 26 or 33 or a sequence with at least 85% identity thereto.
3. The regulatory nucleic acid molecule of claim 1 or 2, wherein the regulatory nucleic acid molecule has the sequence of SEQ ID NO. 26 or a sequence having at least 85% identity thereto.
4. An expression vector comprising, in 5 'to 3' order:
(a) a promoter region;
(b) a 5' UTR region;
(c) a coding sequence encoding a polypeptide gene product;
(d) a polyadenylation region (polyA);
wherein the 5' UTR region comprises a regulatory nucleic acid molecule of any one of claims 1-3;
the coding sequence is operably linked to the promoter region.
5. The expression vector of claim 4, wherein the (a) promoter region is selected from the group consisting of Cytomegalovirus (CMV) promoter, actin promoter, elongation factor 1 α (EF1 α) promoter, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter;
the promoter region of (a) comprises the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity therewith.
6. The expression vector of claim 4 or 5, wherein the polypeptide gene product is a therapeutic protein;
preferably, the therapeutic protein is selected from an anti-angiogenic polypeptide or alpha-1 antitrypsin;
preferably, the anti-angiogenic polypeptide comprises soluble fms-like tyrosine kinase-1 (sFLT-1) or a VEGF-binding fragment of sFLT-1;
more preferably, the anti-angiogenic polypeptide is aflibercept; preferably, the amino acid of aflibercept is shown in SEQ ID NO 10; more preferably, the nucleic acid encoding aflibercept is shown in SEQ ID NO 11.
7. The expression vector of any one of claims 4-6, wherein the polyadenylation region is selected from the human growth hormone (HGH or hGH), bovine growth hormone (BGH or bGH), or β -globin (β -globin) polyA sequence;
more preferably, the polyadenylation region comprises the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO. 12 or a sequence having at least 85% identity thereto;
preferably, the expression vector comprises the sequence shown as SEQ ID NO 35, 36, 37 or 38 or a sequence having at least 85% identity thereto.
8. The expression vector of any one of claims 4-7, wherein said expression vector further comprises (i) a first enhancer region, said (i) first enhancer region being located upstream of said (a) promoter region;
preferably, the (i) first enhancer region comprises a sequence selected from the CMV enhancer or the EF 1a enhancer;
more preferably, the (i) first enhancer region comprises the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto.
9. The expression vector of any one of claims 4-8, wherein said expression vector further comprises (ii) an intron region downstream of said (b)5' UTR region and upstream of said (c) coding sequence encoding a polypeptide gene product;
preferably, said (ii) intron region comprises a sequence selected from the SV40 intron, the elongation factor 1 α (EF1 α) intron, the actin intron, or the CMVc intron;
more preferably, the (ii) intron region comprises the SV40 intron sequence shown in SEQ ID NO:14 or a sequence having at least 85% identity thereto.
10. The expression vector according to any one of claims 4-wherein said expression vector further comprises (iii) a second enhancer region located downstream of said (c) coding sequence encoding a polypeptide gene product and upstream of said (d) polyadenylation region;
preferably, the (iii) second enhancer region comprises an Expression Enhancer Sequence (EES);
preferably, the (iii) second enhancer region comprises a Scaffold Attachment Region (SAR) for interferon;
preferably, the scaffold attachment region Sequence (SAR) is a human scaffold attachment region of human interferon-beta (IFNB SAR);
more preferably, the human interferon-beta human scaffold attachment region (IFNB SAR) comprises the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto.
11. The expression vector of any one of claims 4-10, wherein said expression vector further comprises (iv) an Inverted Terminal Repeat (ITR) at the 5 'end upstream of said (i) first enhancer and (v) an Inverted Terminal Repeat (ITR) at the 3' end downstream of said (d) polyadenylation region;
preferably, said (iv) Inverted Terminal Repeat (ITR) at the 5 'end or said (v) Inverted Terminal Repeat (ITR) at the 3' end comprises an Inverted Terminal Repeat (ITR) selected from Adenovirus (AV) or adeno-associated virus (AAV);
more preferably, the (iv) Inverted Terminal Repeat (ITR) at the 5' end comprises an AAV ITR as set forth in SEQ ID NO 16 or a sequence having at least 85% identity thereto;
more preferably, the Inverted Terminal Repeat (ITR) at the 3' terminus of (v) comprises the AAV ITR shown in SEQ ID NO 17 or a sequence having at least 85% identity thereto.
12. The expression vector of any one of claims 4-11, wherein the expression vector further comprises (vi) a selectable marker gene;
preferably, said (vi) selectable marker gene is located downstream of the Inverted Terminal Repeat (ITR) at the 3' end of (v);
preferably, said (vi) selectable marker gene is selected from the group consisting of ampicillin resistance gene, hygromycin resistance gene, neomycin resistance gene, bialaphos resistance gene, and dihydrofolate reductase gene;
preferably, the ampicillin resistance gene comprises the sequence shown as SEQ ID NO 18 or a sequence having at least 85% identity thereto.
13. The expression vector of any one of claims 4-12, wherein the expression vector comprises, 5 'to 3':
(i) a first enhancer region comprising the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto;
(a) a promoter region comprising the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity thereto;
(b) a 5'UTR region, the 5' UTR region comprising a regulatory nucleic acid molecule consisting of the TPL sequence shown in SEQ ID NO. 2 and the eMLP sequence shown in SEQ ID NO. 8 or a sequence having at least 85% identity thereto;
(c) a coding sequence encoding a polypeptide gene product;
(iii) a second enhancer region comprising the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto; and
(d) a polyadenylation region comprising the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto, and
optionally wherein the expression vector does not comprise an RNA export signal.
14. The expression vector of any one of claims 4-13, wherein the expression vector comprises, 5 'to 3':
(i) a first enhancer region comprising the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto;
(a) a promoter region comprising the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity thereto;
(ii) an intron region comprising the SV40 intron sequence shown as SEQ ID NO. 14 or a sequence having at least 85% identity thereto;
(b) a 5'UTR region, the 5' UTR region comprising a regulatory nucleic acid molecule consisting of the TPL sequence shown in SEQ ID NO. 2 and the eMLP sequence shown in SEQ ID NO. 8 or a sequence having at least 85% identity thereto;
(c) a coding sequence encoding a polypeptide gene product, wherein the coding sequence is operably linked to the promoter region;
(iii) a second enhancer region comprising the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto;
(d) a polyadenylation region comprising the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto.
15. The expression vector of any one of claims 4-14, wherein the expression vector comprises, 5 'to 3':
(iv) an Inverted Terminal Repeat (ITR) at the 5 'end, the Inverted Terminal Repeat (ITR) at the 5' end comprising the AAV ITR set forth in SEQ ID NO 16 or a sequence having at least 85% identity thereto;
(i) a first enhancer region comprising the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto;
(a) a promoter region comprising the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity thereto;
(ii) an intron region comprising the SV40 intron sequence shown as SEQ ID NO. 14 or a sequence having at least 85% identity thereto;
(b) a 5'UTR region, the 5' UTR region comprising a regulatory nucleic acid molecule consisting of the TPL sequence shown in SEQ ID NO. 2 and the eMLP sequence shown in SEQ ID NO. 8 or a sequence having at least 85% identity thereto;
(c) a coding sequence encoding a polypeptide gene product;
(iii) a second enhancer region comprising the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto;
(d) a polyadenylation region comprising the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto.
16. The expression vector according to any one of claims 4-15, comprising 5 'to 3':
(iv) an Inverted Terminal Repeat (ITR) at the 5 'end, the Inverted Terminal Repeat (ITR) at the 5' end comprising the AAV ITR set forth in SEQ ID NO 16 or a sequence having at least 85% identity thereto;
(i) a first enhancer region comprising the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto;
(a) a promoter region comprising the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity thereto;
(ii) an intron region comprising the SV40 intron sequence shown as SEQ ID NO. 14 or a sequence having at least 85% identity thereto;
(b) a 5'UTR region, the 5' UTR region comprising a regulatory nucleic acid molecule consisting of the TPL sequence shown in SEQ ID NO. 2 and the eMLP sequence shown in SEQ ID NO. 8 or a sequence having at least 85% identity thereto;
(c) a coding sequence encoding a polypeptide gene product;
(iii) a second enhancer region comprising the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto;
(d) a polyadenylation region comprising the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto;
(v) (iv) a 3 'terminal Inverted Terminal Repeat (ITR), said (v)3' terminal Inverted Terminal Repeat (ITR) comprising the AAV ITR set forth in SEQ ID NO:17 or a sequence having at least 85% identity thereto.
17. The expression vector according to any one of claims 4-16, comprising 5 'to 3':
(iv) an Inverted Terminal Repeat (ITR) at the 5 'end, the Inverted Terminal Repeat (ITR) at the 5' end comprising the AAV ITR set forth in SEQ ID NO 16 or a sequence having at least 85% identity thereto;
(i) a first enhancer region comprising the CMV enhancer sequence shown in SEQ ID NO 13 or a sequence having at least 85% identity thereto;
(a) a promoter region comprising the Cytomegalovirus (CMV) promoter sequence shown in SEQ ID NO:9 or a sequence having at least 85% identity thereto;
(ii) an intron region comprising the SV40 intron sequence shown as SEQ ID NO. 14 or a sequence having at least 85% identity thereto;
(b) a 5'UTR region, the 5' UTR region comprising a regulatory nucleic acid molecule consisting of the TPL sequence shown in SEQ ID NO. 2 and the eMLP sequence shown in SEQ ID NO. 8 or a sequence having at least 85% identity thereto;
(c) a coding sequence encoding a polypeptide gene product, which is aflibercept; preferably, the amino acid of aflibercept is shown in SEQ ID NO 10; more preferably, the nucleic acid encoding aflibercept (aflibercept) is shown in SEQ ID NO 11;
(iii) a second enhancer region comprising the SAR sequence shown in SEQ ID NO. 15 or a sequence having at least 85% identity thereto;
(d) a polyadenylation region comprising the bovine growth hormone (BGH or bGH) polyA sequence shown in SEQ ID NO:12 or a sequence having at least 85% identity thereto;
(v) (iv) a 3' terminal Inverted Terminal Repeat (ITR) comprising the AAV ITR of SEQ ID No. 17 or a sequence having at least 85% identity thereto;
preferably, the expression vector comprises the sequence shown as SEQ ID NO. 36 or a sequence having at least 85% identity thereto.
18. A recombinant virus, comprising:
a) a capsid protein; and
b) an expression vector according to any one of claims 4 to 17.
19. The recombinant virus of claim 18, wherein the recombinant virus is a recombinant adeno-associated virus; preferably, the adeno-associated virus is selected from the group consisting of AAV type 1 (AAV-1), AAV type 2 (AAV-2), AAV type 3 (AAV-3), AAV type 4 (AAV-4), AAV type 5 (AAV-5), AAV type 6 (AAV-6), AAV type 7 (AAV-7), AAV type 8 (AAV-8), avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, and ovine AAV;
more preferably, the adeno-associated virus is selected from AAV type 5 (AAV-5) or AAV type 6 (AAV-6).
20. The recombinant virus of claim 19, wherein the capsid protein is an AAV variant 7m8 capsid protein or is derived from said AAV variant 7m8 capsid protein.
21. A pharmaceutical composition comprising an expression vector according to any one of claims 4-17 and/or a recombinant virus according to any one of claims 18-20 and a pharmaceutically acceptable excipient.
22. An isolated host cell transfected or transduced with the expression vector according to any one of claims 4-17.
23. An isolated host cell infected with the recombinant virus of any one of claims 18-20.
24. A method for expressing a transgene in a mammalian cell, the method comprising contacting one or more mammalian cells with an amount of the expression vector of any one of claims 4-17 and/or the recombinant virus of any one of claims 18 to 20, wherein the secreted polypeptide is expressed in the one or more mammalian cells at a level.
25. A method for treating or preventing a disease in a mammal in need of such treatment or prevention, the method comprising administering to the mammal an effective amount of the expression vector of any one of claims 4-17, the recombinant virus of any one of claims 18-20, the pharmaceutical composition of claim 21, and/or the host cell of claim 22 or 23;
preferably, the disease is an ocular disease and the pharmaceutical composition is administered to the eye of the mammal;
preferably, the pharmaceutical composition is administered to the eye of the mammal by intraocular injection or intravitreal injection;
preferably, the ocular disease is selected from the group consisting of age-related macular degeneration (AMD), wet AMD, dry AMD, retinal neovascularization, choroidal neovascularization, and diabetic retinopathy.
26. Use of an expression vector according to any one of claims 4 to 17, a recombinant virus according to any one of claims 18 to 20, a pharmaceutical composition according to claim 21 and/or a host cell according to claim 22 or 23 for the preparation of a medicament for the treatment or prevention of a disease in a mammal in need of such treatment or prevention;
preferably, the disease is an ocular disease and the pharmaceutical composition is administered to the eye of the mammal;
preferably, the pharmaceutical composition is administered to the eye of the mammal by intraocular injection or intravitreal injection;
preferably, the ocular disease is selected from the group consisting of age-related macular degeneration (AMD), wet AMD, dry AMD, retinal neovascularization, choroidal neovascularization, and diabetic retinopathy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011026481.5A CN114250227A (en) | 2020-09-25 | 2020-09-25 | Expression vector for high-level expression of foreign gene |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011026481.5A CN114250227A (en) | 2020-09-25 | 2020-09-25 | Expression vector for high-level expression of foreign gene |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114250227A true CN114250227A (en) | 2022-03-29 |
Family
ID=80790646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011026481.5A Pending CN114250227A (en) | 2020-09-25 | 2020-09-25 | Expression vector for high-level expression of foreign gene |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114250227A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022217110A1 (en) * | 2021-04-09 | 2022-10-13 | Avirmax, Inc. | Compositions and methods for ocular transgene expression |
-
2020
- 2020-09-25 CN CN202011026481.5A patent/CN114250227A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022217110A1 (en) * | 2021-04-09 | 2022-10-13 | Avirmax, Inc. | Compositions and methods for ocular transgene expression |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102604096B1 (en) | Gene therapy to treat Wilson's disease | |
KR101470472B1 (en) | Long lasting drug formulations | |
CN113453702A (en) | Cell reprogramming to reverse senescence and promote tissue and tissue regeneration | |
KR20170109537A (en) | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof | |
AU2016343979A1 (en) | Delivery of central nervous system targeting polynucleotides | |
KR101591887B1 (en) | Long lasting drug formulations | |
CN114651003A (en) | CA2-IL15 fusion protein for adjustable regulation | |
CN111979240B (en) | Gene expression regulation method and system based on Type I-F CRISPR/Cas | |
CN112980885B (en) | Expression vector of anti-SARS-COV-2 neutralizing antibody | |
KR20200095462A (en) | Adeno-associated virus composition for restoring HBB gene function and method of use thereof | |
KR20230133869A (en) | Compositions and methods for expansion of T cells and tumor infiltrating lymphocytes | |
CN114250227A (en) | Expression vector for high-level expression of foreign gene | |
CN112301058B (en) | Recombinant adeno-associated virus vector and preparation method and application thereof | |
AU2021209287B1 (en) | Expression Vector for Anti-Sars-Cov-2 Neutralizing Antibodies | |
KR20230002681A (en) | Integration of large adenovirus payloads | |
CN108159434B (en) | Gene vector and gene therapy medicine for treating glaucoma | |
CN114250226A (en) | Expression vector for high-level expression of foreign gene | |
CN112203697A (en) | Bicistronic AAV vectors encoding hexosaminidase alpha and beta subunits and uses thereof | |
KR20230061441A (en) | Adeno-associated virus for delivery of KH902 (Convertcept) and its use | |
CN109022487A (en) | A kind of genophore for expressing p65 and its gene therapy medicament for treating retinal ganglion cells degeneration | |
CN117136232A (en) | Chimeric Antigen Receptor (CAR) NK cells and uses thereof | |
US6465715B1 (en) | Expression of DNA or proteins in C. elegans | |
CN112342228B (en) | AAV viral vector for expressing VEGF fusion protein and application thereof | |
CN113710809A (en) | One-step gene therapy for duchenne muscular dystrophy by gene replacement and anti-inflammation | |
CN114686521A (en) | Recombinant adeno-associated virus vector and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 101318 1st Floor, Building 1, No. 10 Anqing Street, Shunyi District, Beijing Applicant after: Beijing Anlong biomedical Co.,Ltd. Address before: 102206 310-2, floor 3, building 1, yard 1, energy East Road, Shahe Town, Changping District, Beijing Applicant before: Beijing Anlong gene Pharmaceutical Technology Co.,Ltd. Country or region before: China |